Page 5: Sixth Report on Human Biomonitoring of Environmental Chemicals in Canada

14 Summaries and results for plasticizers

14.1 Phthalates

Diesters of phthalic acid, commonly called phthalates, are a class of high-production volume industrial chemicals that are used in the manufacture of a variety of products available to consumers and industrial products. Table 14.1.1 lists phthalates commonly found in commerce and their major metabolites measured in the Canadian Health Measures Survey (CHMS).

Table 14.1.1: Phthalate metabolites measured in the Canadian Health Measures Survey and their parent phthalate compounds
Phthalate CASRN Metabolite CASRN
Dimethyl phthalate (DMP) 131-11-3 Monomethyl phthalate (MMP) 4376-18-5
Diethyl-phthalate (DEP) 84-66-2 Monoethyl phthalate (MEP) 2306-33-4
Di-n-butyl phthalate (DnBP) 84-74-2 Mono-n-butyl phthalate (MnBP) 131-70-4
Mono-3-hydroxy-n-butyl phthalate (3OH-MBP)
Diisobutyl phthalate (DiBP) 84-69-5 Monoisobutyl phthalate (MiBP) 30833-53-5
Dicyclohexyl phthalate (DCHP) 84-61-7 Monocyclohexyl phthalate (MCHP) 7517-36-4
Benzyl butyl phthalate (BBP) 85-68-7 Monobenzyl phthalate (MBzP) (some MnBP) 2528-16-7
Di-2-ethylhexyl phthalate (DEHP) 117-81-7 Mono[2-(carboxymethyl)hexyl] phthalate (MCMHP) 82975-93-7
Mono(2-ethylhexyl) phthalate (MEHP) 4376-20-9
Mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) 40809-41-4
Mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) 40321-98-0
Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 40321-99-1
Di-n-octyl phthalate (DOP) 117-84-0 Mono(3-carboxypropyl) phthalate (MCPP) 66851-46-5
Mono-carboxy-n-heptyl phthalate (MCHpP)
Mono-n-octyl phthalate (MOP) 5393-19-1
Diisononyl phthalate (DINP) 28553-12-0,
68515-48-0
Mono(carboxyisooctyl) phthalate (MCiOP) 898544-09-7
Monoisononyl phthalate (MiNP) 519056-28-1
Monooxoisononyl phthalate (MOiNP)
Monohydroxyisononyl phthalate (MHiNP)
Di-isodecyl phthalate (DIDP) 26761-40-0 Monocarboxyisononyl phthalate (MCiNP)
Monohydroxyisodecyl phthalate (MHiDP)
Monoisodecyl phthalate (MiDP)
Monooxoisodecyl phthalate (MOiDP)

Phthalates are primarily used as plasticizers to impart flexibility and resilience to plastics (Frederiksen et al., 2007; Graham, 1973; HC, 2020). They are also used as solvents in household products, including self-care products, construction and renovation products, and textiles (HC, 2020). In particular, BBP, DnBP, DMP and DEP are found in self-care products such as cosmetics (e.g., hair-care products and fragrance) and non-prescription drugs (Cosmetic Ingredient Review Expert Panel, 2005; ECCC and HC, 2020; EC and HC, 2000; 2015e). DINP, DiBP, DCHP, DnBP, BBP and DEHP are used in construction and renovation products, such as lubricants and greases, adhesives and sealants, paints and coatings, and building materials (ECCC and HC, 2020; EC and HC, 2000; 2015b; 2015d; HC, 2020). DOP, BBP, DMP, DnBP, DIDP, DiBP and DINP are used in electrical items and electronics (ECCC and HC, 2020; EC and HC, 2015b; 2015c; 2015d; 2015e; HC, 2020). Phthalates are also used in the automotive sector (e.g., BBP, DEHP, DiBP and DCHP), in printing ink (e.g., DINP and BBP), and in the formulation of pesticides (e.g., BBP) (ECCC and HC, 2020; EC and HC, 2015d; HC, 2020). Finally, certain phthalates, including BBP, DEHP, DIDP and DMP, can be found in food-packaging materials (ECCC and HC, 2020; EC and HC, 2015c; 2015e; HC, 2020). Prior to restrictions enacted in 2010 (see below), phthalates, namely BBP, DnBP, DINP and DEHP, were used in Canada as plasticizers in soft vinyl toys and childcare articles.

There are no known natural sources of phthalates. Releases to the environment are associated with anthropogenic activities (ECCC and HC, 2020). Releases may occur during the manufacture, processing, transportation and storage of phthalates as well as during the production, use and disposal of products that contain phthalates (ECCC and HC, 2020). Although release into air may occur, water is expected to be the primary receiving medium for phthalates through wastewater effluents from industrial sources and disperse releases from products available to consumers (ECCC and HC, 2020; EC and HC, 2015d).

Phthalates have been detected in food, water, air, soil and dust (Clark, 2003; ECCC and HC, 2020). The general population can be exposed through the inhalation of indoor air; through the ingestion of water, food, beverages, soil and dust; and through the use of products available to consumers (HC, 2020). Other potential sources of exposure are breast milk and the mouthing of children's toys and articles (ECCC and HC, 2020).

In laboratory animals, phthalates have been observed to undergo rapid absorption following oral exposure and generally slow absorption following dermal exposure (ATSDR, 1995; 1997; 2001). Phthalate diesters are converted to their corresponding monoesters in the gastrointestinal tract or saliva prior to absorption (ATSDR, 1995; 1997; 2001; NRC, 2008). Phthalates are rapidly metabolized in the body to form hydrolytic and oxidative monoesters, which can either be excreted in the urine and feces unchanged or can undergo phase II biotransformation to produce glucuronide conjugates with increased water solubility and, as a result, increased urinary excretion (Hauser and Calafat, 2005; Samandar et al., 2009). Although the metabolism and excretion of monoester phthalates varies based on a number of factors, they are generally characterized by rapid metabolism and short biological half-lives (ATSDR, 1995; 1997; 2001; Hauser and Calafat, 2005). Phthalates do not bioaccumulate in humans (CDC, 2009). Measurement of phthalate metabolites in urine has become the most common approach to assessing phthalate exposure in humans, and reflects relatively recent exposure (Blount et al., 2000; Calafat and McKee, 2006).

In laboratory animals, exposure to some phthalates adversely affects the male reproductive system. In particular, prenatal exposure to phthalates, such as DnBP, BBP, DEHP, DCHP and DINP, has been shown to disrupt the androgen-mediated development of the male reproductive tract (David, 2006; EC and HC, 2015b; 2015d; Foster, 2005; Gray et al., 2000; Howdeshell et al., 2007; Main et al., 2006; Mariana et al., 2016; Wine et al., 1997). This response, termed "rat phthalate syndrome," is characterized by malformations of the epididymis, vas deferens, seminal vesicles, prostate and external genitalia, among other effects (Lioy et al., 2015). Adverse effects on the testes have also been observed in mature laboratory animals, although these effects occurred at higher doses (David, 2006; Foster, 2005). There is also evidence from animal studies that phthalates exert adverse effects on the ovaries (EC and HC, 2015b; Hannon and Flaws, 2015; Mariana et al., 2016). Other target organs identified in animal studies include the liver and kidneys, where phthalate exposure may lead to increased organ weights and peroxisome proliferation in the liver (David and Gans, 2003; EC and HC, 2015b; 2015c; 2015d; 2015e; Howdeshell et al., 2007; Main et al., 2006; Wine et al., 1997).

Numerous studies demonstrate exposure to phthalates in the human population, including prenatal exposure (Becker et al., 2009; Blount et al., 2000; HC, 2018a; 2018b; Lioy et al., 2015; Marsee et al., 2006; NTP-CERHR, 2003a; 2003b; 2003c; 2003d; 2003e; 2003f; 2006; Praveena et al., 2018; Silva et al., 2003; Wittassek et al., 2011). An evaluation by Health Canada of 134 epidemiologic studies of phthalates and health outcomes in categories including hormonal effects, growth and development, and reproductive parameters (HC, 2018a) — as well as a Health Canada evaluation of 125 epidemiologic studies of phthalates and health outcomes in categories including behaviour and neurodevelopment, cardiovascular function, oxidative stress, breast cancer, obesity, allergy (inflammation of the airways and skin) and metabolic disorders (HC, 2018b) — determined that no health outcome had sufficient evidence of an association with any assessed phthalate or its metabolite (HC, 2018a; 2018b). The International Agency for Research on Cancer has classified DEHP as possibly carcinogenic to humans (Group 2B) and has determined that BBP's carcinogenicity to humans is not classifiable (Group 3) (IARC, 1999; 2013).

Environment Canada and Health Canada assessed 4 phthalates (DBP, BBP, DEHP and DOP) on an individual basis as part of the First and Second Priority Substances Lists (PSL1 and PSL2) (EC and HC, 1993; 1994a; 1994b; 2000). DBP and BBP were determined not to present a risk to the environment or to human health. DOP was found not to present a risk to the environment; however, at the time of the assessment, the available information was not sufficient to allow a conclusion in terms of human health. A subsequent report concluded that DOP did not pose a risk to human health (EC and HC, 2003). DEHP was determined to present a risk to human health in Canada; however, there was insufficient information to conclude on the potential for risk to the environment at the time of the assessment. State of the Science reports were published in 2015 for the short-chain phthalate DMP, medium-chain phthalates (including DCHP and DiBP), long-chain phthalates (including DIDP) and DINP (EC and HC, 2015b; 2015c; 2015d; 2015e). A screening assessment concluded that the 14 substances in the Phthalate Substance Grouping (including DMP, DiBP, DINP and DIDP) are not harmful to the environment or to human health as set out in section 64 of the Canadian Environmental Protection Act, 1999 (CEPA 1999), but that DEHP, previously assessed under the Priority Substances Assessment Program, is harmful to the environment as set out in section 64(a) of CEPA 1999 (Canada, 1999; ECCC and HC, 2020). In addition, a cumulative risk assessment using a conservative, lower-tiered hazard index approach indicated no concern for potential cumulative risk of medium-chain phthalates for the general Canadian population, specifically the more sensitive subpopulations (pregnant women, women of child-bearing age, infants and children) at current exposure levels (EC and HC, 2015a; ECCC and HC, 2020).

Health Canada has developed and implemented the Phthalates Regulations under the Canada Consumer Product Safety Act concerning the use of 6 phthalates (DEHP, DnBP, BBP, DINP, DIDP and DOP) in soft vinyl children's toys and childcare articles (Canada, 2010). Phthalates used in children's toys and childcare articles are also regulated in the United States and the European Union. DEHP is on the List of Ingredients that are Prohibited for Use in Cosmetic Products (HC, 2019).

Phthalate metabolite concentrations in urine have been measured in a number of biomonitoring studies conducted in Canada, including the Maternal–Infant Research on Environmental Chemicals study (Arbuckle et al., 2014), the First Nations Biomonitoring Initiative (AFN, 2013), and the Canadian Healthy Infant Longitudinal Development (CHILD) study (Navaranjan et al., 2020).

Eleven phthalate metabolites (MnBP, MEP, MBzP, MCHP, MEHP, MOP, MiNP, MMP, MCPP, MEHHP and MEOHP) were measured in the urine of CHMS participants aged 6–49 in cycle 1 (2007–2009) and aged 3–79 in cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019). MiBP was measured in the urine of CHMS participants aged 3–79 in cycles 2, 5 and 6. MCMHP, MECPP, MCiNP, MHiDP, MiDP, MOiDP, MCiOP, MHiNP, MOiNP, 3OH-MBP and MCHpP were measured in the urine of CHMS participants aged 3–79 in cycles 5 and 6. Data from these cycles are presented as both µg/L and µg/g creatinine (Tables 14.1.2 to 14.1.47). Finding a measurable amount of phthalate metabolites in urine is an indicator of exposure to parent phthalates and does not necessarily mean that an adverse health effect will occur.

Table 14.1.2: Monomethyl phthalate (MMP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.2 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 2559 27.8
(24.8–31.1)
<LOD <LOD 8.4
(7.9–8.8)
15Table 14.1.2 footnote E
(6.4–23)
5 (2016–2017) 2677 95.9
(93.0–97.6)
2.0
(1.8–2.3)
0.56
(0.38–0.74)
2.2
(1.8–2.5)
6.8
(5.4–8.1)
9.9
(7.6–12)
6 (2018–2019) 2462 93.2
(90.6–95.2)
1.7
(1.5–1.8)
0.36
(0.26–0.47)
1.9
(1.7–2.1)
6.3
(5.6–7.1)
9.2
(7.6–11)
Males, 3–79 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 1280 35.3
(29.7–41.4)
<LOD <LOD 8.7
(6.0–11)
17Table 14.1.2 footnote E
(<LOD–33)
5 (2016–2017) 1335 96.2
(91.1–98.5)
2.1
(1.8–2.5)
0.64Table 14.1.2 footnote E
(0.32–0.95)
2.2
(1.7–2.7)
7.1
(5.2–8.9)
9.9
(7.5–12)
6 (2018–2019) 1215 92.9
(88.2–95.8)
1.9
(1.7–2.1)
0.37Table 14.1.2 footnote E
(<LOD–0.53)
2.1
(1.7–2.5)
6.5
(5.5–7.5)
10Table 14.1.2 footnote E
(5.8–14)
Females, 3–79 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 1279 20.4
(17.3–23.8)
<LOD <LOD 7.6
(6.2–9.0)
9.9Table 14.1.2 footnote E
(<LOD–22)
5 (2016–2017) 1342 95.6
(92.1–97.6)
1.9
(1.7–2.2)
0.53
(0.34–0.73)
2.1
(1.7–2.5)
6.2
(4.4–8.0)
9.9Table 14.1.2 footnote E
(5.3–15)
6 (2018–2019) 1247 93.6
(88.9–96.4)
1.5
(1.3–1.7)
0.34Table 14.1.2 footnote E
(<LOD–0.51)
1.7
(1.3–2.1)
6.2
(4.8–7.7)
8.3
(6.4–10)
3–5 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 523 58.4
(51.9–64.7)
<LOD <LOD
(<LOD–5.9)
20Table 14.1.2 footnote E
(11–28)
29Table 14.1.2 footnote E
(6.9–52)
5 (2016–2017) 549 100
(99.9–100)
3.6
(3.1–4.1)
1.1Table 14.1.2 footnote E
(0.66–1.6)
3.7
(3.2–4.2)
10
(9.1–11)
13
(9.9–16)
6 (2018–2019) 501 99.3
(95.7–99.9)
3.8
(3.2–4.5)
1.2
(0.94–1.5)
3.8
(2.7–4.8)
10
(7.6–12)
14Table 14.1.2 footnote E
(4.0–25)
6–11 years
1 (2007–2009) 1037 34.0
(26.7–42.2)
<LOD <LOD 14Table 14.1.2 footnote E
(5.2–22)
25Table 14.1.2 footnote E
(15–34)
2 (2009–2011) 515 64.1
(54.9–72.3)
<LOD <LOD
(<LOD–6.5)
23
(17–29)
34Table 14.1.2 footnote E
(19–49)
5 (2016–2017) 533 99.7
(99.0–99.9)
3.7
(3.3–4.3)
1.1
(0.86–1.4)
3.7
(3.1–4.4)
12
(9.2–15)
16
(13–19)
6 (2018–2019) 491 99.6
(98.8–99.9)
3.4
(2.9–3.9)
0.97Table 14.1.2 footnote E
(0.61–1.3)
3.3
(2.5–4.0)
11
(7.8–14)
18
(15–20)
12–19 years
1 (2007–2009) 991 32.5
(25.4–40.5)
<LOD <LOD 9.3
(8.7–9.9)
11
(6.8–14)
2 (2009–2011) 512 46.0
(38.4–53.8)
<LOD <LOD 8.6
(7.6–9.7)
17Table 14.1.2 footnote E
(9.1–25)
5 (2016–2017) 533 99.3
(97.4–99.8)
3.1
(2.8–3.6)
0.85
(0.61–1.1)
3.1
(2.8–3.4)
9.0
(7.1–11)
13Table 14.1.2 footnote E
(4.4–22)
6 (2018–2019) 490 98.7
(93.5–99.8)
2.7
(2.1–3.4)
0.72Table 14.1.2 footnote E
(0.35–1.1)
2.9
(2.2–3.7)
8.0
(6.1–9.8)
11Table 14.1.2 footnote E
(6.0–16)
20–39 years
1 (2007–2009) 730 17.0Table 14.1.2 footnote E
(10.8–25.7)
<LOD <LOD 6.9Table 14.1.2 footnote E
(<LOD–9.4)
9.4
(8.1–11)
2 (2009–2011) 359 26.4
(20.3–33.4)
<LOD <LOD 7.7
(6.2–9.1)
8.9Table 14.1.2 footnote E
(<LOD–17)
5 (2016–2017) 370 97.1
(93.7–98.7)
2.1
(1.7–2.7)
0.54Table 14.1.2 footnote E
(<LOD–0.94)
2.3
(1.7–2.9)
6.5Table 14.1.2 footnote E
(4.1–9.0)
9.9Table 14.1.2 footnote E
(6.1–14)
6 (2018–2019) 325 93.0
(85.8–96.7)
1.8
(1.5–2.2)
0.49Table 14.1.2 footnote E
(<LOD–0.89)
2.1
(1.8–2.5)
6.2
(4.6–7.8)
7.4
(6.0–8.8)
40–59 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 360 17.7
(12.4–24.6)
<LOD <LOD 8.1Table 14.1.2 footnote E
(<LOD–13)
9.0Table 14.1.2 footnote E
(<LOD–51)
5 (2016–2017) 350 94.2
(85.9–97.7)
1.6
(1.3–2.1)
0.45Table 14.1.2 footnote E
(<LOD–0.78)
1.7
(1.3–2.2)
4.8
(3.3–6.3)
7.1Table 14.1.2 footnote E
(2.8–11)
6 (2018–2019) 330 90.4
(80.8–95.5)
1.3
(1.0–1.6)
0.24Table 14.1.2 footnote E
(<LOD–0.45)
1.6Table 14.1.2 footnote E
(0.98–2.2)
5.1
(3.4–6.8)
8.2Table 14.1.2 footnote E
(5.0–11)
60–79 years
1 (2007–2009)Table 14.1.2 footnote b
2 (2009–2011) 290 17.8
(13.6–23.0)
<LOD <LOD 6.8
(5.3–8.3)
8.5
(7.5–9.4)
5 (2016–2017) 342 93.1
(89.4–95.6)
1.5
(1.4–1.7)
0.50Table 14.1.2 footnote E
(0.31–0.69)
1.5
(1.2–1.7)
4.9
(3.6–6.1)
7.8Table 14.1.2 footnote E
(4.1–12)
6 (2018–2019) 325 91.8
(85.4–95.5)
1.2
(0.99–1.5)
0.26Table 14.1.2 footnote E
(<LOD–0.42)
1.1
(0.84–1.4)
4.2Table 14.1.2 footnote E
(2.6–5.7)
7.2Table 14.1.2 footnote E
(2.4–12)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 5, 5, 0.21 and 0.21 μg/L, respectively.

Table 14.1.3: Monomethyl phthalate (MMP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.3 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 2549 27.8
(24.8–31.1)
<LOD <LOD 10
(9.6–10)
19
(17–22)
5 (2016–2017) 2645 95.9
(93.0–97.6)
2.0
(1.8–2.1)
0.66
(0.54–0.78)
1.9
(1.7–2.0)
6.2
(5.5–7.0)
9.1
(7.6–11)
6 (2018–2019) 2461 93.2
(90.6–95.2)
1.8
(1.6–1.9)
0.56
(0.48–0.64)
1.7
(1.5–2.0)
6.0
(4.9–7.2)
8.8
(7.4–10)
Males, 3–79 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 1276 35.3
(29.7–41.4)
<LOD <LOD 9.7
(7.6–12)
19Table 14.1.3 footnote E
(<LOD–28)
5 (2016–2017) 1320 96.2
(91.1–98.5)
1.8
(1.6–2.2)
0.65Table 14.1.3 footnote E
(0.37–0.94)
1.7
(1.5–1.9)
5.6
(4.0–7.1)
9.5Table 14.1.3 footnote E
(5.9–13)
6 (2018–2019) 1214 92.9
(88.2–95.8)
1.7
(1.6–1.8)
0.52
(<LOD–0.65)
1.6
(1.5–1.7)
5.0
(3.7–6.3)
8.4Table 14.1.3 footnote E
(4.3–12)
Females, 3–79 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 1273 20.4
(17.3–23.8)
<LOD <LOD 10
(8.4–12)
19
(<LOD–22)
5 (2016–2017) 1325 95.6
(92.1–97.6)
2.1
(1.9–2.3)
0.68Table 14.1.3 footnote E
(0.43–0.93)
2.0
(1.8–2.2)
6.8
(5.8–7.9)
8.8
(7.4–10)
6 (2018–2019) 1247 93.6
(88.9–96.4)
1.9
(1.6–2.3)
0.58
(<LOD–0.75)
1.8
(1.4–2.3)
6.3
(4.8–7.7)
8.7
(6.4–11)
3–5 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 522 58.4
(51.9–64.7)
<LOD <LOD 30
(23–37)
49Table 14.1.3 footnote E
(21–77)
5 (2016–2017) 538 100
(99.9–100)
6.2
(5.8–6.6)
2.5
(2.1–3.0)
6.1
(5.6–6.5)
14
(11–17)
22Table 14.1.3 footnote E
(14–30)
6 (2018–2019) 500 99.3
(95.7–99.9)
6.2
(5.3–7.3)
2.3
(1.5–3.1)
6.0
(5.2–6.8)
15Table 14.1.3 footnote E
(8.0–22)
22Table 14.1.3 footnote E
(11–32)
6–11 years
1 (2007–2009) 1034 34.0
(26.7–42.2)
<LOD <LOD 23
(16–30)
38
(25–50)
2 (2009–2011) 513 64.1
(54.9–72.3)
<LOD <LOD 26Table 14.1.3 footnote E
(16–36)
32Table 14.1.3 footnote E
(13–51)
5 (2016–2017) 525 99.7
(99.0–99.9)
4.3
(3.9–4.8)
1.9
(1.6–2.1)
3.8
(3.2–4.4)
11
(8.4–13)
18
(12–24)
6 (2018–2019) 491 99.6
(98.8–99.9)
4.0
(3.7–4.4)
1.6
(1.4–1.7)
3.6
(3.4–3.8)
12
(9.1–15)
16
(12–20)
12–19 years
1 (2007–2009) 989 32.5
(25.4–40.5)
<LOD <LOD 9.2
(8.8–9.7)
10Table 14.1.3 footnote E
(5.7–14)
2 (2009–2011) 510 46.0
(38.4–53.8)
<LOD <LOD 9.0
(7.0–11)
12
(9.0–15)
5 (2016–2017) 526 99.3
(97.4–99.8)
2.4
(2.2–2.6)
1.0
(0.88–1.1)
2.2
(1.9–2.5)
6.1
(4.9–7.4)
8.2Table 14.1.3 footnote E
(4.1–12)
6 (2018–2019) 490 98.7
(93.5–99.8)
2.2
(1.8–2.7)
0.87
(0.71–1.0)
2.0
(1.7–2.4)
5.3
(3.8–6.8)
7.0Table 14.1.3 footnote E
(3.3–11)
20–39 years
1 (2007–2009) 728 17.0Table 14.1.3 footnote E
(10.8–25.7)
<LOD <LOD 9.1
(<LOD–9.8)
19Table 14.1.3 footnote E
(8.6–29)
2 (2009–2011) 357 26.4
(20.3–33.4)
<LOD <LOD 7.4Table 14.1.3 footnote E
(4.4–10)
9.9Table 14.1.3 footnote E
(<LOD–25)
5 (2016–2017) 366 97.1
(93.7–98.7)
1.9
(1.6–2.3)
0.77Table 14.1.3 footnote E
(<LOD–1.1)
1.8
(1.6–2.1)
5.7
(3.7–7.8)
8.3Table 14.1.3 footnote E
(4.8–12)
6 (2018–2019) 325 93.0
(85.8–96.7)
1.7
(1.4–2.0)
0.74Table 14.1.3 footnote E
(<LOD–1.0)
1.6
(1.3–1.9)
6.0Table 14.1.3 footnote E
(3.5–8.5)
8.5Table 14.1.3 footnote E
(4.9–12)
40–59 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 358 17.7
(12.4–24.6)
<LOD <LOD 9.6
(<LOD–13)
18Table 14.1.3 footnote E
(<LOD–31)
5 (2016–2017) 349 94.2
(85.9–97.7)
1.5
(1.2–1.8)
0.46
(<LOD–0.60)
1.5
(1.2–1.8)
3.9
(2.7–5.2)
7.0Table 14.1.3 footnote E
(4.0–10)
6 (2018–2019) 330 90.4
(80.8–95.5)
1.5
(1.2–1.8)
0.46
(<LOD–0.62)
1.5
(1.1–2.0)
4.1
(2.9–5.3)
6.2
(4.5–7.8)
60–79 years
1 (2007–2009)Table 14.1.3 footnote b
2 (2009–2011) 289 17.8
(13.6–23.0)
<LOD <LOD 9.6
(6.6–13)
18Table 14.1.3 footnote E
(8.6–28)
5 (2016–2017) 341 93.1
(89.4–95.6)
1.7
(1.5–1.9)
0.64
(0.49–0.80)
1.7
(1.5–2.0)
5.5
(4.9–6.1)
7.5
(5.8–9.1)
6 (2018–2019) 325 91.8
(85.4–95.5)
1.4
(1.2–1.7)
0.47Table 14.1.3 footnote E
(<LOD–0.69)
1.4
(1.2–1.5)
4.0
(3.0–4.9)
6.8Table 14.1.3 footnote E
(<LOD–15)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.4: Monoethyl phthalate (MEP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.4 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 2561 100 44
(36–54)
7.6
(6.0–9.2)
42
(35–50)
250Table 14.1.4 footnote E
(150–340)
470Table 14.1.4 footnote E
(<LOD–960)
5 (2016–2017) 2712 99.2
(95.9–99.8)
22
(19–25)
3.8
(2.9–4.7)
19
(16–22)
150
(98–210)
280Table 14.1.4 footnote E
(100–450)
6 (2018–2019) 2526 99.4
(97.8–99.8)
17
(15–20)
3.1
(2.3–4.0)
16
(12–19)
98
(70–130)
180
(130–230)
Males, 3–79 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 1282 100 45
(35–59)
8.8
(7.3–10)
38
(25–50)
270Table 14.1.4 footnote E
(130–400)
510Table 14.1.4 footnote E
(<LOD–1100)
5 (2016–2017) 1350 99.5
(98.6–99.9)
21
(17–26)
3.7Table 14.1.4 footnote E
(2.1–5.3)
19
(15–22)
110Table 14.1.4 footnote E
(40–190)
240Table 14.1.4 footnote E
(100–370)
6 (2018–2019) 1253 99.0
(95.8–99.8)
16
(13–20)
3.3
(2.3–4.3)
14
(10–18)
73Table 14.1.4 footnote E
(41–110)
140Table 14.1.4 footnote E
(<LOD–550)
Females, 3–79 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 1279 100 43
(36–53)
6.9
(5.0–8.7)
45
(35–54)
230Table 14.1.4 footnote E
(98–350)
420Table 14.1.4 footnote E
(<LOD–900)
5 (2016–2017) 1362 98.8
(92.5–99.8)
23
(19–27)
3.9
(3.0–4.9)
19
(15–24)
180Table 14.1.4 footnote E
(120–250)
350Table 14.1.4 footnote E
(<LOD–700)
6 (2018–2019) 1273 99.7
(98.9–99.9)
18
(15–22)
2.9
(2.0–3.9)
17
(12–22)
120Table 14.1.4 footnote E
(66–160)
190
(140–240)
3–5 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 523 100 21
(18–24)
6.8
(5.4–8.2)
19
(16–23)
80
(58–100)
120
(92–140)
5 (2016–2017) 553 100 13
(10–17)
3.5Table 14.1.4 footnote E
(2.1–4.9)
12
(11–13)
50
(37–63)
85Table 14.1.4 footnote E
(8.9–160)
6 (2018–2019) 509 99.7
(99.0–99.9)
12
(9.6–15)
3.5
(2.8–4.1)
11
(8.7–13)
32Table 14.1.4 footnote E
(<LOD–67)
67Table 14.1.4 footnote E
(39–94)
6–11 years
1 (2007–2009) 1037 100
(96.5–100)
26
(21–32)
6.3
(4.5–8.0)
23
(19–28)
120
(80–160)
200Table 14.1.4 footnote E
(120–290)
2 (2009–2011) 516 100 29
(23–37)
6.6
(4.4–8.8)
25Table 14.1.4 footnote E
(14–36)
120Table 14.1.4 footnote E
(60–180)
240Table 14.1.4 footnote E
(110–380)
5 (2016–2017) 536 99.5
(98.8–99.8)
18
(14–23)
4.0
(3.2–4.8)
15
(13–18)
110Table 14.1.4 footnote E
(34–190)
240Table 14.1.4 footnote E
(<LOD–520)
6 (2018–2019) 498 99.9
(99.5–100)
16
(13–20)
4.5
(3.6–5.5)
14
(11–17)
71Table 14.1.4 footnote E
(26–120)
130
(83–170)
12–19 years
1 (2007–2009) 991 100 65
(55–77)
14
(9.7–18)
60
(47–73)
340
(300–390)
550Table 14.1.4 footnote E
(320–780)
2 (2009–2011) 512 100 51
(43–61)
10
(7.1–14)
47
(38–57)
230
(150–310)
490Table 14.1.4 footnote E
(270–710)
5 (2016–2017) 537 99.0
(95.3–99.8)
25
(19–32)
5.4
(4.0–6.8)
21
(15–28)
130Table 14.1.4 footnote E
(61–200)
320Table 14.1.4 footnote E
(59–580)
6 (2018–2019) 504 100
(97.0–100)
20
(14–27)
3.8Table 14.1.4 footnote E
(2.2–5.5)
20Table 14.1.4 footnote E
(13–28)
89Table 14.1.4 footnote E
(41–140)
180Table 14.1.4 footnote E
(84–270)
20–39 years
1 (2007–2009) 730 100 62
(51–75)
11
(7.3–14)
51
(35–68)
440Table 14.1.4 footnote E
(130–740)
920Table 14.1.4 footnote E
(<LOD–1900)
2 (2009–2011) 359 100 48Table 14.1.4 footnote E
(31–73)
7.6
(4.8–10)
45Table 14.1.4 footnote E
(25–65)
320Table 14.1.4 footnote E
(120–520)
520Table 14.1.4 footnote E
(<LOD–1300)
5 (2016–2017) 374 97.9
(83.7–99.8)
20Table 14.1.4 footnote E
(13–32)
3.1Table 14.1.4 footnote E
(<LOD–6.1)
17Table 14.1.4 footnote E
(11–24)
190Table 14.1.4 footnote E
(77–300)
250Table 14.1.4 footnote E
(<LOD–500)
6 (2018–2019) 332 98.3
(93.8–99.6)
17
(13–22)
2.5Table 14.1.4 footnote E
(1.2–3.8)
17
(11–23)
88Table 14.1.4 footnote E
(51–120)
180Table 14.1.4 footnote E
(59–310)
40–59 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 360 100 44Table 14.1.4 footnote E
(29–69)
6.9Table 14.1.4 footnote E
(3.1–11)
43Table 14.1.4 footnote E
(27–60)
240Table 14.1.4 footnote E
(<LOD–690)
330Table 14.1.4 footnote E
(<LOD–1400)
5 (2016–2017) 359 99.9
(99.4–100)
23Table 14.1.4 footnote E
(15–33)
3.6Table 14.1.4 footnote E
(2.1–5.0)
20
(15–26)
160Table 14.1.4 footnote E
(23–300)
290Table 14.1.4 footnote E
(<LOD–640)
6 (2018–2019) 341 100 18
(14–22)
3.2
(2.2–4.3)
13Table 14.1.4 footnote E
(8.0–18)
160Table 14.1.4 footnote E
(76–250)
250Table 14.1.4 footnote E
(<LOD–960)
60–79 years
1 (2007–2009)Table 14.1.4 footnote b
2 (2009–2011) 291 100 49
(38–62)
9.1
(6.8–11)
44
(33–56)
240Table 14.1.4 footnote E
(82–390)
920Table 14.1.4 footnote E
(110–1700)
5 (2016–2017) 353 99.8
(98.7–100)
25
(20–31)
5.6
(3.9–7.3)
20
(14–26)
110Table 14.1.4 footnote E
(31–180)
270Table 14.1.4 footnote E
(<LOD–580)
6 (2018–2019) 342 99.5
(93.9–100)
17
(13–22)
3.4Table 14.1.4 footnote E
(2.0–4.8)
16
(12–21)
78
(52–100)
120
(100–140)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.5, 0.3, 0.98 and 0.76 μg/L, respectively.

Table 14.1.5: Monoethyl phthalate (MEP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.5 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 2551 100 44
(38–52)
10
(8.5–12)
37
(30–44)
220Table 14.1.5 footnote E
(120–320)
410Table 14.1.5 footnote E
(<LOD–620)
5 (2016–2017) 2680 99.2
(95.9–99.8)
21
(19–23)
5.3
(4.6–6.0)
16
(14–18)
110
(88–140)
200
(140–270)
6 (2018–2019) 2525 99.4
(97.8–99.8)
18
(16–22)
4.8
(4.0–5.7)
15
(13–18)
86
(65–110)
140Table 14.1.5 footnote E
(66–210)
Males, 3–79 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 1278 100 39
(31–49)
9.4
(8.0–11)
30
(23–38)
220Table 14.1.5 footnote E
(110–330)
390Table 14.1.5 footnote E
(<LOD–600)
5 (2016–2017) 1335 99.5
(98.6–99.9)
18
(15–21)
4.9
(3.8–6.0)
14
(12–16)
86Table 14.1.5 footnote E
(45–130)
140Table 14.1.5 footnote E
(67–220)
6 (2018–2019) 1252 99.0
(95.8–99.8)
15
(12–18)
4.3
(3.5–5.1)
12
(8.9–15)
53Table 14.1.5 footnote E
(27–78)
120Table 14.1.5 footnote E
(<LOD–360)
Females, 3–79 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 1273 100 50
(41–60)
14
(11–17)
43
(38–49)
230Table 14.1.5 footnote E
(43–410)
410Table 14.1.5 footnote E
(<LOD–950)
5 (2016–2017) 1345 98.8
(92.5–99.8)
25
(22–29)
5.6
(4.8–6.4)
20
(17–24)
130Table 14.1.5 footnote E
(79–170)
230Table 14.1.5 footnote E
(<LOD–320)
6 (2018–2019) 1273 99.7
(98.9–99.9)
23
(19–28)
5.8
(4.8–6.9)
20
(15–24)
110
(79–140)
170Table 14.1.5 footnote E
(61–270)
3–5 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 522 100 36
(32–41)
14
(12–16)
30
(25–35)
110
(82–140)
180
(120–230)
5 (2016–2017) 542 100 23
(19–28)
7.6
(5.7–9.6)
18
(13–22)
72Table 14.1.5 footnote E
(28–120)
170
(110–230)
6 (2018–2019) 508 99.7
(99.0–99.9)
19
(16–24)
8.4
(6.3–10)
16
(13–19)
47Table 14.1.5 footnote E
(<LOD–78)
77Table 14.1.5 footnote E
(11–140)
6–11 years
1 (2007–2009) 1034 100
(96.5–100)
40
(33–48)
14
(12–17)
33
(27–38)
130Table 14.1.5 footnote E
(80–190)
210Table 14.1.5 footnote E
(97–320)
2 (2009–2011) 514 100 34
(27–42)
10
(8.2–12)
27
(20–35)
130Table 14.1.5 footnote E
(60–200)
230Table 14.1.5 footnote E
(130–330)
5 (2016–2017) 528 99.5
(98.8–99.8)
21
(17–27)
6.9
(6.2–7.6)
15
(12–18)
93Table 14.1.5 footnote E
(<LOD–220)
310Table 14.1.5 footnote E
(<LOD–570)
6 (2018–2019) 498 99.9
(99.5–100)
19
(14–25)
6.7
(5.5–7.8)
14
(11–17)
88Table 14.1.5 footnote E
(46–130)
120Table 14.1.5 footnote E
(64–180)
12–19 years
1 (2007–2009) 989 100 55
(49–62)
14
(13–16)
49
(41–57)
250
(200–300)
420
(350–480)
2 (2009–2011) 510 100 39
(34–45)
10
(8.7–12)
33
(26–39)
160Table 14.1.5 footnote E
(100–220)
300Table 14.1.5 footnote E
(190–410)
5 (2016–2017) 530 99.0
(95.3–99.8)
19
(15–23)
6.1
(5.2–7.0)
13
(11–16)
85Table 14.1.5 footnote E
(38–130)
180Table 14.1.5 footnote E
(<LOD–390)
6 (2018–2019) 504 100
(97.0–100)
16
(13–21)
4.9
(4.2–5.6)
13
(9.2–17)
87Table 14.1.5 footnote E
(45–130)
120Table 14.1.5 footnote E
(54–200)
20–39 years
1 (2007–2009) 728 100 65
(55–75)
14
(13–16)
54
(45–64)
340Table 14.1.5 footnote E
(190–490)
840Table 14.1.5 footnote E
(<LOD–1600)
2 (2009–2011) 357 100 42
(30–59)
9.9
(7.2–13)
34Table 14.1.5 footnote E
(16–52)
210Table 14.1.5 footnote E
(12–410)
370Table 14.1.5 footnote E
(<LOD–770)
5 (2016–2017) 370 97.9
(83.7–99.8)
18
(14–24)
3.8Table 14.1.5 footnote E
(<LOD–5.4)
15
(11–19)
100Table 14.1.5 footnote E
(58–140)
150Table 14.1.5 footnote E
(<LOD–240)
6 (2018–2019) 332 98.3
(93.8–99.6)
16
(13–20)
4.0
(3.1–5.0)
12Table 14.1.5 footnote E
(6.6–17)
75
(48–100)
140Table 14.1.5 footnote E
(<LOD–310)
40–59 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 358 100 45
(32–64)
9.7Table 14.1.5 footnote E
(5.4–14)
39
(27–50)
280Table 14.1.5 footnote E
(<LOD–540)
410Table 14.1.5 footnote E
(<LOD–990)
5 (2016–2017) 358 99.9
(99.4–100)
21
(16–27)
5.4
(4.3–6.4)
15
(10–20)
120Table 14.1.5 footnote E
(62–190)
200Table 14.1.5 footnote E
(<LOD–340)
6 (2018–2019) 341 100 21
(17–26)
5.0
(3.7–6.3)
16
(12–20)
110Table 14.1.5 footnote E
(65–150)
250Table 14.1.5 footnote E
(<LOD–710)
60–79 years
1 (2007–2009)Table 14.1.5 footnote b
2 (2009–2011) 290 100 57
(47–70)
14
(9.7–18)
47
(33–62)
280Table 14.1.5 footnote E
(61–500)
570Table 14.1.5 footnote E
(220–910)
5 (2016–2017) 352 99.8
(98.7–100)
28
(24–34)
7.4
(5.4–9.4)
23
(18–27)
130Table 14.1.5 footnote E
(65–190)
230Table 14.1.5 footnote E
(<LOD–410)
6 (2018–2019) 342 99.5
(93.9–100)
20
(17–23)
5.4
(3.5–7.3)
17
(14–20)
66Table 14.1.5 footnote E
(33–99)
130
(110–160)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.6: Mono(3-carboxypropyl) phthalate (MCPP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.6 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 2543 98.1
(95.7–99.2)
1.9
(1.8–2.1)
0.45
(0.36–0.54)
2.0
(1.7–2.2)
7.0
(6.1–7.8)
11
(9.0–12)
5 (2016–2017) 2670 90.5
(86.8–93.3)
0.73
(0.61–0.86)
0.15Table 14.1.6 footnote E
(<LOD–0.20)
0.75
(0.63–0.88)
2.8
(2.2–3.4)
4.5
(3.4–5.5)
6 (2018–2019) 2455 89.2
(87.4–90.8)
0.60
(0.55–0.65)
<LOD 0.62
(0.56–0.68)
2.2
(1.7–2.7)
3.8
(2.6–5.0)
Males, 3–79 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 1273 98.6
(95.2–99.6)
2.1
(1.8–2.5)
0.53Table 14.1.6 footnote E
(0.33–0.72)
2.0
(1.6–2.4)
7.8
(5.1–10)
12
(9.0–15)
5 (2016–2017) 1331 92.2
(88.4–94.9)
0.72
(0.60–0.85)
0.16
(<LOD–0.20)
0.75
(0.58–0.92)
2.7
(1.8–3.6)
4.1
(2.9–5.4)
6 (2018–2019) 1226 90.9
(87.8–93.3)
0.66
(0.58–0.76)
0.15Table 14.1.6 footnote E
(<LOD–0.21)
0.73
(0.62–0.83)
2.1Table 14.1.6 footnote E
(1.3–2.9)
3.4Table 14.1.6 footnote E
(1.0–5.7)
Females, 3–79 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 1270 97.7
(92.9–99.3)
1.7
(1.5–2.0)
0.39
(0.26–0.53)
1.9
(1.6–2.2)
6.7
(5.2–8.2)
8.6
(6.4–11)
5 (2016–2017) 1339 88.8
(83.2–92.8)
0.74
(0.58–0.95)
<LOD 0.75
(0.58–0.92)
3.2
(2.3–4.2)
5.1Table 14.1.6 footnote E
(0.74–9.5)
6 (2018–2019) 1229 87.4
(84.2–90.0)
0.54
(0.48–0.61)
<LOD 0.55
(0.46–0.63)
2.3
(1.6–3.0)
3.9
(2.7–5.0)
3–5 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 517 99.8
(99.4–100)
3.2
(2.8–3.7)
0.94
(0.63–1.2)
3.1
(2.6–3.6)
9.3
(6.5–12)
14Table 14.1.6 footnote E
(8.5–19)
5 (2016–2017) 550 97.2
(91.8–99.1)
1.3Table 14.1.6 footnote E
(0.92–1.9)
0.37Table 14.1.6 footnote E
(0.22–0.51)
1.3Table 14.1.6 footnote E
(0.66–2.0)
4.2Table 14.1.6 footnote E
(1.2–7.2)
6.4Table 14.1.6 footnote E
(3.1–9.8)
6 (2018–2019) 502 98.9
(96.4–99.7)
1.2
(1.1–1.4)
0.41
(0.35–0.47)
1.2
(0.97–1.4)
3.9Table 14.1.6 footnote E
(2.2–5.6)
5.6
(4.1–7.1)
6–11 years
1 (2007–2009) 1037 97.3
(94.9–98.6)
2.7
(2.2–3.2)
0.70Table 14.1.6 footnote E
(0.41–0.99)
3.1
(2.5–3.7)
8.8
(7.5–10)
12
(9.8–15)
2 (2009–2011) 515 99.6
(98.3–99.9)
3.3
(2.8–4.0)
1.0
(0.80–1.2)
3.4
(2.9–3.9)
11Table 14.1.6 footnote E
(7.0–15)
15
(11–19)
5 (2016–2017) 531 97.4
(94.7–98.8)
1.3
(1.1–1.6)
0.40
(0.26–0.54)
1.3
(1.1–1.6)
4.0
(3.3–4.7)
6.3Table 14.1.6 footnote E
(3.4–9.2)
6 (2018–2019) 494 95.7
(85.7–98.8)
1.1
(0.93–1.4)
0.31Table 14.1.6 footnote E
(<LOD–0.50)
1.2
(0.92–1.4)
3.5
(2.6–4.3)
4.9
(3.6–6.2)
12–19 years
1 (2007–2009) 991 96.2
(94.7–97.2)
2.2
(1.9–2.6)
0.40Table 14.1.6 footnote E
(<LOD–0.60)
2.6
(2.3–2.9)
8.0
(6.4–9.6)
11Table 14.1.6 footnote E
(6.5–15)
2 (2009–2011) 509 99.7
(98.8–99.9)
2.6
(2.2–3.1)
0.65Table 14.1.6 footnote E
(0.33–0.98)
2.5
(2.2–2.8)
9.6
(6.3–13)
16Table 14.1.6 footnote E
(8.0–24)
5 (2016–2017) 532 92.0
(88.3–94.6)
0.88
(0.73–1.0)
0.17Table 14.1.6 footnote E
(<LOD–0.26)
0.94
(0.84–1.0)
3.0
(2.4–3.5)
4.1Table 14.1.6 footnote E
(<LOD–10)
6 (2018–2019) 497 91.8
(84.8–95.8)
0.69
(0.54–0.88)
<LODTable 14.1.6 footnote E
(<LOD–0.21)
0.71
(0.47–0.96)
2.4
(1.6–3.2)
3.8
(2.6–5.0)
20–39 years
1 (2007–2009) 730 90.5
(86.3–93.5)
1.3
(1.1–1.6)
<LOD 1.5
(1.2–1.8)
5.6
(4.1–7.2)
8.4
(5.8–11)
2 (2009–2011) 359 96.8
(91.4–98.9)
1.9
(1.5–2.5)
0.43Table 14.1.6 footnote E
(0.19–0.66)
2.0
(1.3–2.7)
7.1
(5.2–9.0)
10
(6.9–13)
5 (2016–2017) 365 92.0
(80.4–97.0)
0.70
(0.50–0.97)
<LOD 0.71
(0.49–0.93)
2.3Table 14.1.6 footnote E
(0.89–3.8)
4.3Table 14.1.6 footnote E
(2.4–6.2)
6 (2018–2019) 317 89.5
(84.8–92.9)
0.57
(0.44–0.75)
<LOD 0.55
(0.37–0.73)
1.8Table 14.1.6 footnote E
(0.20–3.5)
5.0Table 14.1.6 footnote E
(<LOD–9.8)
40–59 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 359 98.2
(95.1–99.4)
1.6
(1.4–1.9)
0.42Table 14.1.6 footnote E
(0.20–0.64)
1.8
(1.4–2.1)
5.3Table 14.1.6 footnote E
(2.9–7.7)
8.7Table 14.1.6 footnote E
(3.4–14)
5 (2016–2017) 348 86.8
(76.3–93.1)
0.66
(0.48–0.90)
<LOD 0.69Table 14.1.6 footnote E
(0.41–0.97)
2.7
(2.1–3.3)
4.0Table 14.1.6 footnote E
(<LOD–8.6)
6 (2018–2019) 321 86.3
(79.9–90.8)
0.50
(0.39–0.64)
<LOD 0.58
(0.46–0.70)
1.7Table 14.1.6 footnote E
(0.73–2.8)
2.9Table 14.1.6 footnote E
(1.7–4.0)
60–79 years
1 (2007–2009)Table 14.1.6 footnote b
2 (2009–2011) 284 98.3
(94.4–99.5)
1.5
(1.2–1.7)
0.39Table 14.1.6 footnote E
(0.24–0.54)
1.5
(1.3–1.7)
5.1Table 14.1.6 footnote E
(2.7–7.5)
8.7Table 14.1.6 footnote E
(5.5–12)
5 (2016–2017) 344 89.5
(83.7–93.4)
0.61
(0.50–0.73)
<LOD 0.64
(0.52–0.76)
2.6
(2.0–3.3)
4.4
(2.9–5.9)
6 (2018–2019) 324 87.4
(81.4–91.7)
0.53
(0.44–0.64)
<LOD 0.51
(0.39–0.63)
1.9
(1.6–2.3)
2.9Table 14.1.6 footnote E
(1.3–4.6)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.2, 0.2, 0.14 and 0.14 μg/L, respectively.

Table 14.1.7: Mono(3-carboxypropyl) phthalate (MCPP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.7 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 2533 98.1
(95.7–99.2)
1.9
(1.7–2.0)
0.66
(0.58–0.74)
1.7
(1.6–1.9)
5.9
(4.8–7.0)
9.1
(7.3–11)
5 (2016–2017) 2639 90.5
(86.8–93.3)
0.70
(0.62–0.78)
0.22
(<LOD–0.25)
0.62
(0.54–0.70)
2.3
(1.6–3.0)
4.1
(3.1–5.2)
6 (2018–2019) 2454 89.2
(87.4–90.8)
0.64
(0.59–0.70)
<LOD 0.56
(0.49–0.64)
2.1
(1.7–2.4)
3.2Table 14.1.7 footnote E
(1.7–4.7)
Males, 3–79 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 1269 98.6
(95.2–99.6)
1.8
(1.6–2.0)
0.60
(0.48–0.71)
1.6
(1.3–1.9)
6.4
(4.7–8.2)
9.9
(6.6–13)
5 (2016–2017) 1317 92.2
(88.4–94.9)
0.61
(0.54–0.70)
0.20
(<LOD–0.24)
0.58
(0.51–0.65)
1.9
(1.6–2.3)
3.2Table 14.1.7 footnote E
(1.9–4.5)
6 (2018–2019) 1225 90.9
(87.8–93.3)
0.61
(0.54–0.69)
0.21
(<LOD–0.25)
0.55
(0.46–0.65)
1.9
(1.3–2.5)
2.9Table 14.1.7 footnote E
(1.7–4.1)
Females, 3–79 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 1264 97.7
(92.9–99.3)
1.9
(1.7–2.2)
0.69
(0.57–0.82)
1.9
(1.7–2.2)
5.5
(4.4–6.6)
8.4
(7.0–9.9)
5 (2016–2017) 1322 88.8
(83.2–92.8)
0.79
(0.65–0.96)
<LOD 0.71
(0.56–0.87)
2.8Table 14.1.7 footnote E
(1.2–4.5)
5.8Table 14.1.7 footnote E
(3.0–8.7)
6 (2018–2019) 1229 87.4
(84.2–90.0)
0.67
(0.61–0.74)
<LOD 0.60
(0.53–0.66)
2.3
(1.7–3.0)
3.8Table 14.1.7 footnote E
(0.78–6.8)
3–5 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 516 99.8
(99.4–100)
5.6
(4.8–6.4)
2.4
(2.0–2.8)
5.5
(4.6–6.4)
13
(10–17)
21Table 14.1.7 footnote E
(12–30)
5 (2016–2017) 539 97.2
(91.8–99.1)
2.3
(1.8–3.0)
0.94
(0.70–1.2)
2.2
(1.7–2.8)
5.6Table 14.1.7 footnote E
(3.2–8.0)
8.7Table 14.1.7 footnote E
(4.0–13)
6 (2018–2019) 501 98.9
(96.4–99.7)
2.0
(1.8–2.3)
0.87Table 14.1.7 footnote E
(0.54–1.2)
1.9
(1.7–2.1)
5.4
(4.0–6.8)
6.9
(5.2–8.6)
6–11 years
1 (2007–2009) 1034 97.3
(94.9–98.6)
4.1
(3.6–4.6)
1.4
(1.1–1.7)
3.9
(3.4–4.3)
12
(8.6–15)
16
(11–20)
2 (2009–2011) 513 99.6
(98.3–99.9)
3.8
(3.4–4.3)
1.5
(1.1–1.8)
3.7
(3.3–4.1)
10Table 14.1.7 footnote E
(6.3–14)
15
(11–20)
5 (2016–2017) 523 97.4
(94.7–98.8)
1.5
(1.3–1.9)
0.67
(0.57–0.76)
1.4
(1.2–1.7)
3.7
(2.6–4.8)
6.0Table 14.1.7 footnote E
(3.6–8.4)
6 (2018–2019) 494 95.7
(85.7–98.8)
1.3
(1.2–1.5)
0.56
(<LOD–0.71)
1.2
(1.1–1.4)
3.3
(2.6–4.1)
5.1
(3.4–6.8)
12–19 years
1 (2007–2009) 989 96.2
(94.7–97.2)
1.9
(1.7–2.1)
0.69
(<LOD–0.81)
1.7
(1.6–1.9)
5.5
(4.3–6.7)
8.3
(5.3–11)
2 (2009–2011) 507 99.7
(98.8–99.9)
2.0
(1.8–2.3)
0.79
(0.59–0.99)
1.7
(1.5–1.9)
6.1Table 14.1.7 footnote E
(3.5–8.7)
11Table 14.1.7 footnote E
(4.0–18)
5 (2016–2017) 526 92.0
(88.3–94.6)
0.66
(0.54–0.82)
0.22
(<LOD–0.28)
0.58
(0.41–0.76)
1.8
(1.3–2.3)
3.0Table 14.1.7 footnote E
(<LOD–6.6)
6 (2018–2019) 497 91.8
(84.8–95.8)
0.56
(0.47–0.68)
<LOD 0.56
(0.41–0.71)
1.6Table 14.1.7 footnote E
(0.90–2.2)
2.3
(1.6–3.1)
20–39 years
1 (2007–2009) 728 90.5
(86.3–93.5)
1.4
(1.2–1.6)
<LOD 1.3
(1.1–1.5)
4.2
(2.9–5.4)
5.5Table 14.1.7 footnote E
(3.5–7.5)
2 (2009–2011) 357 96.8
(91.4–98.9)
1.6
(1.4–1.9)
0.58
(0.43–0.73)
1.4
(1.1–1.8)
5.3Table 14.1.7 footnote E
(2.9–7.7)
7.8Table 14.1.7 footnote E
(3.4–12)
5 (2016–2017) 361 92.0
(80.4–97.0)
0.63
(0.54–0.73)
<LOD 0.62
(0.44–0.79)
1.8Table 14.1.7 footnote E
(1.1–2.4)
2.5Table 14.1.7 footnote E
(0.89–4.1)
6 (2018–2019) 317 89.5
(84.8–92.9)
0.54
(0.43–0.67)
<LOD 0.48
(0.41–0.56)
1.1Table 14.1.7 footnote E
(<LOD–2.1)
2.7Table 14.1.7 footnote E
(<LOD–6.1)
40–59 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 357 98.2
(95.1–99.4)
1.6
(1.5–1.8)
0.60
(0.47–0.73)
1.7
(1.4–2.0)
4.4
(3.8–5.0)
7.0Table 14.1.7 footnote E
(3.7–10)
5 (2016–2017) 347 86.8
(76.3–93.1)
0.59
(0.47–0.74)
<LOD 0.54
(0.45–0.64)
1.9Table 14.1.7 footnote E
(<LOD–4.7)
4.1Table 14.1.7 footnote E
(<LOD–6.0)
6 (2018–2019) 321 86.3
(79.9–90.8)
0.58
(0.47–0.72)
<LOD 0.52
(0.43–0.61)
1.9
(1.3–2.6)
2.8Table 14.1.7 footnote E
(<LOD–5.6)
60–79 years
1 (2007–2009)Table 14.1.7 footnote b
2 (2009–2011) 283 98.3
(94.4–99.5)
1.7
(1.5–1.9)
0.68Table 14.1.7 footnote E
(0.37–0.99)
1.6
(1.3–1.9)
5.0
(3.9–6.2)
6.1Table 14.1.7 footnote E
(3.2–9.0)
5 (2016–2017) 343 89.5
(83.7–93.4)
0.68
(0.58–0.81)
<LOD 0.58
(0.47–0.70)
2.0
(1.5–2.5)
4.6Table 14.1.7 footnote E
(1.3–7.9)
6 (2018–2019) 324 87.4
(81.4–91.7)
0.63
(0.54–0.74)
<LOD 0.61
(0.49–0.72)
1.9Table 14.1.7 footnote E
(1.1–2.8)
3.2Table 14.1.7 footnote E
(1.6–4.9)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.8: Mono-n-butyl phthalate (MnBP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.8 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 2555 100 20
(18–22)
5.7
(4.3–7.1)
20
(18–22)
67
(57–77)
87
(74–100)
5 (2016–2017) 2711 99.9
(97.9–100)
12
(11–14)
3.7
(2.7–4.6)
12
(10–14)
38
(31–44)
54
(36–71)
6 (2018–2019) 2505 99.7
(97.6–100)
12
(11–13)
3.3
(2.5–4.1)
12
(10–14)
37
(31–43)
49
(36–63)
Males, 3–79 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 1279 100 21
(18–24)
6.4
(4.7–8.1)
21
(18–24)
69
(49–90)
96
(70–120)
5 (2016–2017) 1350 99.7
(95.9–100)
12
(10–15)
3.6
(2.3–4.8)
12
(9.1–14)
39
(27–51)
59Table 14.1.8 footnote E
(26–92)
6 (2018–2019) 1241 99.4
(94.9–99.9)
13
(11–14)
4.0Table 14.1.8 footnote E
(2.5–5.5)
13
(11–14)
41
(33–48)
50
(35–64)
Females, 3–79 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 1276 100 19
(17–22)
5.2Table 14.1.8 footnote E
(3.3–7.2)
19
(16–22)
64
(50–78)
86
(70–100)
5 (2016–2017) 1361 100 13
(11–14)
3.7
(2.9–4.6)
13
(11–15)
36
(32–41)
54
(47–60)
6 (2018–2019) 1264 99.9
(99.4–100)
11
(9.6–13)
2.8
(2.3–3.4)
11
(8.9–14)
33
(25–40)
48Table 14.1.8 footnote E
(30–67)
3–5 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 522 100 32
(28–37)
11
(8.0–14)
30
(26–34)
110
(75–150)
130
(110–150)
5 (2016–2017) 555 100 20
(16–25)
5.9
(4.4–7.4)
19
(14–25)
66Table 14.1.8 footnote E
(36–95)
85
(67–100)
6 (2018–2019) 509 100 19
(16–22)
6.1
(4.7–7.6)
19
(16–22)
52
(39–64)
72
(51–94)
6–11 years
1 (2007–2009) 1037 100 33
(29–38)
8.6
(6.4–11)
32
(27–38)
110
(89–130)
160
(130–200)
2 (2009–2011) 515 100 36
(30–43)
9.7
(7.7–12)
32
(26–37)
110Table 14.1.8 footnote E
(<LOD–240)
220Table 14.1.8 footnote E
(<LOD–540)
5 (2016–2017) 536 100 20
(18–23)
6.9
(5.7–8.1)
19
(16–22)
65
(47–84)
84
(71–98)
6 (2018–2019) 492 100 19
(16–22)
5.9Table 14.1.8 footnote E
(3.7–8.1)
21
(17–25)
49
(35–63)
72
(56–87)
12–19 years
1 (2007–2009) 991 100 32
(29–35)
9.1
(7.4–11)
33
(29–36)
98
(81–120)
140
(130–140)
2 (2009–2011) 512 100 28
(25–33)
9.1
(7.0–11)
28
(23–33)
77
(67–88)
110
(81–130)
5 (2016–2017) 537 100 16
(14–18)
4.6
(3.5–5.7)
18
(16–20)
39
(33–46)
58
(37–79)
6 (2018–2019) 500 99.8
(99.1–100)
14
(11–17)
3.8Table 14.1.8 footnote E
(1.7–5.9)
15
(12–19)
40
(30–51)
60Table 14.1.8 footnote E
(37–83)
20–39 years
1 (2007–2009) 730 99.9
(99.6–100)
22
(20–25)
6.0
(4.2–7.8)
22
(18–27)
69
(48–90)
100Table 14.1.8 footnote E
(34–170)
2 (2009–2011) 358 100 20
(16–25)
6.3Table 14.1.8 footnote E
(3.9–8.7)
21
(16–26)
54
(47–61)
77
(56–99)
5 (2016–2017) 372 99.6
(93.2–100)
12
(9.4–15)
3.3Table 14.1.8 footnote E
(1.1–5.5)
11
(7.7–14)
44
(29–58)
58Table 14.1.8 footnote E
(17–99)
6 (2018–2019) 327 98.9
(92.0–99.9)
12
(9.7–14)
3.6
(2.3–4.8)
12
(9.4–15)
35
(24–47)
49
(38–60)
40–59 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 357 100 17
(14–21)
4.0Table 14.1.8 footnote E
(1.8–6.2)
17
(15–20)
61Table 14.1.8 footnote E
(31–91)
83
(57–110)
5 (2016–2017) 358 100 11
(8.8–14)
3.3Table 14.1.8 footnote E
(1.9–4.7)
12
(8.5–15)
30
(23–37)
39Table 14.1.8 footnote E
(15–64)
6 (2018–2019) 340 100 9.9
(8.1–12)
2.3Table 14.1.8 footnote E
(1.3–3.3)
11
(7.9–13)
29Table 14.1.8 footnote E
(18–40)
43Table 14.1.8 footnote E
(9.8–75)
60–79 years
1 (2007–2009)Table 14.1.8 footnote b
2 (2009–2011) 291 100 17
(14–21)
5.3
(3.6–7.0)
16
(12–19)
63
(48–79)
81Table 14.1.8 footnote E
(34–130)
5 (2016–2017) 353 100 11
(9.8–12)
3.5
(3.0–4.1)
10
(9.5–11)
28
(22–35)
41
(29–54)
6 (2018–2019) 337 100 11
(9.2–14)
3.7
(2.9–4.5)
10
(6.9–13)
36
(27–46)
45
(32–58)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.4, 0.2, 0.60 and 0.60 μg/L, respectively.

Table 14.1.9: Mono-n-butyl phthalate (MnBP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.9 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 2545 100 20
(18–21)
8.7
(7.7–9.8)
17
(15–19)
48
(42–55)
78
(65–91)
5 (2016–2017) 2679 99.9
(97.9–100)
12
(11–13)
5.1
(4.4–5.9)
11
(9.8–12)
31
(26–35)
41
(35–47)
6 (2018–2019) 2504 99.7
(97.6–100)
13
(11–14)
5.4
(4.6–6.3)
11
(10–12)
31
(25–38)
45
(37–53)
Males, 3–79 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 1275 100 18
(16–20)
7.6
(6.9–8.3)
15
(13–17)
46
(38–54)
73
(60–86)
5 (2016–2017) 1335 99.7
(95.9–100)
11
(9.3–12)
4.4
(3.5–5.3)
9.9
(8.9–11)
27
(21–34)
39
(29–49)
6 (2018–2019) 1240 99.4
(94.9–99.9)
12
(11–13)
4.6
(3.7–5.4)
10
(9.2–11)
28
(21–35)
42Table 14.1.9 footnote E
(25–59)
Females, 3–79 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 1270 100 22
(19–24)
9.9
(8.8–11)
19
(16–22)
52
(41–63)
83
(64–100)
5 (2016–2017) 1344 100 14
(13–15)
6.5
(5.8–7.3)
12
(10–14)
33
(28–39)
45
(40–51)
6 (2018–2019) 1264 99.9
(99.4–100)
14
(12–16)
6.6
(5.9–7.3)
12
(10–14)
33
(23–42)
47
(38–56)
3–5 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 521 100 56
(49–63)
26
(23–30)
52
(45–59)
120
(88–150)
170
(110–220)
5 (2016–2017) 544 100 35
(31–40)
16
(15–17)
33
(27–40)
80
(65–95)
110Table 14.1.9 footnote E
(58–160)
6 (2018–2019) 508 100 30
(26–35)
14
(8.9–19)
29
(24–34)
67
(48–85)
91
(63–120)
6–11 years
1 (2007–2009) 1034 100 51
(46–56)
22
(19–25)
45
(40–51)
120
(110–140)
210
(140–270)
2 (2009–2011) 513 100 42
(36–48)
16
(14–19)
35
(30–39)
110Table 14.1.9 footnote E
(<LOD–260)
220Table 14.1.9 footnote E
(<LOD–600)
5 (2016–2017) 528 100 23
(22–25)
11
(9.4–13)
23
(21–25)
50
(41–60)
63
(55–72)
6 (2018–2019) 492 100 22
(20–25)
10
(9.8–11)
22
(21–23)
47
(30–63)
66
(43–88)
12–19 years
1 (2007–2009) 989 100 27
(25–30)
12
(11–13)
25
(23–27)
68Table 14.1.9 footnote E
(42–93)
99
(89–110)
2 (2009–2011) 510 100 22
(19–25)
10
(8.8–11)
19
(16–22)
48
(38–58)
62
(49–75)
5 (2016–2017) 530 100 12
(11–14)
5.6
(4.8–6.4)
11
(8.5–13)
26
(17–35)
33Table 14.1.9 footnote E
(20–46)
6 (2018–2019) 500 99.8
(99.1–100)
12
(10–13)
5.2
(4.0–6.3)
11
(9.1–12)
28
(21–35)
35
(27–43)
20–39 years
1 (2007–2009) 728 99.9
(99.6–100)
23
(21–26)
9.9
(8.5–11)
21
(19–22)
56
(41–70)
95Table 14.1.9 footnote E
(25–170)
2 (2009–2011) 356 100 17
(15–20)
8.5
(7.2–9.8)
14
(11–17)
36
(29–43)
47Table 14.1.9 footnote E
(16–77)
5 (2016–2017) 368 99.6
(93.2–100)
11
(9.7–12)
4.7
(3.8–5.5)
10
(9.1–11)
24
(16–32)
32Table 14.1.9 footnote E
(20–44)
6 (2018–2019) 327 98.9
(92.0–99.9)
11
(9.7–12)
4.8
(3.8–5.9)
9.9
(9.0–11)
22
(18–27)
32Table 14.1.9 footnote E
(11–52)
40–59 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 355 100 17
(15–19)
7.3
(5.9–8.7)
16
(13–18)
36
(26–46)
55Table 14.1.9 footnote E
(18–92)
5 (2016–2017) 357 100 10
(8.6–12)
4.9
(3.6–6.2)
9.9
(8.6–11)
21
(14–28)
33Table 14.1.9 footnote E
(18–48)
6 (2018–2019) 340 100 12
(10–14)
5.0
(3.2–6.8)
10
(8.7–12)
27Table 14.1.9 footnote E
(15–38)
40Table 14.1.9 footnote E
(25–55)
60–79 years
1 (2007–2009)Table 14.1.9 footnote b
2 (2009–2011) 290 100 20
(17–23)
9.3
(7.6–11)
18
(13–22)
51
(33–68)
71
(61–81)
5 (2016–2017) 352 100 12
(11–14)
5.9
(4.8–6.9)
11
(10–13)
27
(21–34)
36
(26–46)
6 (2018–2019) 337 100 14
(11–16)
6.6
(5.1–8.0)
12
(9.5–14)
31
(23–39)
40Table 14.1.9 footnote E
(23–56)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.10: Monoisobutyl phthalate (MiBP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.10 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
2 (2009–2011) 2547 99.9
(99.6–100)
14
(12–16)
3.5
(2.7–4.4)
14
(12–16)
43
(33–54)
64
(50–79)
5 (2016–2017) 2715 99.7
(97.4–100)
10
(8.6–12)
2.7
(2.2–3.2)
10
(9.1–11)
35
(25–45)
51
(37–64)
6 (2018–2019) 2513 98.9
(96.3–99.7)
8.5
(7.6–9.5)
2.0
(1.8–2.2)
9.1
(7.6–10)
27
(23–32)
43
(32–54)
Males, 3–79 years
2 (2009–2011) 1275 100 14
(12–17)
3.7Table 14.1.10 footnote E
(2.2–5.1)
15
(12–17)
49
(32–67)
67
(43–90)
5 (2016–2017) 1353 99.5
(92.4–100)
10
(8.6–12)
2.8
(2.0–3.6)
10
(8.8–11)
31
(22–41)
46Table 14.1.10 footnote E
(29–64)
6 (2018–2019) 1248 98.5
(92.3–99.7)
9.1
(7.8–11)
2.1
(1.5–2.8)
9.9
(8.2–12)
28Table 14.1.10 footnote E
(18–39)
49
(33–64)
Females, 3–79 years
2 (2009–2011) 1272 99.9
(99.3–100)
13
(12–15)
3.5
(2.5–4.5)
13
(11–16)
39
(33–46)
58
(42–73)
5 (2016–2017) 1362 99.9
(99.7–100)
10
(8.2–12)
2.5
(1.9–3.0)
11
(8.6–12)
39
(26–52)
51
(36–66)
6 (2018–2019) 1265 99.3
(97.8–99.8)
8.0
(7.0–9.1)
1.9
(1.7–2.2)
8.3
(6.6–10)
27
(23–32)
37
(29–46)
3–5 years
2 (2009–2011) 517 100 22
(19–25)
6.9
(5.0–8.9)
22
(18–26)
63Table 14.1.10 footnote E
(38–88)
96
(68–120)
5 (2016–2017) 555 100 16
(13–19)
4.2Table 14.1.10 footnote E
(2.4–6.1)
16
(13–19)
54
(36–72)
77
(49–110)
6 (2018–2019) 509 100 15
(11–19)
4.4
(3.0–5.8)
13
(9.3–17)
49Table 14.1.10 footnote E
(3.8–95)
120Table 14.1.10 footnote E
(<LOD–250)
6–11 years
2 (2009–2011) 515 100 22
(18–27)
6.6
(5.0–8.3)
22
(18–26)
67Table 14.1.10 footnote E
(40–93)
120Table 14.1.10 footnote E
(67–160)
5 (2016–2017) 536 99.9
(99.2–100)
15
(13–17)
5.3
(3.9–6.8)
14
(12–17)
48
(39–57)
74
(50–97)
6 (2018–2019) 494 99.8
(97.9–100)
13
(10–17)
3.9Table 14.1.10 footnote E
(2.2–5.7)
13
(9.8–16)
44
(33–55)
65Table 14.1.10 footnote E
(31–99)
12–19 years
2 (2009–2011) 508 100 18
(16–21)
5.6
(4.0–7.2)
18
(16–20)
49
(34–64)
83Table 14.1.10 footnote E
(38–130)
5 (2016–2017) 538 99.9
(99.5–100)
13
(11–15)
3.7
(2.6–4.8)
13
(11–15)
37
(29–44)
51Table 14.1.10 footnote E
(32–70)
6 (2018–2019) 503 100 11
(8.8–14)
2.9Table 14.1.10 footnote E
(1.8–4.1)
11
(8.5–14)
31
(23–38)
39Table 14.1.10 footnote E
(21–58)
20–39 years
2 (2009–2011) 359 99.8
(98.8–100)
15
(13–18)
3.2Table 14.1.10 footnote E
(1.7–4.7)
18
(15–20)
51
(40–63)
65
(49–81)
5 (2016–2017) 374 99.1
(90.4–99.9)
10
(7.5–14)
2.5Table 14.1.10 footnote E
(<LOD–4.8)
10
(7.0–14)
41Table 14.1.10 footnote E
(15–66)
57Table 14.1.10 footnote E
(28–86)
6 (2018–2019) 332 98.1
(93.4–99.5)
8.5
(7.3–10)
2.3
(1.7–2.9)
9.9
(6.4–13)
25
(18–32)
43Table 14.1.10 footnote E
(26–60)
40–59 years
2 (2009–2011) 359 100 12
(9.7–15)
3.0Table 14.1.10 footnote E
(1.4–4.7)
12
(8.3–15)
36Table 14.1.10 footnote E
(20–51)
47Table 14.1.10 footnote E
(18–75)
5 (2016–2017) 359 100 9.2
(7.3–12)
2.5
(1.9–3.0)
10
(6.9–14)
31Table 14.1.10 footnote E
(17–46)
45
(29–62)
6 (2018–2019) 340 98.5
(93.7–99.7)
7.1
(6.0–8.5)
1.7
(1.3–2.2)
8.0
(6.7–9.3)
25
(20–31)
36Table 14.1.10 footnote E
(16–56)
60–79 years
2 (2009–2011) 289 100 9.7
(7.6–12)
2.4Table 14.1.10 footnote E
(1.4–3.4)
9.3
(7.5–11)
35
(23–47)
42
(29–55)
5 (2016–2017) 353 99.9
(99.1–100)
8.0
(7.3–8.9)
2.4
(2.0–2.8)
7.7
(6.3–9.1)
23
(18–28)
33
(23–44)
6 (2018–2019) 335 99.7
(98.5–99.9)
7.6
(5.8–9.9)
2.0
(1.4–2.5)
7.7
(5.8–9.7)
26
(20–32)
39Table 14.1.10 footnote E
(13–65)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 2, 5 and 6 are 0.1, 0.57 and 0.57 μg/L, respectively.

Table 14.1.11: Monoisobutyl phthalate (MiBP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.11 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
2 (2009–2011) 2537 99.9
(99.6–100)
13
(12–15)
5.4
(4.7–6.1)
13
(12–14)
34
(28–40)
47
(37–58)
5 (2016–2017) 2683 99.7
(97.4–100)
9.8
(8.8–11)
4.0
(3.7–4.3)
8.8
(7.6–9.9)
25
(19–31)
38
(26–50)
6 (2018–2019) 2512 98.9
(96.3–99.7)
9.2
(8.4–10)
4.0
(3.7–4.3)
8.5
(7.6–9.3)
21
(18–24)
32
(26–38)
Males, 3–79 years
2 (2009–2011) 1271 100 12
(11–14)
4.9
(3.8–6.0)
11
(9.7–12)
34
(26–42)
46
(34–58)
5 (2016–2017) 1338 99.5
(92.4–100)
8.7
(8.0–9.5)
3.8
(3.3–4.3)
7.5
(7.0–8.1)
23
(19–27)
33
(27–40)
6 (2018–2019) 1247 98.5
(92.3–99.7)
8.4
(7.5–9.5)
3.7
(3.3–4.1)
7.7
(6.5–8.8)
21
(16–25)
32
(22–41)
Females, 3–79 years
2 (2009–2011) 1266 99.9
(99.3–100)
15
(13–17)
6.2
(5.1–7.2)
14
(12–16)
34
(27–42)
49
(33–65)
5 (2016–2017) 1345 99.9
(99.7–100)
11
(9.6–13)
4.5
(3.8–5.1)
10
(9.1–11)
29
(19–40)
49Table 14.1.11 footnote E
(26–72)
6 (2018–2019) 1265 99.3
(97.8–99.8)
10
(9.1–11)
4.7
(4.1–5.2)
9.3
(8.3–10)
22
(17–26)
33
(24–41)
3–5 years
2 (2009–2011) 516 100 37
(33–42)
16
(13–18)
34
(29–38)
87
(65–110)
120
(86–150)
5 (2016–2017) 544 100 27
(23–32)
11
(8.4–13)
24
(20–28)
79
(62–95)
98Table 14.1.11 footnote E
(51–150)
6 (2018–2019) 508 100 24
(19–30)
9.5
(6.3–13)
23
(18–27)
61Table 14.1.11 footnote E
(23–98)
110Table 14.1.11 footnote E
(<LOD–290)
6–11 years
2 (2009–2011) 513 100 26
(22–30)
11
(8.8–13)
23
(19–27)
63
(45–80)
94Table 14.1.11 footnote E
(40–150)
5 (2016–2017) 528 99.9
(99.2–100)
17
(16–19)
8.1
(7.1–9.1)
15
(13–17)
39
(31–47)
59
(40–77)
6 (2018–2019) 494 99.8
(97.9–100)
16
(14–18)
7.3
(6.2–8.3)
13
(11–15)
38
(24–51)
63Table 14.1.11 footnote E
(37–89)
12–19 years
2 (2009–2011) 506 100 14
(12–16)
7.1
(6.1–8.1)
12
(11–14)
30
(23–38)
41Table 14.1.11 footnote E
(18–64)
5 (2016–2017) 531 99.9
(99.5–100)
9.8
(8.3–11)
4.7
(3.8–5.6)
8.8
(7.2–10)
21
(17–25)
29Table 14.1.11 footnote E
(18–41)
6 (2018–2019) 503 100 9.1
(7.6–11)
3.9
(3.0–4.9)
8.7
(6.9–11)
20
(14–25)
34
(23–44)
20–39 years
2 (2009–2011) 357 99.8
(98.8–100)
13
(12–14)
5.4
(4.3–6.5)
13
(11–14)
33
(23–42)
44Table 14.1.11 footnote E
(26–62)
5 (2016–2017) 370 99.1
(90.4–99.9)
9.4
(7.7–11)
3.9
(<LOD–4.2)
8.7
(7.4–9.9)
24Table 14.1.11 footnote E
(8.4–40)
46Table 14.1.11 footnote E
(14–79)
6 (2018–2019) 332 98.1
(93.4–99.5)
8.1
(7.4–8.8)
3.9
(3.0–4.8)
7.9
(6.8–9.0)
16
(14–18)
20
(16–25)
40–59 years
2 (2009–2011) 357 100 12
(11–14)
5.2
(4.5–6.0)
12
(9.8–13)
24Table 14.1.11 footnote E
(15–33)
32
(22–41)
5 (2016–2017) 358 100 8.4
(7.3–9.8)
3.9
(3.3–4.4)
7.6
(6.2–9.0)
21
(17–25)
26
(19–33)
6 (2018–2019) 340 98.5
(93.7–99.7)
8.5
(7.6–9.4)
4.0
(3.2–4.8)
7.9
(6.8–9.0)
20
(16–24)
27Table 14.1.11 footnote E
(14–41)
60–79 years
2 (2009–2011) 288 100 11
(9.0–14)
4.5
(3.0–6.1)
11
(7.8–13)
30
(23–37)
37
(27–46)
5 (2016–2017) 352 99.9
(99.1–100)
9.2
(8.4–10)
3.9
(3.1–4.6)
8.2
(7.5–9.0)
23
(17–30)
39Table 14.1.11 footnote E
(22–55)
6 (2018–2019) 335 99.7
(98.5–99.9)
8.9
(7.3–11)
3.8
(3.0–4.7)
7.9
(6.3–9.6)
21Table 14.1.11 footnote E
(13–29)
29Table 14.1.11 footnote E
(1.8–57)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.12: Mono-3-hydroxy-n-butyl phthalate (3OH-MBP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.12 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2644 98.9
(97.3–99.5)
1.7
(1.4–1.9)
0.42
(0.32–0.52)
1.7
(1.4–2.0)
5.9
(5.0–6.8)
9.2
(7.0–11)
6 (2018–2019) 2448 98.1
(96.1–99.1)
1.5
(1.4–1.7)
0.45
(0.39–0.51)
1.6
(1.4–1.7)
5.3
(4.6–6.1)
7.3
(6.0–8.5)
Males, 3–79 years
5 (2016–2017) 1309 99.0
(96.9–99.7)
1.6
(1.3–1.9)
0.37Table 14.1.12 footnote E
(0.23–0.52)
1.6
(1.3–1.9)
6.1
(4.7–7.6)
10Table 14.1.12 footnote E
(5.8–14)
6 (2018–2019) 1217 97.3
(93.6–98.9)
1.6
(1.4–1.9)
0.51
(0.33–0.68)
1.6
(1.4–1.9)
6.3
(5.2–7.4)
8.3
(6.2–10)
Females, 3–79 years
5 (2016–2017) 1335 98.8
(96.0–99.6)
1.7
(1.5–1.9)
0.49
(0.41–0.57)
1.8
(1.4–2.2)
5.5
(4.6–6.5)
8.6
(7.2–10)
6 (2018–2019) 1231 98.9
(97.8–99.5)
1.4
(1.2–1.7)
0.44
(0.36–0.52)
1.5
(1.3–1.8)
4.9
(4.0–5.8)
6.7
(5.8–7.7)
3–5 years
5 (2016–2017) 538 99.8
(97.9–100)
3.8
(3.2–4.5)
1.0
(0.69–1.3)
3.9
(3.1–4.7)
12
(8.5–15)
15
(11–20)
6 (2018–2019) 491 99.7
(98.0–99.9)
3.4
(2.8–4.1)
0.97Table 14.1.12 footnote E
(0.55–1.4)
3.4
(2.8–4.1)
11
(9.0–13)
13
(8.6–18)
6–11 years
5 (2016–2017) 525 99.9
(99.2–100)
3.4
(3.0–4.0)
1.1
(0.73–1.5)
3.3
(2.7–3.9)
10
(7.0–13)
15Table 14.1.12 footnote E
(6.9–22)
6 (2018–2019) 483 98.3
(91.0–99.7)
2.9
(2.3–3.7)
0.81Table 14.1.12 footnote E
(0.39–1.2)
3.4
(2.6–4.2)
9.0
(6.7–11)
12
(9.0–14)
12–19 years
5 (2016–2017) 525 99.7
(98.8–99.9)
2.4
(2.0–2.7)
0.57Table 14.1.12 footnote E
(0.30–0.84)
2.5
(2.3–2.8)
7.5
(5.9–9.1)
10
(7.2–14)
6 (2018–2019) 495 99.6
(98.6–99.9)
2.1
(1.7–2.5)
0.61
(0.41–0.81)
2.3
(1.7–2.8)
6.1
(4.6–7.5)
9.4
(7.4–11)
20–39 years
5 (2016–2017) 363 97.4
(92.5–99.1)
1.5
(1.2–2.1)
0.37Table 14.1.12 footnote E
(0.12–0.61)
1.8Table 14.1.12 footnote E
(0.92–2.7)
6.1
(4.1–8.1)
9.0Table 14.1.12 footnote E
(3.7–14)
6 (2018–2019) 317 97.7
(91.2–99.4)
1.5
(1.3–1.7)
0.51
(0.40–0.62)
1.5
(1.3–1.8)
5.3
(3.7–6.9)
6.9
(5.9–8.0)
40–59 years
5 (2016–2017) 351 99.5
(98.1–99.9)
1.4
(1.1–1.8)
0.37
(0.26–0.47)
1.4
(1.1–1.7)
5.1
(3.6–6.6)
6.3Table 14.1.12 footnote E
(2.9–9.7)
6 (2018–2019) 330 97.6
(89.9–99.5)
1.2
(0.91–1.6)
0.32Table 14.1.12 footnote E
(0.17–0.48)
1.2
(0.78–1.6)
4.0
(2.9–5.1)
5.6Table 14.1.12 footnote E
(3.0–8.2)
60–79 years
5 (2016–2017) 342 99.2
(97.9–99.7)
1.3
(1.2–1.5)
0.45
(0.35–0.56)
1.3
(1.1–1.5)
3.5
(2.4–4.6)
5.2Table 14.1.12 footnote E
(2.8–7.6)
6 (2018–2019) 332 98.5
(95.9–99.5)
1.4
(1.1–1.7)
0.42
(0.33–0.50)
1.5
(1.2–1.7)
4.4
(3.0–5.8)
6.8
(4.8–8.8)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 5 and 6 are 0.079 and 0.068 μg/L, respectively.

Table 14.1.13: Mono-3-hydroxy-n-butyl phthalate (3OH-MBP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.13 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2613 98.9
(97.3–99.5)
1.6
(1.5–1.7)
0.60
(0.53–0.66)
1.5
(1.4–1.6)
4.7
(4.2–5.1)
6.8
(6.0–7.5)
6 (2018–2019) 2447 98.1
(96.1–99.1)
1.6
(1.5–1.8)
0.63
(0.53–0.73)
1.5
(1.2–1.8)
4.7
(3.8–5.7)
6.7
(5.4–7.9)
Males, 3–79 years
5 (2016–2017) 1294 99.0
(96.9–99.7)
1.3
(1.2–1.5)
0.54
(0.42–0.66)
1.2
(1.1–1.4)
4.0
(3.0–5.0)
6.5
(4.8–8.1)
6 (2018–2019) 1216 97.3
(93.6–98.9)
1.5
(1.3–1.7)
0.56
(0.46–0.66)
1.3
(1.2–1.5)
4.7
(3.4–6.0)
6.7
(5.0–8.4)
Females, 3–79 years
5 (2016–2017) 1319 98.8
(96.0–99.6)
1.9
(1.7–2.0)
0.72
(0.57–0.88)
1.7
(1.5–1.9)
4.9
(4.4–5.4)
7.1
(6.2–8.0)
6 (2018–2019) 1231 98.9
(97.8–99.5)
1.8
(1.5–2.1)
0.73
(0.59–0.88)
1.7
(1.4–2.0)
4.9
(3.7–6.1)
6.8
(5.4–8.1)
3–5 years
5 (2016–2017) 527 99.8
(97.9–100)
6.5
(5.7–7.4)
2.4
(1.9–3.0)
6.7
(5.9–7.6)
15
(11–19)
25Table 14.1.13 footnote E
(14–37)
6 (2018–2019) 490 99.7
(98.0–99.9)
5.5
(4.5–6.8)
2.3
(1.5–3.0)
5.3
(4.5–6.2)
14
(12–17)
16Table 14.1.13 footnote E
(8.2–23)
6–11 years
5 (2016–2017) 517 99.9
(99.2–100)
4.0
(3.5–4.5)
1.5
(1.1–1.8)
3.9
(3.4–4.4)
8.1
(7.1–9.0)
10
(7.2–14)
6 (2018–2019) 483 98.3
(91.0–99.7)
3.5
(2.8–4.3)
1.4
(0.91–1.9)
3.7
(3.5–4.0)
8.7
(6.3–11)
11
(8.0–14)
12–19 years
5 (2016–2017) 519 99.7
(98.8–99.9)
1.8
(1.5–2.0)
0.77
(0.68–0.87)
1.7
(1.5–1.9)
3.9
(2.9–4.9)
5.0Table 14.1.13 footnote E
(3.1–6.9)
6 (2018–2019) 495 99.6
(98.6–99.9)
1.6
(1.4–1.8)
0.73
(0.59–0.86)
1.6
(1.4–1.8)
3.7
(2.9–4.5)
4.9
(3.8–6.1)
20–39 years
5 (2016–2017) 359 97.4
(92.5–99.1)
1.4
(1.2–1.7)
0.54Table 14.1.13 footnote E
(0.27–0.81)
1.3
(1.1–1.6)
3.5Table 14.1.13 footnote E
(2.2–4.8)
4.8
(3.7–5.9)
6 (2018–2019) 317 97.7
(91.2–99.4)
1.4
(1.2–1.6)
0.55
(0.41–0.69)
1.3
(1.2–1.5)
3.2
(2.4–4.1)
5.4Table 14.1.13 footnote E
(2.7–8.2)
40–59 years
5 (2016–2017) 350 99.5
(98.1–99.9)
1.3
(1.1–1.5)
0.56
(0.48–0.64)
1.2
(1.0–1.4)
2.9
(2.1–3.6)
3.7Table 14.1.13 footnote E
(2.1–5.4)
6 (2018–2019) 330 97.6
(89.9–99.5)
1.4
(1.1–1.8)
0.59
(0.42–0.76)
1.3
(0.96–1.7)
3.6
(2.4–4.7)
5.4
(3.7–7.2)
60–79 years
5 (2016–2017) 341 99.2
(97.9–99.7)
1.5
(1.3–1.7)
0.61
(0.48–0.74)
1.5
(1.2–1.7)
3.6
(2.7–4.5)
4.8
(3.8–5.8)
6 (2018–2019) 332 98.5
(95.9–99.5)
1.6
(1.3–2.0)
0.70
(0.59–0.81)
1.5
(1.1–1.8)
4.3
(2.9–5.7)
5.8
(4.2–7.5)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.14: Monocyclohexyl phthalate (MCHP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.14 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 2551 26.0
(19.8–33.3)
<LOD <LOD 0.24Table 14.1.14 footnote E
(0.15–0.32)
0.47Table 14.1.14 footnote E
(0.28–0.67)
5 (2016–2017) 2706 3.4Table 14.1.14 footnote E
(1.9–6.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2524 2.0Table 14.1.14 footnote E
(1.0–4.1)
<LOD <LOD <LOD <LOD
Males, 3–79 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 1278 26.6
(19.2–35.5)
<LOD <LOD 0.25Table 14.1.14 footnote E
(0.15–0.34)
0.57Table 14.1.14 footnote E
(0.29–0.84)
5 (2016–2017) 1348 3.9Table 14.1.14 footnote E
(1.9–7.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1253 2.9Table 14.1.14 footnote E
(1.1–7.4)
<LOD <LOD <LOD <LOD
Females, 3–79 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 1273 25.3Table 14.1.14 footnote E
(17.3–35.5)
<LOD <LOD 0.22Table 14.1.14 footnote E
(0.11–0.34)
0.44
(0.30–0.59)
5 (2016–2017) 1358 2.9Table 14.1.14 footnote E
(1.5–5.4)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1271 1.1Table 14.1.14 footnote E
(0.60–1.9)
<LOD <LOD <LOD <LOD
3–5 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 522 30.9
(23.2–39.8)
<LOD <LOD 0.74Table 14.1.14 footnote E
(0.21–1.3)
4.2Table 14.1.14 footnote E
(0.29–8.1)
5 (2016–2017) 555 4.6Table 14.1.14 footnote E
(2.8–7.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 511 0.90Table 14.1.14 footnote E
(0.30–2.9)
<LOD <LOD <LOD <LOD
6–11 years
1 (2007–2009) 1037 15.1
(11.0–20.5)
<LOD <LOD 0.43Table 14.1.14 footnote E
(<LOD–0.73)
1.1Table 14.1.14 footnote E
(0.48–1.7)
2 (2009–2011) 516 33.8
(25.6–43.0)
<LOD <LOD 0.49Table 14.1.14 footnote E
(0.28–0.71)
1.3Table 14.1.14 footnote E
(0.46–2.0)
5 (2016–2017) 535 5.6Table 14.1.14 footnote E
(1.6–18.0)
<LOD <LOD <LOD 0.33Table 14.1.14 footnote E
(<LOD–0.46)
6 (2018–2019) 496 0.90Table 14.1.14 footnote E
(0.40–2.3)
<LOD <LOD <LOD <LOD
12–19 years
1 (2007–2009) 991 13.3
(9.5–18.3)
<LOD <LOD 0.28Table 14.1.14 footnote E
(<LOD–0.43)
1.1Table 14.1.14 footnote E
(0.58–1.6)
2 (2009–2011) 507 25.5
(19.4–32.8)
<LOD <LOD 0.30
(0.20–0.40)
0.64Table 14.1.14 footnote E
(<LOD–1.5)
5 (2016–2017) 538 3.6Table 14.1.14 footnote E
(1.4–8.9)
<LOD <LOD <LOD <LOD
6 (2018–2019) 504 0.20Table 14.1.14 footnote E
(0–7.5)
<LOD <LOD <LOD <LOD
20–39 years
1 (2007–2009) 730 11.8
(8.2–16.7)
<LOD <LOD 0.31Table 14.1.14 footnote E
(<LOD–0.61)
0.86Table 14.1.14 footnote E
(0.45–1.3)
2 (2009–2011) 359 25.4
(17.7–35.0)
<LOD <LOD 0.18Table 14.1.14 footnote E
(<LOD–0.29)
0.33Table 14.1.14 footnote E
(0.19–0.47)
5 (2016–2017) 372 4.3Table 14.1.14 footnote E
(1.6–11.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 331 1.9Table 14.1.14 footnote E
(0.50–6.9)
<LOD <LOD <LOD <LOD
40–59 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 358 23.0Table 14.1.14 footnote E
(15.3–33.0)
<LOD <LOD 0.20Table 14.1.14 footnote E
(<LOD–0.35)
0.40Table 14.1.14 footnote E
(<LOD–0.77)
5 (2016–2017) 356 1.4Table 14.1.14 footnote E
(0.40–4.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 342 3.3Table 14.1.14 footnote E
(1.2–9.0)
<LOD <LOD <LOD <LOD
60–79 years
1 (2007–2009)Table 14.1.14 footnote b
2 (2009–2011) 289 28.6
(20.3–38.5)
<LOD <LOD 0.23
(0.16–0.30)
0.39Table 14.1.14 footnote E
(0.10–0.67)
5 (2016–2017) 350 4.0Table 14.1.14 footnote E
(2.1–7.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 340 1.6Table 14.1.14 footnote E
(0.70–4.0)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.2, 0.1, 0.25 and 0.25 μg/L, respectively.

Table 14.1.15: Monocyclohexyl phthalate (MCHP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.15 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 2541 26.0
(19.8–33.3)
<LOD <LOD 0.29
(0.24–0.35)
0.56Table 14.1.15 footnote E
(0.33–0.80)
5 (2016–2017) 2674 3.4Table 14.1.15 footnote E
(1.9–6.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2523 2.0Table 14.1.15 footnote E
(1.0–4.1)
<LOD <LOD <LOD <LOD
Males, 3–79 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 1274 26.6
(19.2–35.5)
<LOD <LOD 0.29
(0.20–0.38)
0.59
(0.38–0.79)
5 (2016–2017) 1333 3.9Table 14.1.15 footnote E
(1.9–7.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1252 2.9Table 14.1.15 footnote E
(1.1–7.4)
<LOD <LOD <LOD <LOD
Females, 3–79 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 1267 25.3Table 14.1.15 footnote E
(17.3–35.5)
<LOD <LOD 0.30
(0.20–0.39)
0.54Table 14.1.15 footnote E
(0.12–0.96)
5 (2016–2017) 1341 2.9Table 14.1.15 footnote E
(1.5–5.4)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1271 1.1Table 14.1.15 footnote E
(0.60–1.9)
<LOD <LOD <LOD <LOD
3–5 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 521 30.9
(23.2–39.8)
<LOD <LOD 1.0Table 14.1.15 footnote E
(<LOD–2.0)
3.2Table 14.1.15 footnote E
(<LOD–10)
5 (2016–2017) 544 4.6Table 14.1.15 footnote E
(2.8–7.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 510 0.90Table 14.1.15 footnote E
(0.30–2.9)
<LOD <LOD <LOD <LOD
6–11 years
1 (2007–2009) 1034 15.1
(11.0–20.5)
<LOD <LOD 0.90Table 14.1.15 footnote E
(<LOD–1.4)
2.0Table 14.1.15 footnote E
(1.1–2.9)
2 (2009–2011) 514 33.8
(25.6–43.0)
<LOD <LOD 0.51Table 14.1.15 footnote E
(0.23–0.79)
1.3Table 14.1.15 footnote E
(0.35–2.2)
5 (2016–2017) 527 5.6Table 14.1.15 footnote E
(1.6–18.0)
<LOD <LOD <LOD 0.48
(<LOD–0.61)
6 (2018–2019) 496 0.90Table 14.1.15 footnote E
(0.40–2.3)
<LOD <LOD <LOD <LOD
12–19 years
1 (2007–2009) 989 13.3
(9.5–18.3)
<LOD <LOD 0.40Table 14.1.15 footnote E
(<LOD–0.55)
0.82Table 14.1.15 footnote E
(0.40–1.2)
2 (2009–2011) 505 25.5
(19.4–32.8)
<LOD <LOD 0.28Table 14.1.15 footnote E
(0.15–0.40)
0.47Table 14.1.15 footnote E
(<LOD–1.0)
5 (2016–2017) 531 3.6Table 14.1.15 footnote E
(1.4–8.9)
<LOD <LOD <LOD <LOD
6 (2018–2019) 504 0.20Table 14.1.15 footnote E
(0–7.5)
<LOD <LOD <LOD <LOD
20–39 years
1 (2007–2009) 728 11.8
(8.2–16.7)
<LOD <LOD 0.54
(<LOD–0.72)
0.89
(0.68–1.1)
2 (2009–2011) 357 25.4
(17.7–35.0)
<LOD <LOD 0.20Table 14.1.15 footnote E
(<LOD–0.31)
0.31Table 14.1.15 footnote E
(<LOD–0.58)
5 (2016–2017) 368 4.3Table 14.1.15 footnote E
(1.6–11.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 331 1.9Table 14.1.15 footnote E
(0.50–6.9)
<LOD <LOD <LOD <LOD
40–59 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 356 23.0Table 14.1.15 footnote E
(15.3–33.0)
<LOD <LOD 0.30Table 14.1.15 footnote E
(<LOD–0.55)
0.46Table 14.1.15 footnote E
(<LOD–1.3)
5 (2016–2017) 355 1.4Table 14.1.15 footnote E
(0.40–4.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 342 3.3Table 14.1.15 footnote E
(1.2–9.0)
<LOD <LOD <LOD <LOD
60–79 years
1 (2007–2009)Table 14.1.15 footnote b
2 (2009–2011) 288 28.6
(20.3–38.5)
<LOD <LOD 0.29
(0.21–0.37)
0.42Table 14.1.15 footnote E
(0.19–0.65)
5 (2016–2017) 349 4.0Table 14.1.15 footnote E
(2.1–7.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 340 1.6Table 14.1.15 footnote E
(0.70–4.0)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.16 : Monobenzyl phthalate (MBzP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.16 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 2559 100 7.5
(6.6–8.6)
1.7
(1.3–2.2)
7.1
(6.1–8.1)
32
(25–38)
57
(48–65)
5 (2016–2017) 2714 96.3
(92.6–98.2)
3.9
(3.1–4.7)
0.82
(0.61–1.0)
3.6
(3.0–4.3)
21
(17–24)
32
(23–40)
6 (2018–2019) 2516 98.3
(96.9–99.1)
2.6
(2.1–3.2)
0.51
(0.38–0.64)
2.6
(2.0–3.2)
13
(11–16)
21Table 14.1.16 footnote E
(13–30)
Males, 3–79 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 1281 100 8.0
(6.9–9.2)
2.1
(1.5–2.7)
7.5
(6.2–8.9)
33
(26–40)
54
(42–65)
5 (2016–2017) 1353 95.9
(89.6–98.4)
3.8
(2.9–5.0)
0.74
(0.48–1.0)
3.5
(2.6–4.3)
21
(17–26)
29
(23–35)
6 (2018–2019) 1250 98.5
(96.1–99.4)
2.8
(2.2–3.5)
0.50Table 14.1.16 footnote E
(0.28–0.72)
2.9
(2.2–3.6)
15
(11–19)
24
(16–33)
Females, 3–79 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 1278 100 7.1
(5.7–8.7)
1.5Table 14.1.16 footnote E
(0.89–2.0)
6.7
(4.8–8.6)
30
(20–40)
58
(41–75)
5 (2016–2017) 1361 96.8
(94.0–98.3)
3.9
(3.2–4.7)
0.91
(0.66–1.2)
3.8
(3.2–4.4)
19
(13–26)
36Table 14.1.16 footnote E
(22–49)
6 (2018–2019) 1266 98.2
(94.7–99.4)
2.4
(2.0–3.0)
0.52
(0.36–0.67)
2.5
(1.9–3.0)
12
(8.7–15)
18Table 14.1.16 footnote E
(7.2–28)
3–5 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 522 100 17
(14–20)
4.1Table 14.1.16 footnote E
(2.6–5.7)
16
(13–18)
59Table 14.1.16 footnote E
(25–92)
120
(86–150)
5 (2016–2017) 555 97.0
(90.5–99.1)
7.7Table 14.1.16 footnote E
(4.3–14)
1.3Table 14.1.16 footnote E
(0.38–2.2)
7.8Table 14.1.16 footnote E
(4.9–11)
42Table 14.1.16 footnote E
(<LOD–100)
86Table 14.1.16 footnote E
(<LOD–210)
6 (2018–2019) 511 99.1
(95.1–99.8)
5.9Table 14.1.16 footnote E
(3.9–8.8)
1.1Table 14.1.16 footnote E
(0.66–1.5)
5.9Table 14.1.16 footnote E
(3.0–8.8)
39Table 14.1.16 footnote E
(22–56)
49
(44–54)
6–11 years
1 (2007–2009) 1037 100 21
(17–25)
4.8
(3.2–6.3)
21
(17–25)
91
(74–110)
120
(98–150)
2 (2009–2011) 516 100 19
(15–23)
4.9
(3.5–6.4)
20
(15–24)
76Table 14.1.16 footnote E
(45–110)
100
(72–140)
5 (2016–2017) 537 99.4
(98.4–99.8)
10
(8.3–12)
2.2Table 14.1.16 footnote E
(1.3–3.2)
9.6
(7.0–12)
42
(34–50)
58
(37–79)
6 (2018–2019) 496 99.9
(99.1–100)
6.3Table 14.1.16 footnote E
(4.2–9.3)
1.3Table 14.1.16 footnote E
(0.23–2.3)
6.1Table 14.1.16 footnote E
(3.5–8.8)
32Table 14.1.16 footnote E
(14–49)
46Table 14.1.16 footnote E
(26–67)
12–19 years
1 (2007–2009) 991 100 19
(16–22)
4.4
(3.1–5.7)
20
(16–24)
74
(56–93)
99
(86–110)
2 (2009–2011) 512 100 12
(10–15)
3.3
(2.2–4.4)
12
(8.9–15)
42
(33–50)
59
(43–75)
5 (2016–2017) 538 99.1
(98.1–99.6)
5.3
(4.2–6.7)
1.0
(0.69–1.3)
5.2Table 14.1.16 footnote E
(3.3–7.2)
24
(15–32)
41
(28–54)
6 (2018–2019) 502 99.5
(98.0–99.9)
3.8
(2.7–5.4)
0.66Table 14.1.16 footnote E
(0.32–1.0)
3.8Table 14.1.16 footnote E
(2.1–5.4)
16Table 14.1.16 footnote E
(8.1–23)
26Table 14.1.16 footnote E
(3.2–50)
20–39 years
1 (2007–2009) 730 100 10
(8.1–13)
2.0
(1.5–2.5)
9.9
(7.0–13)
51
(38–64)
77
(50–100)
2 (2009–2011) 359 100 7.3
(5.5–9.7)
1.8Table 14.1.16 footnote E
(0.78–2.7)
7.0
(5.2–8.7)
30Table 14.1.16 footnote E
(12–48)
60
(39–80)
5 (2016–2017) 374 93.8
(80.2–98.2)
3.7Table 14.1.16 footnote E
(2.3–6.0)
0.83Table 14.1.16 footnote E
(<LOD–1.4)
4.1Table 14.1.16 footnote E
(2.5–5.6)
21Table 14.1.16 footnote E
(8.9–32)
28Table 14.1.16 footnote E
(7.2–50)
6 (2018–2019) 329 97.7
(91.6–99.4)
2.6
(2.0–3.4)
0.48Table 14.1.16 footnote E
(0.25–0.71)
2.8Table 14.1.16 footnote E
(1.6–4.0)
13
(9.3–17)
17
(11–24)
40–59 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 360 100 6.0
(4.8–7.5)
1.6Table 14.1.16 footnote E
(0.95–2.2)
5.6Table 14.1.16 footnote E
(2.9–8.2)
20Table 14.1.16 footnote E
(12–28)
33Table 14.1.16 footnote E
(4.3–61)
5 (2016–2017) 358 97.3
(92.6–99.0)
3.3
(2.4–4.6)
0.72Table 14.1.16 footnote E
(0.41–1.0)
3.1
(2.1–4.1)
18Table 14.1.16 footnote E
(11–25)
23Table 14.1.16 footnote E
(9.3–37)
6 (2018–2019) 340 97.4
(91.3–99.3)
1.9
(1.4–2.6)
0.40Table 14.1.16 footnote E
(0.21–0.59)
2.1Table 14.1.16 footnote E
(1.3–2.9)
6.5Table 14.1.16 footnote E
(3.0–9.9)
13Table 14.1.16 footnote E
(4.1–23)
60–79 years
1 (2007–2009)Table 14.1.16 footnote b
2 (2009–2011) 290 100 5.2
(4.3–6.4)
1.0Table 14.1.16 footnote E
(0.55–1.5)
4.7
(3.7–5.8)
23
(16–30)
36Table 14.1.16 footnote E
(15–57)
5 (2016–2017) 352 96.2
(92.9–98.0)
2.8
(2.4–3.3)
0.65
(0.47–0.82)
2.7
(2.1–3.2)
15Table 14.1.16 footnote E
(7.3–23)
21
(15–27)
6 (2018–2019) 338 99.3
(95.4–99.9)
2.3
(1.8–2.9)
0.52
(0.38–0.66)
2.2
(1.8–2.7)
11Table 14.1.16 footnote E
(<LOD–23)
23Table 14.1.16 footnote E
(8.9–37)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.5, 0.2, 0.37 and 0.14 μg/L, respectively.

Table 14.1.17: Monobenzyl phthalate (MBzP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.17 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 2549 100 7.4
(6.4–8.5)
2.1
(1.8–2.5)
6.8
(5.6–8.0)
28
(22–34)
44
(37–51)
5 (2016–2017) 2682 96.3
(92.6–98.2)
3.7
(3.1–4.4)
0.96
(0.83–1.1)
3.4
(2.7–4.1)
16
(13–19)
25
(18–32)
6 (2018–2019) 2515 98.3
(96.9–99.1)
2.8
(2.3–3.4)
0.69
(0.47–0.91)
2.6
(2.1–3.1)
12
(9.3–15)
20
(16–24)
Males, 3–79 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 1277 100 6.8
(6.0–7.7)
2.1
(1.8–2.4)
5.9
(5.0–6.8)
25
(20–30)
39
(27–50)
5 (2016–2017) 1338 95.9
(89.6–98.4)
3.3
(2.6–4.1)
0.86
(0.67–1.1)
2.9
(2.2–3.6)
16
(9.9–21)
22
(16–28)
6 (2018–2019) 1249 98.5
(96.1–99.4)
2.6
(2.1–3.2)
0.56Table 14.1.17 footnote E
(0.28–0.83)
2.5
(1.9–3.1)
11
(9.0–14)
19
(13–24)
Females, 3–79 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 1272 100 8.1
(6.6–9.9)
2.2
(1.5–3.0)
7.7
(5.7–9.7)
32
(24–41)
46
(40–52)
5 (2016–2017) 1344 96.8
(94.0–98.3)
4.2
(3.6–5.0)
1.1
(0.88–1.3)
3.9
(3.1–4.8)
16
(13–19)
29
(19–39)
6 (2018–2019) 1266 98.2
(94.7–99.4)
3.1
(2.5–3.7)
0.80
(0.55–1.1)
2.7
(2.1–3.2)
13
(8.7–18)
21
(15–27)
3–5 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 521 100 29
(24–35)
9.4
(8.1–11)
26
(20–32)
100
(70–130)
150
(110–200)
5 (2016–2017) 544 97.0
(90.5–99.1)
13Table 14.1.17 footnote E
(8.6–20)
3.2Table 14.1.17 footnote E
(1.9–4.5)
12Table 14.1.17 footnote E
(7.0–17)
60Table 14.1.17 footnote E
(<LOD–130)
120Table 14.1.17 footnote E
(<LOD–190)
6 (2018–2019) 510 99.1
(95.1–99.8)
9.6Table 14.1.17 footnote E
(6.2–15)
1.8Table 14.1.17 footnote E
(0.34–3.2)
8.6Table 14.1.17 footnote E
(4.1–13)
57
(39–76)
80
(57–100)
6–11 years
1 (2007–2009) 1034 100 32
(27–39)
10
(8.5–12)
31
(25–37)
100
(86–110)
140
(110–170)
2 (2009–2011) 514 100 22
(18–26)
6.2
(4.3–8.2)
21
(17–25)
73
(58–88)
98
(78–120)
5 (2016–2017) 529 99.4
(98.4–99.8)
11
(9.7–14)
2.9
(2.0–3.8)
10
(7.4–13)
43
(32–53)
58Table 14.1.17 footnote E
(33–84)
6 (2018–2019) 496 99.9
(99.1–100)
7.5
(5.3–11)
2.4
(1.8–2.9)
6.5Table 14.1.17 footnote E
(3.4–9.7)
32Table 14.1.17 footnote E
(17–47)
47Table 14.1.17 footnote E
(27–67)
12–19 years
1 (2007–2009) 989 100 16
(14–19)
5.6
(4.1–7.1)
15
(13–17)
49Table 14.1.17 footnote E
(30–69)
70
(57–83)
2 (2009–2011) 510 100 9.4
(7.7–11)
3.1
(2.4–3.9)
9.3
(7.7–11)
28
(21–36)
44
(34–54)
5 (2016–2017) 531 99.1
(98.1–99.6)
4.0
(3.0–5.4)
1.0
(0.70–1.3)
3.4Table 14.1.17 footnote E
(2.0–4.8)
16
(10–21)
22Table 14.1.17 footnote E
(8.6–35)
6 (2018–2019) 502 99.5
(98.0–99.9)
3.1
(2.4–4.0)
0.88
(0.59–1.2)
3.0
(2.2–3.8)
10Table 14.1.17 footnote E
(6.0–14)
18
(12–24)
20–39 years
1 (2007–2009) 728 100 11
(8.9–13)
3.0Table 14.1.17 footnote E
(1.9–4.0)
10
(8.1–12)
36
(27–45)
54
(42–65)
2 (2009–2011) 357 100 6.3
(4.8–8.3)
2.0Table 14.1.17 footnote E
(1.1–2.9)
5.6
(4.0–7.2)
22Table 14.1.17 footnote E
(11–34)
36
(26–46)
5 (2016–2017) 370 93.8
(80.2–98.2)
3.4
(2.5–4.6)
0.81Table 14.1.17 footnote E
(<LOD–1.2)
3.3Table 14.1.17 footnote E
(2.0–4.5)
12Table 14.1.17 footnote E
(6.4–18)
21Table 14.1.17 footnote E
(9.6–33)
6 (2018–2019) 329 97.7
(91.6–99.4)
2.5
(1.9–3.1)
0.51Table 14.1.17 footnote E
(0.18–0.85)
2.5
(1.7–3.2)
12Table 14.1.17 footnote E
(5.6–18)
19Table 14.1.17 footnote E
(11–26)
40–59 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 358 100 6.1
(5.1–7.2)
2.0
(1.7–2.4)
5.4Table 14.1.17 footnote E
(3.4–7.4)
17
(13–20)
28Table 14.1.17 footnote E
(16–39)
5 (2016–2017) 357 97.3
(92.6–99.0)
3.0
(2.5–3.6)
0.93
(0.80–1.1)
2.6
(1.9–3.4)
11Table 14.1.17 footnote E
(6.6–16)
15Table 14.1.17 footnote E
(9.6–21)
6 (2018–2019) 340 97.4
(91.3–99.3)
2.2
(1.7–3.0)
0.66Table 14.1.17 footnote E
(0.31–1.0)
2.1
(1.6–2.7)
7.4Table 14.1.17 footnote E
(3.9–11)
12
(7.6–16)
60–79 years
1 (2007–2009)Table 14.1.17 footnote b
2 (2009–2011) 289 100 6.0
(5.2–7.0)
1.9
(1.6–2.3)
5.8
(4.5–7.1)
24
(17–31)
27Table 14.1.17 footnote E
(9.5–44)
5 (2016–2017) 351 96.2
(92.9–98.0)
3.2
(2.6–3.9)
0.93
(0.74–1.1)
2.9
(2.4–3.5)
13
(9.0–18)
18
(16–21)
6 (2018–2019) 338 99.3
(95.4–99.9)
2.7
(2.1–3.4)
0.75
(0.63–0.88)
2.4
(1.6–3.2)
11Table 14.1.17 footnote E
(<LOD–19)
18Table 14.1.17 footnote E
(5.2–30)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.18: Mono[2-(carboxymethyl)hexyl]phthalate (MCMHP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.18 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2705 96.5
(93.9–98.0)
1.8
(1.5–2.1)
0.47
(0.34–0.61)
1.8
(1.5–2.2)
6.1
(4.4–7.7)
8.4
(6.5–10)
6 (2018–2019) 2512 94.4
(91.8–96.2)
1.6
(1.5–1.8)
0.43
(0.37–0.48)
1.8
(1.6–2.0)
5.2
(4.6–5.8)
7.3
(6.2–8.5)
Males, 3–79 years
5 (2016–2017) 1348 97.2
(93.8–98.7)
1.8
(1.5–2.2)
0.50Table 14.1.18 footnote E
(0.27–0.72)
1.8
(1.5–2.2)
6.3
(4.1–8.6)
8.4
(5.8–11)
6 (2018–2019) 1247 94.3
(90.6–96.6)
1.8
(1.6–2.0)
0.51
(0.39–0.64)
2.0
(1.8–2.2)
5.6
(4.2–7.1)
8.5
(6.6–10)
Females, 3–79 years
5 (2016–2017) 1357 95.8
(92.0–97.8)
1.7
(1.4–2.2)
0.46Table 14.1.18 footnote E
(0.28–0.65)
1.9
(1.5–2.3)
5.9
(4.4–7.3)
8.0
(6.2–9.8)
6 (2018–2019) 1265 94.6
(91.1–96.7)
1.5
(1.4–1.6)
0.40
(0.32–0.47)
1.6
(1.3–1.9)
4.9
(4.2–5.6)
6.6
(5.8–7.3)
3–5 years
5 (2016–2017) 553 99.5
(97.8–99.9)
3.3
(2.5–4.4)
0.97
(0.75–1.2)
3.3Table 14.1.18 footnote E
(2.1–4.5)
10
(8.4–12)
14
(11–17)
6 (2018–2019) 511 99.6
(95.2–100)
2.9
(2.4–3.4)
0.99
(0.82–1.2)
2.7
(2.0–3.3)
9.6
(6.7–12)
13
(9.7–17)
6–11 years
5 (2016–2017) 537 98.8
(96.1–99.6)
3.1
(2.7–3.6)
0.99
(0.76–1.2)
3.1
(2.5–3.7)
8.8
(6.2–11)
13Table 14.1.18 footnote E
(5.9–19)
6 (2018–2019) 496 97.3
(86.4–99.5)
2.6
(2.0–3.3)
0.69Table 14.1.18 footnote E
(0.32–1.1)
2.6
(2.0–3.3)
7.6
(6.1–9.1)
9.7
(8.2–11)
12–19 years
5 (2016–2017) 537 97.4
(95.4–98.5)
1.9
(1.7–2.2)
0.60
(0.40–0.80)
2.2
(2.0–2.3)
5.1
(4.3–5.9)
7.3
(5.5–9.2)
6 (2018–2019) 499 95.3
(87.7–98.3)
1.8
(1.4–2.3)
0.57Table 14.1.18 footnote E
(0.28–0.86)
1.8
(1.3–2.3)
5.3
(3.8–6.8)
7.5Table 14.1.18 footnote E
(2.7–12)
20–39 years
5 (2016–2017) 369 95.8
(88.0–98.6)
1.5
(1.1–2.0)
0.29Table 14.1.18 footnote E
(<LOD–0.49)
1.6
(1.1–2.1)
5.5Table 14.1.18 footnote E
(3.1–8.0)
8.5Table 14.1.18 footnote E
(4.7–12)
6 (2018–2019) 326 92.2
(87.8–95.2)
1.6
(1.4–1.9)
0.39Table 14.1.18 footnote E
(<LOD–0.57)
1.9
(1.5–2.3)
5.1
(3.7–6.5)
6.8Table 14.1.18 footnote E
(4.1–9.5)
40–59 years
5 (2016–2017) 358 96.4
(90.4–98.7)
1.7
(1.3–2.1)
0.50
(0.33–0.66)
1.7
(1.3–2.2)
5.2Table 14.1.18 footnote E
(2.8–7.5)
7.4
(4.8–10)
6 (2018–2019) 342 92.3
(85.1–96.2)
1.3
(1.1–1.5)
0.36
(<LOD–0.48)
1.4
(1.0–1.8)
3.9
(3.4–4.5)
4.8
(3.9–5.7)
60–79 years
5 (2016–2017) 351 95.8
(92.5–97.7)
1.7
(1.5–2.0)
0.56
(0.42–0.70)
1.8
(1.4–2.1)
5.1
(3.3–6.9)
7.2
(6.1–8.2)
6 (2018–2019) 338 98.2
(95.5–99.3)
1.7
(1.5–1.9)
0.48
(0.35–0.62)
1.6
(1.3–2.0)
5.3
(4.4–6.3)
7.6
(6.1–9.0)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LOD for cycles 5 and 6 is 0.27 μg/L.

Table 14.1.19: Mono[2-(carboxymethyl)hexyl] phthalate (MCMHP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.19 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2673 96.5
(93.9–98.0)
1.7
(1.5–1.9)
0.71
(0.61–0.81)
1.6
(1.4–1.8)
4.4
(3.8–5.0)
6.5
(4.8–8.2)
6 (2018–2019) 2511 94.4
(91.8–96.2)
1.8
(1.6–1.9)
0.74
(0.66–0.83)
1.7
(1.5–1.8)
4.8
(4.3–5.3)
6.4
(5.4–7.5)
Males, 3–79 years
5 (2016–2017) 1333 97.2
(93.8–98.7)
1.5
(1.4–1.7)
0.68
(0.59–0.77)
1.4
(1.2–1.5)
3.9
(3.5–4.3)
5.9
(4.5–7.3)
6 (2018–2019) 1246 94.3
(90.6–96.6)
1.7
(1.5–1.9)
0.72
(0.61–0.84)
1.5
(1.3–1.7)
4.6
(3.4–5.7)
5.6Table 14.1.19 footnote E
(3.4–7.8)
Females, 3–79 years
5 (2016–2017) 1340 95.8
(92.0–97.8)
1.9
(1.6–2.3)
0.79
(0.56–1.0)
1.8
(1.5–2.2)
4.8
(4.0–5.6)
6.6
(4.4–8.9)
6 (2018–2019) 1265 94.6
(91.1–96.7)
1.9
(1.7–2.1)
0.75
(0.65–0.86)
1.8
(1.6–2.0)
4.8
(4.2–5.5)
6.8
(5.6–8.1)
3–5 years
5 (2016–2017) 542 99.5
(97.8–99.9)
5.8
(4.9–6.9)
2.2Table 14.1.19 footnote E
(1.3–3.1)
5.6
(4.4–6.9)
13
(12–15)
19
(12–25)
6 (2018–2019) 510 99.6
(95.2–100)
4.7
(3.9–5.7)
2.2
(1.6–2.9)
4.3
(3.4–5.3)
11
(7.7–15)
15
(13–18)
6–11 years
5 (2016–2017) 529 98.8
(96.1–99.6)
3.6
(3.1–4.2)
1.5
(1.3–1.8)
3.3
(2.9–3.7)
9.4
(6.3–13)
12Table 14.1.19 footnote E
(7.5–17)
6 (2018–2019) 496 97.3
(86.4–99.5)
3.1
(2.7–3.6)
1.3
(0.87–1.8)
3.1
(2.5–3.8)
6.5
(4.8–8.2)
9.5
(7.8–11)
12–19 years
5 (2016–2017) 530 97.4
(95.4–98.5)
1.5
(1.3–1.7)
0.76
(0.67–0.85)
1.4
(1.2–1.6)
2.9
(2.4–3.4)
3.6Table 14.1.19 footnote E
(2.0–5.1)
6 (2018–2019) 499 95.3
(87.7–98.3)
1.5
(1.3–1.7)
0.73
(0.64–0.83)
1.4
(1.1–1.7)
2.8Table 14.1.19 footnote E
(1.6–3.9)
4.2Table 14.1.19 footnote E
(2.5–5.8)
20–39 years
5 (2016–2017) 365 95.8
(88.0–98.6)
1.4
(1.2–1.5)
0.65
(<LOD–0.74)
1.1
(0.89–1.3)
3.7
(2.7–4.6)
4.3Table 14.1.19 footnote E
(2.2–6.4)
6 (2018–2019) 326 92.2
(87.8–95.2)
1.5
(1.3–1.8)
0.60Table 14.1.19 footnote E
(<LOD–0.82)
1.3
(0.85–1.7)
4.8
(3.4–6.2)
5.6Table 14.1.19 footnote E
(3.5–7.7)
40–59 years
5 (2016–2017) 357 96.4
(90.4–98.7)
1.5
(1.3–1.8)
0.59Table 14.1.19 footnote E
(0.30–0.88)
1.5
(1.2–1.8)
3.8
(2.9–4.7)
4.6
(3.8–5.5)
6 (2018–2019) 342 92.3
(85.1–96.2)
1.5
(1.4–1.7)
0.63
(<LOD–0.81)
1.5
(1.3–1.8)
3.4
(2.4–4.4)
4.8
(3.5–6.0)
60–79 years
5 (2016–2017) 350 95.8
(92.5–97.7)
2.0
(1.7–2.3)
0.85
(0.75–0.95)
1.8
(1.6–2.1)
4.6
(3.4–5.8)
5.6
(3.6–7.6)
6 (2018–2019) 338 98.2
(95.5–99.3)
2.0
(1.7–2.3)
0.90
(0.73–1.1)
1.8
(1.4–2.2)
4.4
(3.3–5.5)
6.1
(4.9–7.3)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.20: Mono(2-ethylhexyl) phthalate (MEHP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.20 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 2498 99.2
(98.0–99.7)
1.9
(1.7–2.1)
0.55
(0.44–0.66)
1.9
(1.6–2.1)
6.5
(5.4–7.6)
9.0
(7.8–10)
5 (2016–2017) 2691 98.5
(96.5–99.4)
1.0
(0.86–1.2)
0.26
(0.20–0.31)
0.96
(0.83–1.1)
3.9
(2.8–4.9)
5.8Table 14.1.20 footnote E
(3.6–8.0)
6 (2018–2019) 2471 99.3
(98.2–99.7)
0.92
(0.81–1.0)
0.22
(0.19–0.25)
0.94
(0.82–1.0)
3.5
(2.8–4.2)
5.1
(4.0–6.2)
Males, 3–79 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 1253 99.3
(97.5–99.8)
2.1
(1.8–2.5)
0.58
(0.39–0.76)
2.2
(1.8–2.5)
7.2
(5.2–9.2)
11
(7.6–14)
5 (2016–2017) 1342 98.4
(94.5–99.6)
1.0
(0.83–1.2)
0.27
(0.19–0.36)
0.99
(0.78–1.2)
3.8
(2.7–4.9)
5.4
(4.1–6.6)
6 (2018–2019) 1225 99.0
(96.3–99.7)
1.0
(0.90–1.2)
0.24
(0.17–0.30)
1.1
(0.92–1.2)
3.9
(3.4–4.5)
5.1
(3.6–6.6)
Females, 3–79 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 1245 99.1
(97.5–99.7)
1.7
(1.5–1.9)
0.55
(0.41–0.69)
1.7
(1.3–2.1)
5.3
(4.2–6.3)
7.9
(6.5–9.3)
5 (2016–2017) 1349 98.6
(96.5–99.4)
1.0
(0.80–1.3)
0.25
(0.17–0.33)
0.90
(0.74–1.1)
4.0Table 14.1.20 footnote E
(2.2–5.8)
7.4Table 14.1.20 footnote E
(4.3–11)
6 (2018–2019) 1246 99.6
(99.2–99.8)
0.82
(0.69–0.96)
0.21
(0.17–0.25)
0.81
(0.68–0.93)
3.1
(2.3–3.9)
4.8Table 14.1.20 footnote E
(2.8–6.7)
3–5 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 512 99.9
(99.4–100)
2.7
(2.4–3.2)
0.94
(0.77–1.1)
2.7
(2.3–3.1)
7.5
(5.8–9.3)
9.6Table 14.1.20 footnote E
(0.44–19)
5 (2016–2017) 553 99.8
(98.6–100)
1.5
(1.3–1.8)
0.36Table 14.1.20 footnote E
(0.21–0.52)
1.4
(1.0–1.7)
5.8
(4.7–7.0)
8.2
(6.9–9.5)
6 (2018–2019) 504 99.9
(99.4–100)
1.5
(1.2–1.8)
0.44
(0.35–0.53)
1.4
(1.1–1.7)
5.2
(3.6–6.7)
7.8Table 14.1.20 footnote E
(3.9–12)
6–11 years
1 (2007–2009) 1037 100 3.3
(2.9–3.8)
0.86
(0.70–1.0)
3.3
(2.7–3.8)
12
(10–13)
18
(14–21)
2 (2009–2011) 508 100 2.7
(2.3–3.1)
0.85Table 14.1.20 footnote E
(0.53–1.2)
2.5
(2.1–2.9)
8.1Table 14.1.20 footnote E
(5.2–11)
11
(8.3–14)
5 (2016–2017) 534 99.9
(98.8–100)
1.4
(1.2–1.6)
0.35
(0.27–0.43)
1.4
(1.1–1.7)
5.1
(3.7–6.4)
5.8
(4.8–6.8)
6 (2018–2019) 489 98.9
(95.9–99.7)
1.1
(0.94–1.4)
0.28Table 14.1.20 footnote E
(0.083–0.48)
1.2
(1.0–1.5)
3.4
(2.8–4.1)
4.3
(3.2–5.3)
12–19 years
1 (2007–2009) 991 99.4
(98.6–99.7)
3.5
(2.8–4.3)
0.79
(0.58–1.0)
3.2
(2.5–3.9)
14
(9.9–19)
23Table 14.1.20 footnote E
(6.6–40)
2 (2009–2011) 501 99.2
(96.9–99.8)
2.4
(2.0–2.8)
0.64
(0.52–0.76)
2.4
(2.0–2.8)
6.8
(5.0–8.6)
13Table 14.1.20 footnote E
(7.7–18)
5 (2016–2017) 530 97.8
(93.8–99.2)
1.1
(0.96–1.2)
0.32
(0.24–0.41)
1.0
(0.89–1.2)
3.8
(3.0–4.5)
5.4
(4.6–6.2)
6 (2018–2019) 489 99.4
(97.9–99.8)
1.1
(0.88–1.3)
0.25Table 14.1.20 footnote E
(0.14–0.36)
1.1
(0.89–1.3)
3.9
(2.9–4.9)
5.5
(3.6–7.4)
20–39 years
1 (2007–2009) 730 99.9
(99.3–100)
4.0
(3.5–4.5)
0.95
(0.72–1.2)
3.9
(3.2–4.6)
15
(11–19)
23Table 14.1.20 footnote E
(12–34)
2 (2009–2011) 349 99.5
(97.2–99.9)
1.9
(1.6–2.2)
0.44Table 14.1.20 footnote E
(0.19–0.70)
1.9
(1.5–2.4)
7.1
(5.3–8.8)
8.8Table 14.1.20 footnote E
(4.9–13)
5 (2016–2017) 371 99.6
(98.5–99.9)
1.2
(0.95–1.6)
0.28Table 14.1.20 footnote E
(<LOD–0.50)
1.0
(0.67–1.4)
5.0Table 14.1.20 footnote E
(1.3–8.7)
11Table 14.1.20 footnote E
(5.5–17)
6 (2018–2019) 324 99.9
(99.6–100)
1.2
(0.91–1.5)
0.28Table 14.1.20 footnote E
(0.17–0.40)
1.2
(0.81–1.5)
4.1Table 14.1.20 footnote E
(2.3–6.0)
5.8
(4.0–7.5)
40–59 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 349 98.9
(96.3–99.7)
1.9
(1.5–2.2)
0.63
(0.55–0.72)
1.9
(1.4–2.3)
5.4
(3.7–7.1)
9.0Table 14.1.20 footnote E
(4.8–13)
5 (2016–2017) 356 96.9
(89.5–99.1)
0.87
(0.66–1.1)
0.20
(0.13–0.27)
0.90
(0.72–1.1)
2.8Table 14.1.20 footnote E
(1.0–4.7)
5.2Table 14.1.20 footnote E
(1.7–8.7)
6 (2018–2019) 335 98.8
(94.8–99.7)
0.73
(0.62–0.87)
0.20
(0.15–0.25)
0.74
(0.58–0.89)
3.0
(2.2–3.9)
4.2
(3.0–5.4)
60–79 years
1 (2007–2009)Table 14.1.20 footnote b
2 (2009–2011) 279 98.8
(94.7–99.7)
1.3
(1.1–1.5)
0.44
(0.29–0.59)
1.2
(0.96–1.5)
4.7Table 14.1.20 footnote E
(2.8–6.5)
7.1Table 14.1.20 footnote E
(4.2–9.9)
5 (2016–2017) 347 98.8
(97.2–99.5)
0.78
(0.71–0.86)
0.25
(0.22–0.29)
0.73
(0.61–0.85)
2.3
(1.6–3.0)
3.7
(2.8–4.6)
6 (2018–2019) 330 99.2
(97.5–99.8)
0.71
(0.62–0.82)
0.20
(0.14–0.25)
0.75
(0.55–0.95)
2.2
(1.7–2.8)
3.6
(2.8–4.4)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.3, 0.09, 0.11 and 0.077 μg/L, respectively.

Table 14.1.21: Mono(2-ethylhexyl) phthalate (MEHP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.21 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 2489 99.2
(98.0–99.7)
1.8
(1.7–2.0)
0.64
(0.52–0.76)
1.7
(1.6–1.9)
5.5
(4.8–6.1)
8.7
(7.3–10)
5 (2016–2017) 2660 98.5
(96.5–99.4)
0.98
(0.86–1.1)
0.29
(0.24–0.34)
0.97
(0.85–1.1)
3.3
(2.6–4.1)
4.6
(3.0–6.2)
6 (2018–2019) 2470 99.3
(98.2–99.7)
0.99
(0.88–1.1)
0.31
(0.27–0.35)
0.95
(0.86–1.1)
3.4
(2.9–3.8)
4.5
(3.5–5.4)
Males, 3–79 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 1249 99.3
(97.5–99.8)
1.7
(1.5–2.0)
0.58
(0.45–0.70)
1.6
(1.3–1.8)
5.7
(4.7–6.7)
9.3
(6.6–12)
5 (2016–2017) 1328 98.4
(94.5–99.6)
0.87
(0.77–0.99)
0.28
(0.22–0.34)
0.83
(0.62–1.0)
2.8
(2.1–3.5)
3.9
(3.2–4.7)
6 (2018–2019) 1224 99.0
(96.3–99.7)
0.95
(0.85–1.1)
0.31
(0.26–0.36)
0.95
(0.84–1.1)
3.2
(2.5–3.9)
4.1
(3.3–5.0)
Females, 3–79 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 1240 99.1
(97.5–99.7)
1.9
(1.7–2.2)
0.75
(0.59–0.91)
1.8
(1.6–2.1)
5.2
(4.3–6.0)
7.9
(6.3–9.6)
5 (2016–2017) 1332 98.6
(96.5–99.4)
1.1
(0.91–1.3)
0.30
(0.21–0.39)
1.0
(0.86–1.2)
3.7
(2.6–4.8)
6.0Table 14.1.21 footnote E
(3.3–8.6)
6 (2018–2019) 1246 99.6
(99.2–99.8)
1.0
(0.86–1.2)
0.33
(0.24–0.41)
0.95
(0.81–1.1)
3.4
(2.6–4.1)
5.0Table 14.1.21 footnote E
(2.3–7.6)
3–5 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 511 99.9
(99.4–100)
4.7
(4.1–5.4)
1.8
(1.4–2.2)
4.4
(3.9–4.9)
12
(7.6–16)
19Table 14.1.21 footnote E
(12–26)
5 (2016–2017) 542 99.8
(98.6–100)
2.7
(2.2–3.2)
1.0
(0.91–1.1)
2.5
(2.0–2.9)
8.3
(7.0–9.6)
10Table 14.1.21 footnote E
(6.2–14)
6 (2018–2019) 503 99.9
(99.4–100)
2.4
(2.0–2.9)
0.98
(0.72–1.2)
2.1
(1.5–2.7)
6.7
(5.4–7.9)
10Table 14.1.21 footnote E
(5.8–15)
6–11 years
1 (2007–2009) 1034 100 5.1
(4.5–5.7)
1.9
(1.6–2.1)
4.8
(4.3–5.3)
16
(14–18)
22
(18–25)
2 (2009–2011) 506 100 3.1
(2.7–3.5)
1.1
(0.83–1.3)
2.8
(2.4–3.2)
8.8
(7.0–11)
11
(8.5–13)
5 (2016–2017) 526 99.9
(98.8–100)
1.6
(1.4–1.9)
0.59
(0.43–0.75)
1.4
(1.2–1.7)
4.6
(3.6–5.5)
5.7
(4.3–7.0)
6 (2018–2019) 489 98.9
(95.9–99.7)
1.4
(1.2–1.5)
0.47
(0.36–0.57)
1.4
(1.2–1.5)
3.4
(2.9–4.0)
4.3
(3.1–5.5)
12–19 years
1 (2007–2009) 989 99.4
(98.6–99.7)
3.0
(2.3–3.8)
0.82
(0.63–1.0)
2.8
(2.3–3.2)
10
(6.6–14)
19Table 14.1.21 footnote E
(0.21–38)
2 (2009–2011) 499 99.2
(96.9–99.8)
1.8
(1.6–2.0)
0.64
(0.56–0.72)
1.8
(1.6–2.0)
4.8
(3.4–6.2)
6.4Table 14.1.21 footnote E
(3.2–9.6)
5 (2016–2017) 524 97.8
(93.8–99.2)
0.82
(0.68–1.0)
0.24
(0.20–0.29)
0.82
(0.64–1.0)
2.2
(1.5–2.9)
3.1
(2.0–4.3)
6 (2018–2019) 489 99.4
(97.9–99.8)
0.88
(0.76–1.0)
0.27Table 14.1.21 footnote E
(0.14–0.39)
0.88
(0.79–0.96)
2.9
(2.4–3.4)
3.7
(3.1–4.4)
20–39 years
1 (2007–2009) 728 99.9
(99.3–100)
4.2
(3.7–4.8)
1.2Table 14.1.21 footnote E
(0.75–1.7)
3.7
(3.1–4.3)
14
(11–16)
21Table 14.1.21 footnote E
(13–30)
2 (2009–2011) 347 99.5
(97.2–99.9)
1.6
(1.3–1.9)
0.65Table 14.1.21 footnote E
(0.41–0.90)
1.4
(1.1–1.7)
4.8
(3.3–6.4)
6.6Table 14.1.21 footnote E
(3.4–9.9)
5 (2016–2017) 367 99.6
(98.5–99.9)
1.1
(0.88–1.4)
0.29
(<LOD–0.37)
0.96
(0.71–1.2)
3.6Table 14.1.21 footnote E
(0.55–6.6)
6.8Table 14.1.21 footnote E
(0.78–13)
6 (2018–2019) 324 99.9
(99.6–100)
1.1
(0.87–1.4)
0.32
(0.24–0.41)
0.97
(0.76–1.2)
3.4Table 14.1.21 footnote E
(1.9–4.8)
5.2Table 14.1.21 footnote E
(<LOD–12)
40–59 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 348 98.9
(96.3–99.7)
1.8
(1.6–2.1)
0.59Table 14.1.21 footnote E
(0.35–0.83)
1.8
(1.5–2.1)
4.8
(4.1–5.5)
7.6Table 14.1.21 footnote E
(4.0–11)
5 (2016–2017) 355 96.9
(89.5–99.1)
0.79
(0.66–0.96)
0.22Table 14.1.21 footnote E
(0.088–0.35)
0.81
(0.55–1.1)
2.5
(1.7–3.3)
3.5
(2.5–4.4)
6 (2018–2019) 335 98.8
(94.8–99.7)
0.86
(0.74–1.0)
0.28
(0.20–0.37)
0.85
(0.67–1.0)
3.4Table 14.1.21 footnote E
(1.9–4.8)
4.2
(3.4–5.0)
60–79 years
1 (2007–2009)Table 14.1.21 footnote b
2 (2009–2011) 278 98.8
(94.7–99.7)
1.5
(1.3–1.7)
0.50
(0.33–0.68)
1.4
(1.1–1.6)
4.6
(3.3–5.8)
7.2Table 14.1.21 footnote E
(4.4–10)
5 (2016–2017) 346 98.8
(97.2–99.5)
0.89
(0.80–1.0)
0.30
(0.26–0.34)
0.88
(0.76–1.0)
2.6
(2.0–3.3)
4.2
(2.9–5.5)
6 (2018–2019) 330 99.2
(97.5–99.8)
0.84
(0.73–0.96)
0.29
(0.22–0.36)
0.82
(0.69–0.94)
2.5
(1.8–3.2)
3.4
(2.5–4.2)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.22: Mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.22 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2705 99.5
(97.0–99.9)
6.1
(5.2–7.3)
1.8
(1.3–2.3)
6.3
(5.1–7.4)
21
(16–26)
30
(23–36)
6 (2018–2019) 2501 99.5
(98.3–99.8)
5.2
(4.7–5.7)
1.5
(1.3–1.6)
5.3
(4.7–5.9)
16
(13–19)
22
(18–26)
Males, 3–79 years
5 (2016–2017) 1346 99.1
(93.6–99.9)
6.0
(4.9–7.3)
1.7Table 14.1.22 footnote E
(1.0–2.4)
6.2
(5.1–7.3)
21
(15–27)
29Table 14.1.22 footnote E
(15–44)
6 (2018–2019) 1240 99.0
(96.6–99.7)
5.4
(4.7–6.3)
1.6
(1.1–2.0)
5.7
(4.9–6.5)
18
(14–21)
25
(19–31)
Females, 3–79 years
5 (2016–2017) 1359 99.9
(99.5–100)
6.3
(5.0–8.0)
1.9
(1.3–2.5)
6.4
(4.6–8.2)
21
(16–27)
30
(23–37)
6 (2018–2019) 1261 99.9
(99.7–100)
4.9
(4.4–5.4)
1.4
(1.3–1.6)
5.0
(4.1–5.8)
14
(12–15)
20
(17–24)
3–5 years
5 (2016–2017) 555 100 15
(12–19)
4.7Table 14.1.22 footnote E
(2.9–6.5)
15
(11–19)
49
(40–57)
57
(49–64)
6 (2018–2019) 509 100 12
(10–15)
4.4
(3.3–5.5)
11
(8.9–13)
38
(29–46)
51Table 14.1.22 footnote E
(32–70)
6–11 years
5 (2016–2017) 535 100 13
(11–15)
4.2
(2.7–5.7)
13
(11–14)
38
(26–49)
52Table 14.1.22 footnote E
(29–75)
6 (2018–2019) 496 100 9.8
(8.1–12)
3.3
(2.2–4.4)
10
(8.7–11)
28
(21–34)
34
(29–39)
12–19 years
5 (2016–2017) 536 99.9
(99.5–100)
6.9
(6.1–7.7)
2.0
(1.6–2.3)
7.8
(7.0–8.6)
19
(15–22)
23
(18–29)
6 (2018–2019) 497 98.8
(94.5–99.7)
6.3
(5.0–7.9)
2.0Table 14.1.22 footnote E
(1.2–2.8)
6.8
(5.3–8.3)
18
(15–22)
26Table 14.1.22 footnote E
(14–37)
20–39 years
5 (2016–2017) 373 100
(99.9–100)
5.6
(4.1–7.5)
1.5Table 14.1.22 footnote E
(0.56–2.4)
5.3Table 14.1.22 footnote E
(3.1–7.5)
22
(15–29)
24Table 14.1.22 footnote E
(4.5–44)
6 (2018–2019) 326 100
(99.9–100)
5.1
(4.2–6.2)
1.3Table 14.1.22 footnote E
(0.74–1.9)
5.7
(4.0–7.5)
14Table 14.1.22 footnote E
(8.2–19)
21
(14–28)
40–59 years
5 (2016–2017) 355 98.6
(89.5–99.8)
5.3
(4.1–6.8)
1.6
(1.0–2.1)
5.6
(4.4–6.8)
15Table 14.1.22 footnote E
(7.1–24)
24Table 14.1.22 footnote E
(14–35)
6 (2018–2019) 337 98.5
(93.5–99.7)
4.0
(3.5–4.4)
1.4
(1.2–1.6)
4.5
(4.2–4.8)
11
(9.1–12)
14
(11–17)
60–79 years
5 (2016–2017) 351 99.8
(98.6–100)
5.7
(5.1–6.3)
2.1
(1.8–2.4)
5.4
(4.4–6.5)
15
(12–18)
21
(13–28)
6 (2018–2019) 336 100 4.9
(4.2–5.6)
1.7
(1.2–2.2)
5.1
(3.9–6.4)
15
(11–18)
19
(16–22)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LOD for cycles 5 and 6 is 0.28 μg/L.

Table 14.1.23: Mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.23 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2673 99.5
(97.0–99.9)
5.9
(5.2–6.7)
2.4
(2.0–2.8)
5.4
(4.5–6.3)
17
(13–21)
26
(21–31)
6 (2018–2019) 2500 99.5
(98.3–99.8)
5.6
(5.0–6.3)
2.2
(2.0–2.4)
5.1
(4.3–5.9)
14
(12–16)
23
(18–29)
Males, 3–79 years
5 (2016–2017) 1331 99.1
(93.6–99.9)
5.2
(4.6–5.7)
2.1
(1.9–2.4)
4.6
(4.0–5.3)
14
(11–16)
22
(18–26)
6 (2018–2019) 1239 99.0
(96.6–99.7)
5.0
(4.4–5.7)
2.1
(1.8–2.4)
4.5
(3.7–5.3)
14
(12–16)
20
(15–26)
Females, 3–79 years
5 (2016–2017) 1342 99.9
(99.5–100)
6.8
(5.7–8.3)
2.9
(2.5–3.3)
6.6
(5.3–7.9)
20
(15–26)
28
(21–35)
6 (2018–2019) 1261 99.9
(99.7–100)
6.2
(5.4–7.1)
2.4
(2.0–2.9)
5.6
(4.5–6.8)
14
(11–18)
31Table 14.1.23 footnote E
(17–45)
3–5 years
5 (2016–2017) 544 100 26
(23–30)
10
(8.5–12)
25
(21–29)
61
(52–71)
76
(56–95)
6 (2018–2019) 508 100 20
(16–25)
8.7
(5.8–12)
18
(14–23)
47
(42–51)
64Table 14.1.23 footnote E
(34–95)
6–11 years
5 (2016–2017) 527 100 14
(12–17)
6.2
(4.9–7.6)
14
(12–15)
34Table 14.1.23 footnote E
(19–49)
54
(36–72)
6 (2018–2019) 496 100 12
(11–13)
6.0
(4.7–7.3)
11
(8.3–13)
24
(22–27)
33
(25–41)
12–19 years
5 (2016–2017) 529 99.9
(99.5–100)
5.2
(4.5–6.1)
2.1
(1.6–2.6)
5.4
(4.6–6.2)
11
(9.0–14)
15
(12–18)
6 (2018–2019) 497 98.8
(94.5–99.7)
5.1
(4.3–6.1)
2.2
(1.8–2.6)
4.9
(4.3–5.5)
14
(11–16)
16
(11–20)
20–39 years
5 (2016–2017) 369 100
(99.9–100)
5.0
(4.2–6.0)
2.2
(1.7–2.7)
3.7
(3.1–4.3)
18Table 14.1.23 footnote E
(7.6–28)
25Table 14.1.23 footnote E
(16–35)
6 (2018–2019) 326 100
(99.9–100)
4.9
(3.9–6.0)
2.0
(1.6–2.5)
4.1
(2.9–5.2)
13Table 14.1.23 footnote E
(8.0–18)
21Table 14.1.23 footnote E
(6.9–35)
40–59 years
5 (2016–2017) 354 98.6
(89.5–99.8)
4.8
(4.0–5.7)
2.1
(1.5–2.7)
4.8
(4.0–5.5)
10
(9.1–11)
11
(8.1–14)
6 (2018–2019) 337 98.5
(93.5–99.7)
4.7
(4.1–5.3)
2.2
(1.9–2.5)
4.5
(3.7–5.4)
9.6
(8.0–11)
13Table 14.1.23 footnote E
(8.3–18)
60–79 years
5 (2016–2017) 350 99.8
(98.6–100)
6.5
(5.8–7.4)
2.7
(2.2–3.2)
6.5
(5.3–7.7)
13
(10–16)
18
(13–23)
6 (2018–2019) 336 100 5.7
(5.0–6.5)
2.4
(2.0–2.9)
5.6
(4.8–6.4)
12
(10–14)
14Table 14.1.23 footnote E
(8.0–20)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.24: Mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.24 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 2561 100 7.4
(6.9–8.0)
2.3
(2.1–2.5)
7.4
(6.7–8.1)
23
(20–26)
34
(30–39)
5 (2016–2017) 2716 99.3
(97.1–99.8)
3.5
(3.0–4.0)
0.99
(0.83–1.2)
3.5
(2.9–4.1)
12
(9.3–14)
17
(14–21)
6 (2018–2019) 2524 99.4
(98.3–99.8)
3.1
(2.8–3.4)
0.86
(0.74–0.98)
3.1
(2.8–3.5)
9.8
(9.1–11)
13
(11–15)
Males, 3–79 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 1282 100 7.9
(6.8–9.1)
2.4
(2.0–2.8)
7.8
(7.0–8.7)
25
(20–31)
37Table 14.1.24 footnote E
(22–52)
5 (2016–2017) 1353 99.2
(93.7–99.9)
3.4
(2.8–4.1)
0.98
(0.70–1.3)
3.4
(2.8–4.1)
12
(8.5–16)
17Table 14.1.24 footnote E
(8.6–26)
6 (2018–2019) 1252 98.9
(96.6–99.7)
3.3
(2.9–3.7)
1.0
(0.80–1.2)
3.3
(3.0–3.7)
10
(8.7–11)
15
(12–17)
Females, 3–79 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 1279 100 7.0
(6.5–7.6)
2.3
(2.0–2.6)
6.7
(5.7–7.8)
22
(18–25)
29
(23–36)
5 (2016–2017) 1363 99.5
(95.1–99.9)
3.5
(2.9–4.3)
1.0
(0.86–1.1)
3.7
(2.8–4.5)
11
(8.5–14)
17
(13–22)
6 (2018–2019) 1272 99.8
(96.1–100)
2.9
(2.6–3.2)
0.79
(0.64–0.94)
2.9
(2.3–3.4)
9.7
(8.0–11)
12
(10–14)
3–5 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 523 100 17
(15–19)
6.0
(4.7–7.2)
17
(15–20)
46
(35–57)
67Table 14.1.24 footnote E
(38–95)
5 (2016–2017) 555 100 8.5
(6.9–10)
2.6
(1.8–3.5)
8.7
(6.6–11)
27
(23–30)
34
(26–42)
6 (2018–2019) 512 100 7.4
(6.1–8.9)
2.6
(2.1–3.1)
7.3
(5.8–8.9)
22Table 14.1.24 footnote E
(12–31)
34
(24–44)
6–11 years
1 (2007–2009) 1037 100 20
(18–22)
5.5
(4.7–6.4)
20
(17–22)
69
(59–78)
100
(84–120)
2 (2009–2011) 516 100 15
(13–18)
4.7
(3.4–6.1)
16
(12–20)
44
(28–60)
57
(50–65)
5 (2016–2017) 537 100 7.0
(6.0–8.2)
2.1
(1.5–2.8)
7.5
(6.2–8.8)
20Table 14.1.24 footnote E
(12–28)
31Table 14.1.24 footnote E
(19–43)
6 (2018–2019) 497 100 5.8
(4.7–7.0)
1.8Table 14.1.24 footnote E
(1.1–2.5)
6.1
(4.7–7.5)
16
(13–19)
19
(16–22)
12–19 years
1 (2007–2009) 991 100 18
(15–21)
4.5
(3.6–5.5)
17
(15–20)
61
(51–72)
99Table 14.1.24 footnote E
(43–150)
2 (2009–2011) 512 100 10
(8.6–12)
3.2Table 14.1.24 footnote E
(1.7–4.7)
9.9
(8.6–11)
30
(22–38)
44
(30–59)
5 (2016–2017) 538 99.9
(99.5–100)
4.0
(3.6–4.6)
1.2Table 14.1.24 footnote E
(0.73–1.6)
4.5
(4.1–4.9)
11
(9.3–13)
14
(9.6–19)
6 (2018–2019) 503 99.7
(97.5–100)
3.8
(3.1–4.6)
1.2E
(0.65–1.8)
4.1
(3.0–5.3)
11
(8.5–13)
14Table 14.1.24 footnote E
(5.8–21)
20–39 years
1 (2007–2009) 730 100 13
(11–15)
3.5
(2.6–4.4)
13
(10–15)
48
(34–62)
75Table 14.1.24 footnote E
(32–120)
2 (2009–2011) 359 100 6.6
(5.6–7.8)
2.4
(1.9–2.9)
6.7
(5.4–8.0)
19
(16–21)
24Table 14.1.24 footnote E
(14–35)
5 (2016–2017) 374 99.1
(91.7–99.9)
3.1
(2.4–4.1)
0.86Table 14.1.24 footnote E
(0.33–1.4)
3.0Table 14.1.24 footnote E
(1.9–4.2)
12
(8.2–15)
17Table 14.1.24 footnote E
(9.7–24)
6 (2018–2019) 331 99.8
(83.7–100)
3.2
(2.6–3.8)
0.94
(0.67–1.2)
3.4
(2.3–4.4)
9.3
(7.7–11)
11
(8.7–14)
40–59 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 360 100 6.6
(5.5–7.8)
2.3
(1.7–2.8)
6.2
(5.1–7.2)
19
(15–23)
26Table 14.1.24 footnote E
(16–36)
5 (2016–2017) 359 98.6
(89.7–99.8)
3.0
(2.3–3.8)
0.98
(0.62–1.3)
2.9
(2.2–3.5)
8.4Table 14.1.24 footnote E
(3.3–13)
13Table 14.1.24 footnote E
(7.1–20)
6 (2018–2019) 341 98.2
(94.3–99.5)
2.3
(2.0–2.6)
0.68
(0.50–0.87)
2.7
(2.3–3.1)
6.9
(5.5–8.3)
10
(6.8–14)
60–79 years
1 (2007–2009)Table 14.1.24 footnote b
2 (2009–2011) 291 100 6.0
(5.1–7.0)
2.0
(1.5–2.5)
6.0
(4.7–7.4)
17
(12–22)
23Table 14.1.24 footnote E
(4.9–41)
5 (2016–2017) 353 100 3.2
(2.8–3.6)
0.99
(0.83–1.2)
3.2
(2.8–3.6)
8.7
(7.7–9.8)
14Table 14.1.24 footnote E
(7.7–19)
6 (2018–2019) 340 100 2.8
(2.4–3.3)
1.0
(0.85–1.2)
2.8
(2.0–3.7)
8.2
(6.7–9.8)
11
(9.5–12)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.2, 0.1, 0.17 and 0.17 μg/L, respectively.

Table 14.1.25: Mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.25 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 2551 100 7.3
(6.9–7.7)
2.8
(2.5–3.1)
6.9
(6.3–7.5)
19
(17–21)
31
(27–34)
5 (2016–2017) 2684 99.3
(97.1–99.8)
3.4
(3.0–3.7)
1.3
(1.1–1.5)
3.1
(2.7–3.6)
9.5
(8.3–11)
15
(12–19)
6 (2018–2019) 2523 99.4
(98.3–99.8)
3.3
(3.0–3.7)
1.3
(1.1–1.4)
3.0
(2.5–3.4)
9.3
(7.7–11)
14
(10–18)
Males, 3–79 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 1278 100 6.7
(6.0–7.4)
2.6
(2.1–3.1)
6.1
(5.3–7.0)
20
(14–26)
32
(26–37)
5 (2016–2017) 1338 99.2
(93.7–99.9)
3.0
(2.7–3.3)
1.1
(1.0–1.3)
2.5
(2.2–2.8)
8.1
(6.9–9.4)
13
(9.7–16)
6 (2018–2019) 1251 98.9
(96.6–99.7)
3.0
(2.7–3.5)
1.1
(0.98–1.3)
2.7
(2.4–2.9)
8.9
(7.2–11)
13
(8.3–17)
Females, 3–79 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 1273 100 8.0
(7.3–8.8)
3.2
(2.5–3.8)
7.8
(6.8–8.7)
19
(17–21)
26
(20–32)
5 (2016–2017) 1346 99.5
(95.1–99.9)
3.8
(3.3–4.5)
1.4
(1.3–1.6)
3.7
(2.9–4.5)
10
(7.0–13)
17
(12–22)
6 (2018–2019) 1272 99.8
(96.1–100)
3.6
(3.1–4.2)
1.4
(1.3–1.6)
3.3
(2.6–4.0)
10
(7.6–12)
17Table 14.1.25 footnote E
(10–24)
3–5 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 522 100 30
(27–33)
13
(11–15)
28
(25–31)
71
(58–85)
90
(58–120)
5 (2016–2017) 544 100 15
(13–17)
6.2
(4.4–8.0)
14
(12–15)
35
(31–39)
43
(28–58)
6 (2018–2019) 511 100 12
(10–15)
5.7
(3.9–7.6)
10
(7.8–13)
27
(18–36)
40
(26–54)
6–11 years
1 (2007–2009) 1034 100 30
(27–34)
12
(9.7–14)
28
(24–31)
84
(74–94)
120
(95–140)
2 (2009–2011) 514 100 17
(16–19)
7.7
(6.5–8.8)
17
(15–18)
45
(35–56)
52
(40–65)
5 (2016–2017) 529 100 8.2
(7.0–9.6)
3.4
(2.8–4.0)
8.0
(7.1–9.0)
19
(12–26)
31
(20–41)
6 (2018–2019) 497 100 6.9
(6.2–7.6)
3.1
(2.7–3.4)
6.7
(5.7–7.8)
14
(12–16)
19
(16–22)
12–19 years
1 (2007–2009) 989 100 15
(13–18)
5.5
(4.5–6.4)
13
(11–15)
45
(31–60)
76Table 14.1.25 footnote E
(19–130)
2 (2009–2011) 510 100 7.8
(6.9–8.9)
3.2
(2.8–3.7)
7.6
(6.5–8.8)
17
(13–21)
25Table 14.1.25 footnote E
(14–35)
5 (2016–2017) 531 99.9
(99.5–100)
3.1
(2.6–3.7)
1.3
(1.1–1.5)
3.1
(2.3–3.8)
6.7
(4.9–8.4)
9.4
(7.7–11)
6 (2018–2019) 503 99.7
(97.5–100)
3.1
(2.7–3.6)
1.3
(1.1–1.6)
3.0
(2.5–3.5)
7.3
(6.3–8.3)
9.2
(6.7–12)
20–39 years
1 (2007–2009) 728 100 14
(12–16)
5.2
(4.3–6.1)
12
(10–13)
46
(33–59)
84
(56–110)
2 (2009–2011) 357 100 5.6
(4.8–6.6)
2.2
(1.6–2.7)
4.9
(3.9–5.9)
13Table 14.1.25 footnote E
(7.4–19)
19
(14–25)
5 (2016–2017) 370 99.1
(91.7–99.9)
2.8
(2.4–3.3)
1.1
(0.80–1.4)
2.4
(2.1–2.6)
8.5Table 14.1.25 footnote E
(2.9–14)
14Table 14.1.25 footnote E
(6.5–22)
6 (2018–2019) 331 99.8
(83.7–100)
3.0
(2.4–3.7)
1.2
(0.86–1.5)
2.7
(2.2–3.2)
8.3Table 14.1.25 footnote E
(4.4–12)
15Table 14.1.25 footnote E
(5.3–24)
40–59 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 358 100 6.6
(5.9–7.4)
2.8
(2.3–3.3)
6.6
(5.8–7.5)
14
(12–17)
21Table 14.1.25 footnote E
(13–29)
5 (2016–2017) 358 98.6
(89.7–99.8)
2.7
(2.4–3.2)
1.1
(0.78–1.5)
2.7
(2.4–3.0)
5.8
(4.4–7.3)
7.6
(5.0–10)
6 (2018–2019) 341 98.2
(94.3–99.5)
2.7
(2.4–3.1)
1.1
(0.78–1.4)
2.6
(2.2–3.0)
6.9
(5.2–8.7)
10
(6.9–14)
60–79 years
1 (2007–2009)Table 14.1.25 footnote b
2 (2009–2011) 290 100 6.9
(6.3–7.6)
3.1
(2.5–3.7)
7.0
(6.3–7.7)
14
(11–16)
18
(11–24)
5 (2016–2017) 352 100 3.6
(3.3–4.1)
1.6
(1.3–1.8)
3.6
(3.1–4.1)
7.5
(6.2–8.7)
10
(6.6–14)
6 (2018–2019) 340 100 3.3
(2.9–3.9)
1.3
(1.1–1.6)
3.3
(2.7–4.0)
6.9
(5.4–8.3)
10
(6.9–14)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.26: Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.26 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 2561 99.5
(97.5–99.9)
13
(12–14)
3.9
(3.4–4.4)
12
(12–13)
39
(34–44)
59
(48–70)
5 (2016–2017) 2716 99.5
(97.0–99.9)
5.2
(4.4–6.1)
1.5
(1.1–1.8)
5.3
(4.3–6.3)
17
(12–21)
26
(20–31)
6 (2018–2019) 2529 100
(99.8–100)
4.7
(4.2–5.1)
1.3
(1.1–1.4)
4.8
(4.3–5.4)
14
(13–15)
20
(17–23)
Males, 3–79 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 1282 99.2
(94.3–99.9)
14
(12–16)
4.2
(3.1–5.2)
13
(12–15)
43
(31–54)
69
(53–84)
5 (2016–2017) 1353 99.2
(93.7–99.9)
5.1
(4.3–6.2)
1.4
(0.91–1.8)
5.3
(4.2–6.3)
17
(12–21)
26
(20–32)
6 (2018–2019) 1254 100 5.1
(4.6–5.8)
1.4
(1.0–1.8)
5.3
(4.6–5.9)
15
(12–18)
24
(21–27)
Females, 3–79 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 1279 99.9
(98.6–100)
12
(11–12)
3.8
(3.2–4.4)
11
(9.4–13)
35
(31–40)
47
(39–56)
5 (2016–2017) 1363 99.9
(99.4–100)
5.2
(4.3–6.4)
1.5
(1.1–2.0)
5.5
(3.9–7.0)
17
(11–22)
24
(18–31)
6 (2018–2019) 1275 99.9
(99.7–100)
4.2
(3.8–4.7)
1.1
(0.85–1.3)
4.3
(3.5–5.0)
14
(11–16)
17
(15–19)
3–5 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 523 100 26
(23–30)
8.6
(6.4–11)
25
(21–30)
69
(53–86)
99Table 14.1.26 footnote E
(59–140)
5 (2016–2017) 555 100 12
(9.5–14)
3.6
(2.7–4.5)
11
(8.5–14)
36
(33–39)
44
(33–55)
6 (2018–2019) 512 100 9.9
(8.2–12)
3.3
(2.8–3.8)
10
(8.4–12)
30Table 14.1.26 footnote E
(16–44)
47
(33–61)
6–11 years
1 (2007–2009) 1037 100 31
(28–35)
8.8
(7.6–10)
31
(27–35)
100
(90–120)
180
(130–230)
2 (2009–2011) 516 100 24
(20–27)
7.0
(5.4–8.7)
24
(19–29)
71
(52–90)
97
(73–120)
5 (2016–2017) 537 100 9.7
(8.3–11)
3.1Table 14.1.26 footnote E
(1.9–4.4)
9.9
(8.2–12)
29
(19–39)
44Table 14.1.26 footnote E
(25–63)
6 (2018–2019) 497 100 8.0
(6.5–9.8)
2.3Table 14.1.26 footnote E
(0.92–3.6)
8.0
(5.7–10)
23
(19–26)
26
(18–33)
12–19 years
1 (2007–2009) 991 100 29
(24–34)
7.5
(5.8–9.3)
29
(25–32)
99
(78–120)
160Table 14.1.26 footnote E
(64–260)
2 (2009–2011) 512 100 16
(14–20)
4.6Table 14.1.26 footnote E
(2.4–6.8)
16
(13–20)
47
(36–58)
68
(49–87)
5 (2016–2017) 538 100 5.9
(5.3–6.6)
2.1
(1.5–2.8)
6.6
(5.8–7.5)
15
(10–20)
23
(17–29)
6 (2018–2019) 504 99.8
(97.9–100)
5.4
(4.5–6.6)
1.7Table 14.1.26 footnote E
(0.94–2.5)
5.8
(4.5–7.2)
15
(12–19)
22Table 14.1.26 footnote E
(13–32)
20–39 years
1 (2007–2009) 730 100 22
(19–26)
5.7
(4.5–6.9)
21
(16–26)
90
(67–110)
150Table 14.1.26 footnote E
(83–220)
2 (2009–2011) 359 98.6
(90.7–99.8)
11
(9.1–13)
3.8
(3.0–4.6)
12
(10–13)
30
(23–37)
40Table 14.1.26 footnote E
(20–60)
5 (2016–2017) 374 100 4.7
(3.5–6.3)
1.2Table 14.1.26 footnote E
(0.50–2.0)
4.8Table 14.1.26 footnote E
(2.6–7.0)
16Table 14.1.26 footnote E
(6.4–25)
25
(16–34)
6 (2018–2019) 332 100
(99.9–100)
4.9
(4.1–5.8)
1.3
(0.93–1.7)
5.3
(3.9–6.7)
14
(11–16)
19Table 14.1.26 footnote E
(12–26)
40–59 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 360 99.8
(97.8–100)
12
(9.7–14)
4.1Table 14.1.26 footnote E
(2.6–5.5)
11
(8.7–13)
35
(28–41)
44Table 14.1.26 footnote E
(21–67)
5 (2016–2017) 359 98.6
(89.7–99.8)
4.6
(3.6–5.8)
1.5Table 14.1.26 footnote E
(0.91–2.1)
4.7
(3.5–5.9)
14Table 14.1.26 footnote E
(8.7–19)
19
(14–25)
6 (2018–2019) 342 100 3.6
(3.3–4.0)
1.0
(0.93–1.2)
4.0
(3.1–4.8)
11
(7.9–13)
15
(11–19)
60–79 years
1 (2007–2009)Table 14.1.26 footnote b
2 (2009–2011) 291 100 10
(8.8–12)
3.4
(2.5–4.3)
10
(7.4–13)
28Table 14.1.26 footnote E
(17–38)
44Table 14.1.26 footnote E
(23–66)
5 (2016–2017) 353 99.8
(98.6–100)
4.7
(4.2–5.4)
1.5
(1.2–1.8)
4.8
(4.0–5.5)
12
(9.7–15)
18Table 14.1.26 footnote E
(7.9–29)
6 (2018–2019) 342 100 4.3
(3.7–5.0)
1.5
(1.1–1.9)
4.3
(3.1–5.5)
13
(10–15)
16Table 14.1.26 footnote E
(8.5–23)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.4, 0.5, 0.22 and 0.22 μg/L, respectively.

Table 14.1.27: Mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.27 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 2551 99.5
(97.5–99.9)
12
(12–13)
5.0
(4.5–5.4)
12
(11–12)
32
(28–35)
51
(44–59)
5 (2016–2017) 2684 99.5
(97.0–99.9)
5.0
(4.5–5.6)
2.0
(1.7–2.4)
4.6
(4.1–5.2)
13
(11–15)
20
(16–23)
6 (2018–2019) 2528 100
(99.8–100)
5.1
(4.5–5.7)
2.0
(1.8–2.1)
4.6
(4.0–5.2)
14
(11–16)
23
(16–30)
Males, 3–79 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 1278 99.2
(94.3–99.9)
12
(10–13)
4.3
(3.4–5.2)
10
(9.3–11)
33
(24–43)
58
(45–72)
5 (2016–2017) 1338 99.2
(93.7–99.9)
4.4
(4.0–4.9)
1.8
(1.5–2.1)
3.9
(3.4–4.4)
12
(10–13)
19
(14–25)
6 (2018–2019) 1253 100 4.8
(4.3–5.4)
1.9
(1.7–2.0)
4.3
(3.9–4.7)
14
(11–17)
22
(15–30)
Females, 3–79 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 1273 99.9
(98.6–100)
13
(12–14)
5.4
(4.8–5.9)
13
(11–14)
30
(26–35)
43
(34–51)
5 (2016–2017) 1346 99.9
(99.4–100)
5.7
(4.9–6.7)
2.4
(2.0–2.7)
5.5
(4.8–6.2)
15
(10–19)
20Table 14.1.27 footnote E
(12–28)
6 (2018–2019) 1275 99.9
(99.7–100)
5.4
(4.7–6.2)
2.3
(1.9–2.6)
4.9
(4.1–5.7)
14
(11–18)
24Table 14.1.27 footnote E
(12–36)
3–5 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 522 100 46
(41–51)
20
(17–23)
42
(37–46)
110
(89–120)
130Table 14.1.27 footnote E
(67–190)
5 (2016–2017) 544 100 20
(18–23)
8.5
(6.2–11)
19
(16–22)
49
(44–54)
62
(43–81)
6 (2018–2019) 511 100 16
(13–20)
7.5
(5.4–9.6)
14
(10–19)
38Table 14.1.27 footnote E
(24–53)
64
(44–84)
6–11 years
1 (2007–2009) 1034 100 48
(44–53)
19
(16–22)
44
(39–48)
130
(110–150)
190
(150–240)
2 (2009–2011) 514 100 27
(24–30)
11
(9.6–13)
24
(22–27)
70
(56–83)
90
(68–110)
5 (2016–2017) 529 100 11
(9.5–13)
4.8
(3.5–6.0)
10
(8.9–12)
29
(19–40)
43
(30–56)
6 (2018–2019) 497 100 9.6
(8.6–11)
4.3
(3.8–4.7)
9.8
(8.6–11)
19
(16–22)
26
(19–34)
12–19 years
1 (2007–2009) 989 100 25
(21–29)
9.0
(7.9–10)
22
(18–25)
76Table 14.1.27 footnote E
(44–110)
120Table 14.1.27 footnote E
(13–230)
2 (2009–2011) 510 100 12
(11–14)
5.0
(4.2–5.9)
12
(10–14)
27
(21–34)
37Table 14.1.27 footnote E
(15–60)
5 (2016–2017) 531 100 4.5
(3.9–5.3)
2.0
(1.6–2.4)
4.5
(3.6–5.5)
9.7
(7.2–12)
13
(8.1–17)
6 (2018–2019) 504 99.8
(97.9–100)
4.5
(4.0–5.1)
1.9
(1.6–2.2)
4.3
(3.6–5.0)
11
(8.8–13)
13
(11–16)
20–39 years
1 (2007–2009) 728 100 23
(21–26)
8.5
(6.7–10)
20
(18–22)
80
(53–110)
140
(93–190)
2 (2009–2011) 357 98.6
(90.7–99.8)
9.4
(7.9–11)
3.9
(2.6–5.2)
8.5
(6.2–11)
23
(18–27)
29Table 14.1.27 footnote E
(16–42)
5 (2016–2017) 370 100 4.3
(3.6–5.0)
1.8
(1.4–2.2)
3.9
(3.2–4.6)
12Table 14.1.27 footnote E
(4.1–19)
19Table 14.1.27 footnote E
(10–27)
6 (2018–2019) 332 100
(99.9–100)
4.6
(3.8–5.7)
1.8
(1.4–2.3)
4.1
(3.1–5.2)
12Table 14.1.27 footnote E
(6.6–18)
26Table 14.1.27 footnote E
(7.4–45)
40–59 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 358 99.8
(97.8–100)
12
(11–13)
5.1
(4.3–5.9)
11
(10–13)
27
(22–33)
36Table 14.1.27 footnote E
(18–54)
5 (2016–2017) 358 98.6
(89.7–99.8)
4.2
(3.6–4.9)
1.8
(1.3–2.3)
4.1
(3.8–4.5)
8.8
(6.5–11)
13
(8.7–17)
6 (2018–2019) 342 100 4.3
(3.9–4.8)
1.8
(1.5–2.1)
4.1
(3.6–4.6)
10
(7.2–13)
17Table 14.1.27 footnote E
(8.2–25)
60–79 years
1 (2007–2009)Table 14.1.27 footnote b
2 (2009–2011) 290 100 12
(11–13)
5.2
(4.2–6.1)
12
(11–14)
24
(21–27)
35
(27–42)
5 (2016–2017) 352 99.8
(98.6–100)
5.4
(4.9–6.1)
2.5
(2.1–2.8)
5.3
(4.7–5.8)
11
(9.0–13)
14Table 14.1.27 footnote E
(8.1–20)
6 (2018–2019) 342 100 5.1
(4.4–5.8)
2.1
(1.8–2.5)
5.0
(4.2–5.7)
11
(8.3–13)
15
(13–17)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.28: Mono-carboxy-n-heptyl phthalate (MCHpP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.28 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2213 0.50Table 14.1.28 footnote E
(0.10–2.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2115 0.30Table 14.1.28 footnote E
(0–1.7)
<LOD <LOD <LOD <LOD
Males, 3–79 years
5 (2016–2017) 1106 0.30Table 14.1.28 footnote E
(0–2.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1051 0.40Table 14.1.28 footnote E
(0.10–3.6)
<LOD <LOD <LOD <LOD
Females, 3–79 years
5 (2016–2017) 1107 0.70Table 14.1.28 footnote E
(0.10–4.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1064 0Table 14.1.28 footnote E
(0–0.30)
<LOD <LOD <LOD <LOD
3–5 years
5 (2016–2017) 441 0.20Table 14.1.28 footnote E
(0–2.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 430 0.10Table 14.1.28 footnote E
(0–2.4)
<LOD <LOD <LOD <LOD
6–11 years
5 (2016–2017) 425 0.30Table 14.1.28 footnote E
(0.10–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 412 0.50Table 14.1.28 footnote E
(0.10–2.6)
<LOD <LOD <LOD <LOD
12–19 years
5 (2016–2017) 433 0.30Table 14.1.28 footnote E
(0–2.8)
<LOD <LOD <LOD <LOD
6 (2018–2019) 412 0.30Table 14.1.28 footnote E
(0.10–1.2)
<LOD <LOD <LOD <LOD
20–39 years
5 (2016–2017) 308 0.50Table 14.1.28 footnote E
(0.10–3.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 275 0.60Table 14.1.28 footnote E
(0–11.1)
<LOD <LOD <LOD <LOD
40–59 years
5 (2016–2017) 303 0.10Table 14.1.28 footnote E
(0–0.70)
<LOD <LOD <LOD <LOD
6 (2018–2019) 294 0 <LOD <LOD <LOD <LOD
60–79 years
5 (2016–2017) 303 1.0Table 14.1.28 footnote E
(0.10–10.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 292 0.10Table 14.1.28 footnote E
(0–0.80)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LOD for cycles 5 and 6 is 0.083 μg/L.

Table 14.1.29: Mono-carboxy-n-heptyl phthalate (MCHpP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.29 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2184 0.50Table 14.1.29 footnote E
(0.10–2.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2115 0.30Table 14.1.29 footnote E
(0–1.7)
<LOD <LOD <LOD <LOD
Males, 3–79 years
5 (2016–2017) 1092 0.30Table 14.1.29 footnote E
(0–2.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1051 0.40Table 14.1.29 footnote E
(0.10–3.6)
<LOD <LOD <LOD <LOD
Females, 3–79 years
5 (2016–2017) 1092 0.70Table 14.1.29 footnote E
(0.10–4.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1064 0Table 14.1.29 footnote E
(0–0.30)
<LOD <LOD <LOD <LOD
3–5 years
5 (2016–2017) 433 0.20Table 14.1.29 footnote E
(0–2.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 430 0.10Table 14.1.29 footnote E
(0–2.4)
<LOD <LOD <LOD <LOD
6–11 years
5 (2016–2017) 417 0.30Table 14.1.29 footnote E
(0.10–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 412 0.50Table 14.1.29 footnote E
(0.10–2.6)
<LOD <LOD <LOD <LOD
12–19 years
5 (2016–2017) 426 0.30Table 14.1.29 footnote E
(0–2.8)
<LOD <LOD <LOD <LOD
6 (2018–2019) 412 0.30Table 14.1.29 footnote E
(0.10–1.2)
<LOD <LOD <LOD <LOD
20–39 years
5 (2016–2017) 304 0.50Table 14.1.29 footnote E
(0.10–3.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 275 0.60Table 14.1.29 footnote E
(0–11.1)
<LOD <LOD <LOD <LOD
40–59 years
5 (2016–2017) 302 0.10Table 14.1.29 footnote E
(0–0.70)
<LOD <LOD <LOD <LOD
6 (2018–2019) 294 0 <LOD <LOD <LOD <LOD
60–79 years
5 (2016–2017) 302 1.0Table 14.1.29 footnote E
(0.10–10.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 292 0.10Table 14.1.29 footnote E
(0–0.80)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.30: Mono-n-octyl phthalate (MOP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.30 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 2558 0.90Table 14.1.30 footnote E
(0.30–2.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 2715 0.70Table 14.1.30 footnote E
(0.20–2.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2528 0.60Table 14.1.30 footnote E
(0.20–1.7)
<LOD <LOD <LOD <LOD
Males, 3–79 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 1280 0.90Table 14.1.30 footnote E
(0.20–3.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1353 0.40Table 14.1.30 footnote E
(0.10–1.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1254 0.70Table 14.1.30 footnote E
(0.20–3.3)
<LOD <LOD <LOD <LOD
Females, 3–79 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 1278 0.90Table 14.1.30 footnote E
(0.30–2.4)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1362 0.90Table 14.1.30 footnote E
(0.20–4.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1274 0.50Table 14.1.30 footnote E
(0.20–1.4)
<LOD <LOD <LOD <LOD
3–5 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 523 2.3Table 14.1.30 footnote E
(1.4–3.6)
<LOD <LOD <LOD <LOD
5 (2016–2017) 554 0.90Table 14.1.30 footnote E
(0.40–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 512 2.5Table 14.1.30 footnote E
(0.50–12.4)
<LOD <LOD <LOD <LOD
6–11 years
1 (2007–2009) 1037 4.6Table 14.1.30 footnote E
(1.8–11.3)
<LOD <LOD <LOD <LOD
2 (2009–2011) 516 0.10Table 14.1.30 footnote E
(0–0.40)
<LOD <LOD <LOD <LOD
5 (2016–2017) 537 1.2Table 14.1.30 footnote E
(0.20–6.3)
<LOD <LOD <LOD <LOD
6 (2018–2019) 497 0.40Table 14.1.30 footnote E
(0.10–2.2)
<LOD <LOD <LOD <LOD
12–19 years
1 (2007–2009) 991 3.3Table 14.1.30 footnote E
(1.2–8.6)
<LOD <LOD <LOD <LOD
2 (2009–2011) 511 1.4Table 14.1.30 footnote E
(0.70–2.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 538 1.3Table 14.1.30 footnote E
(0.80–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 502 1.8Table 14.1.30 footnote E
(0.50–6.7)
<LOD <LOD <LOD <LOD
20–39 years
1 (2007–2009) 730 7.4Table 14.1.30 footnote E
(3.4–15.4)
<LOD <LOD <LOD <LOD
2 (2009–2011) 358 1.1Table 14.1.30 footnote E
(0.20–5.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 374 0.40Table 14.1.30 footnote E
(0–3.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 332 0.10Table 14.1.30 footnote E
(0–0.40)
<LOD <LOD <LOD <LOD
40–59 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 360 0.50Table 14.1.30 footnote E
(0.10–2.4)
<LOD <LOD <LOD <LOD
5 (2016–2017) 359 1.0Table 14.1.30 footnote E
(0.10–9.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 343 0 <LOD <LOD <LOD <LOD
60–79 years
1 (2007–2009)Table 14.1.30 footnote b
2 (2009–2011) 290 0.90Table 14.1.30 footnote E
(0.20–4.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 353 0 <LOD <LOD <LOD <LOD
6 (2018–2019) 342 1.5Table 14.1.30 footnote E
(0.30–7.2)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.6, 0.3, 0.16 and 0.16 μg/L, respectively.

Table 14.1.31: Mono-n-octyl phthalate (MOP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.31 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 2548 0.90Table 14.1.31 footnote E
(0.30–2.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 2683 0.70Table 14.1.31 footnote E
(0.20–2.1)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2527 0.60Table 14.1.31 footnote E
(0.20–1.7)
<LOD <LOD <LOD <LOD
Males, 3–79 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 1276 0.90Table 14.1.31 footnote E
(0.20–3.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1338 0.40Table 14.1.31 footnote E
(0.10–1.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1253 0.70Table 14.1.31 footnote E
(0.20–3.3)
<LOD <LOD <LOD <LOD
Females, 3–79 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 1272 0.90Table 14.1.31 footnote E
(0.30–2.4)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1345 0.90Table 14.1.31 footnote E
(0.20–4.5)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1274 0.50Table 14.1.31 footnote E
(0.20–1.4)
<LOD <LOD <LOD <LOD
3–5 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 522 2.3Table 14.1.31 footnote E
(1.4–3.6)
<LOD <LOD <LOD <LOD
5 (2016–2017) 543 0.90Table 14.1.31 footnote E
(0.40–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 511 2.5Table 14.1.31 footnote E
(0.50–12.4)
<LOD <LOD <LOD <LOD
6–11 years
1 (2007–2009) 1034 4.6Table 14.1.31 footnote E
(1.8–11.3)
<LOD <LOD <LOD <LOD
2 (2009–2011) 514 0.10Table 14.1.31 footnote E
(0–0.40)
<LOD <LOD <LOD <LOD
5 (2016–2017) 529 1.2Table 14.1.31 footnote E
(0.20–6.3)
<LOD <LOD <LOD <LOD
6 (2018–2019) 497 0.40Table 14.1.31 footnote E
(0.10–2.2)
<LOD <LOD <LOD <LOD
12–19 years
1 (2007–2009) 989 3.3Table 14.1.31 footnote E
(1.2–8.6)
<LOD <LOD <LOD <LOD
2 (2009–2011) 509 1.4Table 14.1.31 footnote E
(0.70–2.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 531 1.3Table 14.1.31 footnote E
(0.80–2.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 502 1.8Table 14.1.31 footnote E
(0.50–6.7)
<LOD <LOD <LOD <LOD
20–39 years
1 (2007–2009) 728 7.4Table 14.1.31 footnote E
(3.4–15.4)
<LOD <LOD <LOD <LOD
2 (2009–2011) 356 1.1Table 14.1.31 footnote E
(0.20–5.9)
<LOD <LOD <LOD <LOD
5 (2016–2017) 370 0.40Table 14.1.31 footnote E
(0–3.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 332 0.10Table 14.1.31 footnote E
(0–0.40)
<LOD <LOD <LOD <LOD
40–59 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 358 0.50Table 14.1.31 footnote E
(0.10–2.4)
<LOD <LOD <LOD <LOD
5 (2016–2017) 358 1.0Table 14.1.31 footnote E
(0.10–9.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 343 0 <LOD <LOD <LOD <LOD
60–79 years
1 (2007–2009)Table 14.1.31 footnote b
2 (2009–2011) 289 0.90Table 14.1.31 footnote E
(0.20–4.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 352 0 <LOD <LOD <LOD <LOD
6 (2018–2019) 342 1.5Table 14.1.31 footnote E
(0.30–7.2)
<LOD <LOD <LOD <LOD

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.32: Mono(carboxyisooctyl) phthalate (MCiOP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.32 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2713 84.2
(79.2–88.2)
0.97
(0.85–1.1)
<LOD 0.98
(0.84–1.1)
4.2
(3.1–5.3)
7.2
(4.8–9.7)
6 (2018–2019) 2528 87.4
(83.6–90.4)
0.78
(0.69–0.88)
<LOD 0.80
(0.66–0.95)
3.6
(2.9–4.3)
7.2
(5.2–9.1)
Males, 3–79 years
5 (2016–2017) 1350 83.2
(75.8–88.7)
0.96
(0.79–1.2)
<LOD 0.99
(0.83–1.2)
3.9
(2.8–5.1)
6.8
(5.8–7.8)
6 (2018–2019) 1255 89.5
(85.9–92.3)
0.90
(0.78–1.0)
<LOD 0.92
(0.78–1.1)
4.7
(3.3–6.2)
7.6
(5.2–10)
Females, 3–79 years
5 (2016–2017) 1363 85.1
(80.3–88.9)
0.99
(0.86–1.2)
<LOD 0.96
(0.81–1.1)
4.6Table 14.1.32 footnote E
(2.9–6.4)
9.4Table 14.1.32 footnote E
(<LOD–19)
6 (2018–2019) 1273 85.2
(78.7–90.0)
0.68
(0.57–0.80)
<LOD 0.68
(0.54–0.83)
2.9
(2.1–3.6)
4.9Table 14.1.32 footnote E
(1.7–8.0)
3–5 years
5 (2016–2017) 555 91.8
(84.4–95.9)
1.3
(1.0–1.7)
0.33Table 14.1.32 footnote E
(<LOD–0.48)
1.3Table 14.1.32 footnote E
(0.81–1.8)
5.6Table 14.1.32 footnote E
(2.2–8.9)
9.9Table 14.1.32 footnote E
(4.2–15)
6 (2018–2019) 512 94.8
(89.6–97.5)
1.1
(0.97–1.3)
0.32Table 14.1.32 footnote E
(0.18–0.46)
1.1
(0.98–1.2)
4.2
(3.2–5.2)
5.3Table 14.1.32 footnote E
(3.3–7.2)
6–11 years
5 (2016–2017) 537 91.9
(86.3–95.3)
1.3
(1.1–1.6)
0.36Table 14.1.32 footnote E
(<LOD–0.51)
1.4
(1.0–1.7)
4.6Table 14.1.32 footnote E
(2.4–6.7)
9.3Table 14.1.32 footnote E
(4.3–14)
6 (2018–2019) 497 91.2
(82.3–95.8)
1.1
(0.88–1.4)
0.22Table 14.1.32 footnote E
(<LOD–0.38)
1.1
(0.92–1.4)
5.2
(3.7–6.7)
6.7Table 14.1.32 footnote E
(1.5–12)
12–19 years
5 (2016–2017) 537 85.8
(81.2–89.5)
1.2
(0.97–1.4)
<LOD 1.2
(0.85–1.5)
5.1
(3.6–6.6)
9.9Table 14.1.32 footnote E
(<LOD–21)
6 (2018–2019) 502 90.7
(85.3–94.3)
0.92
(0.77–1.1)
0.14Table 14.1.32 footnote E
(<LOD–0.22)
1.0
(0.87–1.1)
4.7
(3.1–6.3)
7.0
(5.0–9.0)
20–39 years
5 (2016–2017) 373 82.8
(69.7–91.0)
0.95
(0.67–1.4)
<LOD 1.0Table 14.1.32 footnote E
(0.55–1.5)
3.7Table 14.1.32 footnote E
(2.1–5.4)
7.5Table 14.1.32 footnote E
(<LOD–18)
6 (2018–2019) 332 84.4
(73.1–91.5)
0.77
(0.62–0.95)
<LOD 0.78
(0.53–1.0)
4.7Table 14.1.32 footnote E
(2.2–7.2)
7.7Table 14.1.32 footnote E
(<LOD–16)
40–59 years
5 (2016–2017) 359 82.8
(76.5–87.7)
0.92
(0.77–1.1)
<LOD 0.95
(0.66–1.2)
5.3Table 14.1.32 footnote E
(2.9–7.6)
7.2Table 14.1.32 footnote E
(1.3–13)
6 (2018–2019) 343 87.9
(82.2–92.0)
0.69
(0.55–0.87)
<LOD 0.67
(0.43–0.91)
2.9
(2.4–3.5)
3.6Table 14.1.32 footnote E
(1.4–5.8)
60–79 years
5 (2016–2017) 352 83.5
(75.7–89.1)
0.86
(0.72–1.0)
<LOD 0.83
(0.70–0.96)
4.1Table 14.1.32 footnote E
(1.8–6.3)
6.6
(5.1–8.0)
6 (2018–2019) 342 87.0
(81.5–91.0)
0.74
(0.58–0.93)
<LOD 0.72
(0.58–0.85)
3.2
(2.3–4.0)
8.4Table 14.1.32 footnote E
(4.3–12)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 5 and 6 are 0.30 and 0.13 μg/L, respectively.

Table 14.1.33: Mono(carboxyisooctyl) phthalate (MCiOP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.33 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2681 84.2
(79.2–88.2)
0.94
(0.84–1.1)
<LOD 0.82
(0.73–0.91)
3.7
(3.1–4.3)
6.4
(5.5–7.4)
6 (2018–2019) 2527 87.4
(83.6–90.4)
0.85
(0.76–0.94)
<LOD 0.81
(0.72–0.91)
3.5
(2.7–4.3)
6.3
(4.9–7.6)
Males, 3–79 years
5 (2016–2017) 1335 83.2
(75.8–88.7)
0.82
(0.70–0.96)
<LOD 0.77
(0.63–0.91)
3.3
(2.4–4.3)
6.0
(4.7–7.4)
6 (2018–2019) 1254 89.5
(85.9–92.3)
0.84
(0.72–0.97)
<LOD 0.80
(0.62–0.99)
3.6
(2.4–4.7)
5.9Table 14.1.33 footnote E
(3.4–8.4)
Females, 3–79 years
5 (2016–2017) 1346 85.1
(80.3–88.9)
1.1
(0.95–1.2)
<LOD 0.92
(0.79–1.0)
4.0Table 14.1.33 footnote E
(2.2–5.8)
7.3Table 14.1.33 footnote E
(<LOD–12)
6 (2018–2019) 1273 85.2
(78.7–90.0)
0.86
(0.73–1.0)
<LOD 0.83
(0.68–0.97)
3.5Table 14.1.33 footnote E
(2.2–4.8)
6.4Table 14.1.33 footnote E
(3.9–8.9)
3–5 years
5 (2016–2017) 544 91.8
(84.4–95.9)
2.4
(2.0–2.8)
0.73
(<LOD–0.96)
2.2
(1.8–2.6)
8.1Table 14.1.33 footnote E
(4.3–12)
13Table 14.1.33 footnote E
(6.1–19)
6 (2018–2019) 511 94.8
(89.6–97.5)
1.8
(1.6–2.0)
0.58Table 14.1.33 footnote E
(0.31–0.86)
1.6
(1.3–1.9)
5.8
(4.5–7.0)
10Table 14.1.33 footnote E
(5.8–15)
6–11 years
5 (2016–2017) 529 91.9
(86.3–95.3)
1.6
(1.3–1.9)
0.51
(<LOD–0.63)
1.4
(1.2–1.6)
5.1
(3.5–6.7)
7.3Table 14.1.33 footnote E
(3.5–11)
6 (2018–2019) 497 91.2
(82.3–95.8)
1.3
(1.1–1.5)
0.43
(<LOD–0.56)
1.3
(1.0–1.5)
5.2Table 14.1.33 footnote E
(3.1–7.3)
6.2Table 14.1.33 footnote E
(<LOD–14)
12–19 years
5 (2016–2017) 530 85.8
(81.2–89.5)
0.90
(0.75–1.1)
<LOD 0.77
(0.66–0.89)
3.5Table 14.1.33 footnote E
(1.5–5.4)
8.2Table 14.1.33 footnote E
(<LOD–15)
6 (2018–2019) 502 90.7
(85.3–94.3)
0.76
(0.67–0.87)
0.24
(<LOD–0.30)
0.73
(0.60–0.86)
2.9
(2.0–3.8)
4.8Table 14.1.33 footnote E
(2.1–7.5)
20–39 years
5 (2016–2017) 369 82.8
(69.7–91.0)
0.85
(0.68–1.1)
<LOD 0.77
(0.61–0.94)
2.6Table 14.1.33 footnote E
(1.5–3.7)
4.9Table 14.1.33 footnote E
(<LOD–11)
6 (2018–2019) 332 84.4
(73.1–91.5)
0.73
(0.61–0.87)
<LOD 0.81
(0.65–0.96)
2.8Table 14.1.33 footnote E
(1.2–4.4)
5.3Table 14.1.33 footnote E
(<LOD–11)
40–59 years
5 (2016–2017) 358 82.8
(76.5–87.7)
0.84
(0.67–1.1)
<LOD 0.75
(0.63–0.88)
3.5Table 14.1.33 footnote E
(0.63–6.4)
6.5
(5.2–7.7)
6 (2018–2019) 343 87.9
(82.2–92.0)
0.82
(0.66–1.0)
<LOD 0.76
(0.51–1.0)
3.2Table 14.1.33 footnote E
(1.7–4.6)
6.3Table 14.1.33 footnote E
(3.1–9.6)
60–79 years
5 (2016–2017) 351 83.5
(75.7–89.1)
0.98
(0.83–1.2)
<LOD 0.83
(0.70–0.95)
4.0
(2.9–5.1)
5.2
(3.4–7.0)
6 (2018–2019) 342 87.0
(81.5–91.0)
0.87
(0.70–1.1)
<LOD 0.73
(0.59–0.87)
4.0Table 14.1.33 footnote E
(2.5–5.6)
6.3Table 14.1.33 footnote E
(3.4–9.1)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.34: Monoisononyl phthalate (MiNP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.34 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 2556 0.90Table 14.1.34 footnote E
(0.30–3.1)
<LOD <LOD <LOD <LOD
5 (2016–2017) 2716 41.9
(33.2–51.1)
<LOD <LOD 1.4Table 14.1.34 footnote E
(0.89–2.0)
3.5Table 14.1.34 footnote E
(1.5–5.4)
6 (2018–2019) 2503 51.3
(45.1–57.5)
<LOD 0.16
(<LOD–0.20)
0.99
(0.71–1.3)
2.1Table 14.1.34 footnote E
(0.96–3.3)
Males, 3–79 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 1280 1.5Table 14.1.34 footnote E
(0.40–6.0)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1353 44.8
(35.8–54.1)
<LOD <LOD 1.1
(0.81–1.3)
2.2Table 14.1.34 footnote E
(1.4–3.0)
6 (2018–2019) 1237 59.3
(52.7–65.6)
<LOD 0.21
(0.17–0.24)
1.0Table 14.1.34 footnote E
(0.48–1.6)
2.2Table 14.1.34 footnote E
(1.0–3.4)
Females, 3–79 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 1276 0.40Table 14.1.34 footnote E
(0.10–1.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1363 38.9
(29.8–48.9)
<LOD <LOD 1.8Table 14.1.34 footnote E
(<LOD–3.6)
4.0Table 14.1.34 footnote E
(1.2–6.8)
6 (2018–2019) 1266 43.4
(35.7–51.5)
<LOD <LOD 0.92Table 14.1.34 footnote E
(0.57–1.3)
1.8Table 14.1.34 footnote E
(<LOD–3.5)
3–5 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 522 0.40Table 14.1.34 footnote E
(0.10–1.2)
<LOD <LOD <LOD <LOD
5 (2016–2017) 555 49.1
(32.5–65.9)
<LOD <LOD 1.5
(1.0–2.0)
2.4Table 14.1.34 footnote E
(<LOD–6.5)
6 (2018–2019) 507 69.8
(59.9–78.2)
0.27
(0.22–0.33)
<LOD 0.21Table 14.1.34 footnote E
(<LOD–0.29)
0.94Table 14.1.34 footnote E
(0.43–1.4)
1.7Table 14.1.34 footnote E
(1.0–2.4)
6–11 years
1 (2007–2009) 1036 0.80Table 14.1.34 footnote E
(0.20–4.3)
<LOD <LOD <LOD <LOD
2 (2009–2011) 514 0.40Table 14.1.34 footnote E
(0.10–1.5)
<LOD <LOD <LOD <LOD
5 (2016–2017) 537 49.5
(38.9–60.2)
<LOD <LOD 1.2
(0.75–1.6)
2.0
(1.5–2.6)
6 (2018–2019) 494 61.0
(52.2–69.3)
<LOD 0.26
(0.18–0.33)
0.93
(0.60–1.3)
1.6Table 14.1.34 footnote E
(<LOD–3.9)
12–19 years
1 (2007–2009) 991 0.90Table 14.1.34 footnote E
(0.30–2.6)
<LOD <LOD <LOD <LOD
2 (2009–2011) 511 0.30Table 14.1.34 footnote E
(0.10–1.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 538 49.1
(38.1–60.2)
<LOD <LOD 1.5Table 14.1.34 footnote E
(0.70–2.3)
3.7Table 14.1.34 footnote E
(<LOD–8.7)
6 (2018–2019) 497 62.1
(51.4–71.6)
<LOD 0.22Table 14.1.34 footnote E
(<LOD–0.32)
1.2
(0.90–1.5)
1.5Table 14.1.34 footnote E
(0.46–2.5)
20–39 years
1 (2007–2009) 730 0.20Table 14.1.34 footnote E
(0–1.9)
<LOD <LOD <LOD <LOD
2 (2009–2011) 358 2.8Table 14.1.34 footnote E
(0.70–10.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 374 50.1
(33.9–66.3)
<LOD <LOD 2.5Table 14.1.34 footnote E
(0.40–4.6)
4.9Table 14.1.34 footnote E
(2.1–7.7)
6 (2018–2019) 330 56.7
(44.3–68.2)
<LOD 0.20
(0.15–0.25)
1.2Table 14.1.34 footnote E
(<LOD–2.6)
4.5Table 14.1.34 footnote E
(<LOD–12)
40–59 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 360 0.10Table 14.1.34 footnote E
(0–0.30)
<LOD <LOD <LOD <LOD
5 (2016–2017) 359 37.2
(29.2–45.9)
<LOD <LOD 1.2Table 14.1.34 footnote E
(0.71–1.8)
2.4Table 14.1.34 footnote E
(<LOD–11)
6 (2018–2019) 338 47.0
(37.9–56.2)
<LOD <LOD 0.72Table 14.1.34 footnote E
(0.28–1.2)
1.8Table 14.1.34 footnote E
(0.15–3.4)
60–79 years
1 (2007–2009)Table 14.1.34 footnote b
2 (2009–2011) 291 0.10Table 14.1.34 footnote E
(0–4.1)
<LOD <LOD <LOD <LOD
5 (2016–2017) 353 29.9
(20.8–40.9)
<LOD <LOD 0.94
(0.63–1.3)
1.5Table 14.1.34 footnote E
(0.75–2.3)
6 (2018–2019) 337 39.1
(31.3–47.4)
<LOD <LOD 0.73Table 14.1.34 footnote E
(0.24–1.2)
1.4Table 14.1.34 footnote E
(0.48–2.2)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 1, 2, 5 and 6 are 0.7, 0.4, 0.37 and 0.15 μg/L, respectively.

Table 14.1.35: Monoisononyl phthalate (MiNP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 1 (2007–2009), cycle 2 (2009–2011), cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.35 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 2546 0.90Table 14.1.35 footnote E
(0.30–3.1)
<LOD <LOD <LOD <LOD
5 (2016–2017) 2684 41.9
(33.2–51.1)
<LOD <LOD 1.3Table 14.1.35 footnote E
(0.73–1.8)
3.3Table 14.1.35 footnote E
(1.4–5.1)
6 (2018–2019) 2502 51.3
(45.1–57.5)
<LOD 0.18
(<LOD–0.21)
0.99
(0.70–1.3)
2.4Table 14.1.35 footnote E
(0.80–3.9)
Males, 3–79 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 1276 1.5Table 14.1.35 footnote E
(0.40–6.0)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1338 44.8
(35.8–54.1)
<LOD <LOD 1.0
(0.89–1.2)
1.8Table 14.1.35 footnote E
(0.67–3.0)
6 (2018–2019) 1236 59.3
(52.7–65.6)
<LOD 0.19
(0.17–0.22)
0.95Table 14.1.35 footnote E
(0.49–1.4)
1.7Table 14.1.35 footnote E
(<LOD–3.9)
Females, 3–79 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 1270 0.40Table 14.1.35 footnote E
(0.10–1.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 1346 38.9
(29.8–48.9)
<LOD <LOD 1.7Table 14.1.35 footnote E
(<LOD–3.4)
4.1Table 14.1.35 footnote E
(0.72–7.5)
6 (2018–2019) 1266 43.4
(35.7–51.5)
<LOD <LOD 1.0
(0.69–1.3)
3.0Table 14.1.35 footnote E
(<LOD–5.0)
3–5 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 521 0.40Table 14.1.35 footnote E
(0.10–1.2)
<LOD <LOD <LOD <LOD
5 (2016–2017) 544 49.1
(32.5–65.9)
<LOD <LOD 2.4Table 14.1.35 footnote E
(1.1–3.8)
4.5Table 14.1.35 footnote E
(<LOD–9.2)
6 (2018–2019) 506 69.8
(59.9–78.2)
0.44
(0.38–0.52)
<LOD 0.38
(<LOD–0.48)
1.7Table 14.1.35 footnote E
(1.0–2.4)
2.9Table 14.1.35 footnote E
(1.7–4.2)
6–11 years
1 (2007–2009) 1033 0.80Table 14.1.35 footnote E
(0.20–4.3)
<LOD <LOD <LOD <LOD
2 (2009–2011) 512 0.40Table 14.1.35 footnote E
(0.10–1.5)
<LOD <LOD <LOD <LOD
5 (2016–2017) 529 49.5
(38.9–60.2)
<LOD <LOD 1.3Table 14.1.35 footnote E
(0.76–1.8)
3.1
(2.0–4.2)
6 (2018–2019) 494 61.0
(52.2–69.3)
<LOD 0.27
(0.21–0.34)
0.81
(0.55–1.1)
1.6Table 14.1.35 footnote E
(<LOD–4.8)
12–19 years
1 (2007–2009) 989 0.90Table 14.1.35 footnote E
(0.30–2.6)
<LOD <LOD <LOD <LOD
2 (2009–2011) 509 0.30Table 14.1.35 footnote E
(0.10–1.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 531 49.1
(38.1–60.2)
<LOD <LOD 1.1Table 14.1.35 footnote E
(0.63–1.6)
2.6Table 14.1.35 footnote E
(<LOD–5.5)
6 (2018–2019) 497 62.1
(51.4–71.6)
<LOD 0.20
(<LOD–0.25)
0.94
(0.71–1.2)
1.3Table 14.1.35 footnote E
(0.70–1.8)
20–39 years
1 (2007–2009) 728 0.20Table 14.1.35 footnote E
(0–1.9)
<LOD <LOD <LOD <LOD
2 (2009–2011) 356 2.8Table 14.1.35 footnote E
(0.70–10.3)
<LOD <LOD <LOD <LOD
5 (2016–2017) 370 50.1
(33.9–66.3)
<LOD <LOD 2.0Table 14.1.35 footnote E
(<LOD–4.7)
4.1Table 14.1.35 footnote E
(0.98–7.2)
6 (2018–2019) 330 56.7
(44.3–68.2)
<LOD 0.17
(0.15–0.20)
0.98Table 14.1.35 footnote E
(<LOD–2.1)
4.2Table 14.1.35 footnote E
(<LOD–9.7)
40–59 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 358 0.10Table 14.1.35 footnote E
(0–0.30)
<LOD <LOD <LOD <LOD
5 (2016–2017) 358 37.2
(29.2–45.9)
<LOD <LOD 0.87Table 14.1.35 footnote E
(<LOD–1.5)
2.5Table 14.1.35 footnote E
(<LOD–6.3)
6 (2018–2019) 338 47.0
(37.9–56.2)
<LOD <LOD 1.1Table 14.1.35 footnote E
(0.46–1.6)
3.0Table 14.1.35 footnote E
(0.59–5.4)
60–79 years
1 (2007–2009)Table 14.1.35 footnote b
2 (2009–2011) 290 0.10Table 14.1.35 footnote E
(0–4.1)
<LOD <LOD <LOD <LOD
5 (2016–2017) 352 29.9
(20.8–40.9)
<LOD <LOD 1.1Table 14.1.35 footnote E
(0.61–1.5)
1.7Table 14.1.35 footnote E
(0.99–2.4)
6 (2018–2019) 337 39.1
(31.3–47.4)
<LOD <LOD 0.80Table 14.1.35 footnote E
(0.42–1.2)
1.5Table 14.1.35 footnote E
(<LOD–3.0)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.36: Monocarboxyisononyl phthalate (MCiNP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.36 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2551 95.9
(92.2–97.9)
0.68
(0.57–0.80)
0.16
(0.12–0.21)
0.71
(0.55–0.88)
2.5
(1.9–3.1)
4.0
(3.0–5.0)
6 (2018–2019) 2233 93.8
(90.8–95.9)
0.47
(0.41–0.53)
0.12
(0.095–0.15)
0.46
(0.41–0.51)
1.6
(1.2–2.0)
2.4Table 14.1.36 footnote E
(1.3–3.6)
Males, 3–79 years
5 (2016–2017) 1272 94.9
(90.7–97.2)
0.68
(0.57–0.83)
0.17Table 14.1.36 footnote E
(0.081–0.25)
0.73
(0.59–0.88)
2.4
(1.8–2.9)
4.2
(3.1–5.4)
6 (2018–2019) 1103 93.0
(87.9–96.1)
0.50
(0.41–0.62)
0.13Table 14.1.36 footnote E
(<LOD–0.20)
0.47
(0.41–0.54)
1.7
(1.3–2.2)
2.5Table 14.1.36 footnote E
(<LOD–5.1)
Females, 3–79 years
5 (2016–2017) 1279 96.9
(91.4–98.9)
0.67
(0.54–0.82)
0.16
(0.11–0.21)
0.67
(0.44–0.90)
2.5
(1.8–3.2)
3.8
(2.6–5.0)
6 (2018–2019) 1130 94.6
(91.3–96.7)
0.44
(0.38–0.50)
0.12
(0.096–0.14)
0.42
(0.36–0.48)
1.6
(1.1–2.0)
2.3Table 14.1.36 footnote E
(0.84–3.7)
3–5 years
5 (2016–2017) 520 99.9
(99.5–100)
0.96Table 14.1.36 footnote E
(0.62–1.5)
0.27Table 14.1.36 footnote E
(0.16–0.38)
0.87Table 14.1.36 footnote E
(0.52–1.2)
3.8Table 14.1.36 footnote E
(1.2–6.3)
6.8Table 14.1.36 footnote E
(<LOD–14)
6 (2018–2019) 459 98.9
(92.2–99.9)
0.70
(0.60–0.82)
0.22
(0.18–0.26)
0.76
(0.61–0.91)
2.1Table 14.1.36 footnote E
(1.2–3.0)
3.3Table 14.1.36 footnote E
(1.8–4.7)
6–11 years
5 (2016–2017) 517 99.5
(99.0–99.8)
1.1
(0.87–1.3)
0.33
(0.24–0.41)
1.0
(0.77–1.2)
3.3
(2.6–4.0)
4.5Table 14.1.36 footnote E
(2.1–6.8)
6 (2018–2019) 462 98.0
(94.4–99.3)
0.73
(0.61–0.87)
0.20Table 14.1.36 footnote E
(0.095–0.31)
0.76
(0.61–0.90)
2.4
(1.7–3.2)
3.1
(2.0–4.2)
12–19 years
5 (2016–2017) 498 97.2
(93.9–98.7)
0.79
(0.68–0.92)
0.22Table 14.1.36 footnote E
(0.098–0.34)
0.85
(0.70–0.99)
2.3
(1.8–2.9)
3.8
(2.6–5.0)
6 (2018–2019) 435 96.4
(90.6–98.7)
0.52
(0.43–0.64)
0.15Table 14.1.36 footnote E
(0.085–0.21)
0.57
(0.46–0.68)
1.8
(1.3–2.4)
2.2
(1.5–2.9)
20–39 years
5 (2016–2017) 356 94.3
(80.2–98.5)
0.58
(0.41–0.84)
0.14Table 14.1.36 footnote E
(<LOD–0.28)
0.56Table 14.1.36 footnote E
(0.28–0.83)
2.3Table 14.1.36 footnote E
(1.4–3.3)
3.5Table 14.1.36 footnote E
(2.0–5.0)
6 (2018–2019) 285 93.4
(87.4–96.6)
0.47
(0.36–0.62)
0.14
(0.096–0.18)
0.46
(0.33–0.58)
1.5Table 14.1.36 footnote E
(0.81–2.3)
2.2Table 14.1.36 footnote E
(0.18–4.3)
40–59 years
5 (2016–2017) 325 95.0
(89.5–97.7)
0.69
(0.53–0.90)
0.15Table 14.1.36 footnote E
(<LOD–0.23)
0.77
(0.58–0.96)
2.8Table 14.1.36 footnote E
(1.8–3.8)
4.6Table 14.1.36 footnote E
(2.6–6.5)
6 (2018–2019) 295 93.8
(88.5–96.7)
0.42
(0.33–0.52)
0.12Table 14.1.36 footnote E
(<LOD–0.16)
0.37
(0.30–0.44)
1.2Table 14.1.36 footnote E
(0.24–2.1)
3.9Table 14.1.36 footnote E
(0.50–7.3)
60–79 years
5 (2016–2017) 335 97.0
(92.1–98.9)
0.60
(0.51–0.70)
0.16
(0.12–0.19)
0.61
(0.47–0.76)
2.1
(1.7–2.6)
3.4
(2.4–4.5)
6 (2018–2019) 297 91.2
(80.2–96.3)
0.42
(0.34–0.53)
0.093Table 14.1.36 footnote E
(<LOD–0.16)
0.47
(0.34–0.60)
1.6
(1.3–1.9)
2.3Table 14.1.36 footnote E
(1.4–3.1)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LODs for cycles 5 and 6 are 0.077 and 0.075 μg/L, respectively.

Table 14.1.37: Monocarboxyisononyl phthalate (MCiNP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.37 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2522 95.9
(92.2–97.9)
0.64
(0.56–0.73)
0.22
(0.18–0.26)
0.58
(0.50–0.66)
2.0
(1.6–2.3)
2.7
(2.2–3.2)
6 (2018–2019) 2233 93.8
(90.8–95.9)
0.51
(0.45–0.57)
0.16
(0.13–0.20)
0.46
(0.40–0.51)
1.7
(1.3–2.1)
2.7
(2.0–3.3)
Males, 3–79 years
5 (2016–2017) 1257 94.9
(90.7–97.2)
0.57
(0.51–0.64)
0.20
(0.15–0.24)
0.52
(0.48–0.56)
1.9
(1.5–2.3)
2.7
(2.1–3.3)
6 (2018–2019) 1103 93.0
(87.9–96.1)
0.46
(0.37–0.58)
0.15
(<LOD–0.18)
0.43
(0.35–0.52)
1.5
(1.2–1.7)
2.3Table 14.1.37 footnote E
(<LOD–3.3)
Females, 3–79 years
5 (2016–2017) 1265 96.9
(91.4–98.9)
0.71
(0.60–0.85)
0.28
(0.23–0.33)
0.64
(0.50–0.78)
2.0
(1.6–2.4)
2.7
(2.0–3.4)
6 (2018–2019) 1130 94.6
(91.3–96.7)
0.55
(0.49–0.62)
0.19
(0.14–0.24)
0.49
(0.43–0.56)
2.0
(1.5–2.5)
2.8
(2.1–3.5)
3–5 years
5 (2016–2017) 510 99.9
(99.5–100)
1.7
(1.2–2.3)
0.63
(0.41–0.85)
1.5
(1.2–1.7)
4.9Table 14.1.37 footnote E
(1.1–8.7)
9.4Table 14.1.37 footnote E
(<LOD–17)
6 (2018–2019) 459 98.9
(92.2–99.9)
1.2
(0.98–1.4)
0.43Table 14.1.37 footnote E
(0.22–0.65)
1.1
(0.88–1.3)
2.7Table 14.1.37 footnote E
(1.1–4.3)
4.8Table 14.1.37 footnote E
(2.7–6.8)
6–11 years
5 (2016–2017) 509 99.5
(99.0–99.8)
1.2
(1.0–1.5)
0.44
(0.40–0.49)
1.1
(0.90–1.2)
2.9Table 14.1.37 footnote E
(1.6–4.2)
6.2Table 14.1.37 footnote E
(1.2–11)
6 (2018–2019) 462 98.0
(94.4–99.3)
0.87
(0.75–1.0)
0.32
(0.29–0.35)
0.84
(0.66–1.0)
2.6Table 14.1.37 footnote E
(1.5–3.7)
3.5
(2.4–4.6)
12–19 years
5 (2016–2017) 493 97.2
(93.9–98.7)
0.58
(0.49–0.68)
0.22
(0.17–0.27)
0.53
(0.41–0.65)
1.8
(1.4–2.2)
2.4
(1.5–3.2)
6 (2018–2019) 435 96.4
(90.6–98.7)
0.44
(0.38–0.51)
0.17
(0.14–0.20)
0.42
(0.34–0.50)
1.3Table 14.1.37 footnote E
(0.59–2.0)
2.1
(1.4–2.8)
20–39 years
5 (2016–2017) 352 94.3
(80.2–98.5)
0.51
(0.42–0.62)
0.18
(<LOD–0.21)
0.47
(0.38–0.56)
1.3Table 14.1.37 footnote E
(0.55–2.1)
2.0Table 14.1.37 footnote E
(0.99–3.0)
6 (2018–2019) 285 93.4
(87.4–96.6)
0.45
(0.37–0.54)
0.16
(0.14–0.18)
0.38
(0.30–0.46)
1.7Table 14.1.37 footnote E
(0.82–2.5)
2.2Table 14.1.37 footnote E
(0.81–3.5)
40–59 years
5 (2016–2017) 324 95.0
(89.5–97.7)
0.61
(0.51–0.74)
0.21Table 14.1.37 footnote E
(<LOD–0.31)
0.57
(0.44–0.70)
2.0
(1.4–2.6)
2.6
(2.0–3.2)
6 (2018–2019) 295 93.8
(88.5–96.7)
0.49
(0.39–0.63)
0.16Table 14.1.37 footnote E
(<LOD–0.22)
0.43
(0.34–0.52)
1.5Table 14.1.37 footnote E
(0.31–2.7)
2.7Table 14.1.37 footnote E
(<LOD–6.2)
60–79 years
5 (2016–2017) 334 97.0
(92.1–98.9)
0.67
(0.58–0.78)
0.26
(0.23–0.30)
0.64
(0.55–0.73)
1.8
(1.4–2.2)
2.5
(1.8–3.1)
6 (2018–2019) 297 91.2
(80.2–96.3)
0.50
(0.41–0.61)
0.14Table 14.1.37 footnote E
(<LOD–0.20)
0.48
(0.38–0.58)
1.5
(1.1–1.9)
2.1
(1.5–2.7)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.38: Monooxoisononyl phthalate (MOiNP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.38 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2640 90.2
(86.5–92.9)
0.67
(0.60–0.75)
<LODTable 14.1.38 footnote E
(<LOD–0.21)
0.63
(0.57–0.69)
3.2
(2.8–3.6)
5.4
(3.7–7.2)
6 (2018–2019) 2412 87.0
(83.9–89.6)
0.56
(0.49–0.64)
<LOD 0.53
(0.46–0.60)
2.3
(1.6–2.9)
4.0Table 14.1.38 footnote E
(1.6–6.4)
Males, 3–79 years
5 (2016–2017) 1318 90.2
(84.4–93.9)
0.65
(0.54–0.78)
<LODTable 14.1.38 footnote E
(<LOD–0.24)
0.61
(0.52–0.70)
2.5
(1.8–3.2)
4.3Table 14.1.38 footnote E
(2.1–6.4)
6 (2018–2019) 1195 89.8
(85.2–93.1)
0.62
(0.51–0.74)
<LOD 0.61
(0.48–0.74)
2.5Table 14.1.38 footnote E
(1.5–3.5)
3.7Table 14.1.38 footnote E
(0.88–6.5)
Females, 3–79 years
5 (2016–2017) 1322 90.2
(86.1–93.2)
0.69
(0.59–0.82)
<LODTable 14.1.38 footnote E
(<LOD–0.18)
0.66
(0.56–0.77)
3.5
(2.6–4.5)
6.1Table 14.1.38 footnote E
(<LOD–14)
6 (2018–2019) 1217 84.1
(78.2–88.7)
0.51
(0.43–0.60)
<LOD 0.47
(0.40–0.53)
2.2
(1.5–2.9)
5.3Table 14.1.38 footnote E
(1.0–9.6)
3–5 years
5 (2016–2017) 548 97.4
(91.5–99.3)
1.1
(0.88–1.4)
0.26Table 14.1.38 footnote E
(<LOD–0.42)
1.1
(0.89–1.2)
4.4
(2.8–6.0)
6.7Table 14.1.38 footnote E
(3.4–10)
6 (2018–2019) 495 95.9
(92.8–97.7)
0.93
(0.79–1.1)
0.31
(0.23–0.40)
0.91
(0.77–1.0)
3.0
(2.0–4.0)
4.7Table 14.1.38 footnote E
(2.0–7.5)
6–11 years
5 (2016–2017) 524 97.5
(94.9–98.8)
1.0
(0.87–1.3)
0.31
(0.27–0.36)
1.0
(0.80–1.3)
3.6
(2.6–4.6)
5.0Table 14.1.38 footnote E
(1.6–8.4)
6 (2018–2019) 478 94.1
(86.8–97.5)
0.81
(0.68–0.97)
0.23Table 14.1.38 footnote E
(<LOD–0.31)
0.81
(0.63–0.98)
3.0Table 14.1.38 footnote E
(1.8–4.1)
5.1Table 14.1.38 footnote E
(0.41–9.8)
12–19 years
5 (2016–2017) 525 94.4
(90.7–96.6)
0.93
(0.79–1.1)
0.20
(<LOD–0.26)
0.90
(0.73–1.1)
3.8Table 14.1.38 footnote E
(2.0–5.5)
7.3Table 14.1.38 footnote E
(0.88–14)
6 (2018–2019) 486 90.2
(82.2–94.8)
0.68
(0.55–0.84)
0.15Table 14.1.38 footnote E
(<LOD–0.27)
0.69
(0.56–0.82)
2.8
(2.1–3.4)
4.4Table 14.1.38 footnote E
(2.6–6.1)
20–39 years
5 (2016–2017) 358 88.4
(76.3–94.8)
0.67
(0.50–0.90)
<LOD 0.59
(0.41–0.76)
3.3
(2.2–4.3)
5.8Table 14.1.38 footnote E
(1.7–9.9)
6 (2018–2019) 318 88.0
(79.1–93.4)
0.60
(0.45–0.79)
<LOD 0.54
(0.36–0.72)
2.6Table 14.1.38 footnote E
(0.95–4.2)
6.0Table 14.1.38 footnote E
(<LOD–24)
40–59 years
5 (2016–2017) 343 89.1
(75.9–95.5)
0.59
(0.46–0.75)
<LOD 0.56
(0.45–0.67)
2.9
(1.9–4.0)
5.2Table 14.1.38 footnote E
(<LOD–14)
6 (2018–2019) 321 84.4
(76.9–89.8)
0.47
(0.39–0.58)
<LOD 0.47
(0.37–0.58)
2.2Table 14.1.38 footnote E
(1.3–3.0)
3.1Table 14.1.38 footnote E
(1.8–4.4)
60–79 years
5 (2016–2017) 342 88.7
(84.1–92.1)
0.55
(0.46–0.66)
<LOD 0.54
(0.40–0.68)
2.6Table 14.1.38 footnote E
(1.4–3.7)
3.7Table 14.1.38 footnote E
(2.1–5.3)
6 (2018–2019) 314 83.7
(76.1–89.3)
0.48
(0.39–0.59)
<LOD 0.44
(0.36–0.52)
1.9Table 14.1.38 footnote E
(0.76–3.1)
4.3Table 14.1.38 footnote E
(<LOD–8.9)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LOD for cycles 5 and 6 is 0.15 μg/L.

Table 14.1.39: Monooxoisononyl phthalate (MOiNP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.39 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2609 90.2
(86.5–92.9)
0.65
(0.59–0.71)
<LOD 0.55
(0.50–0.60)
2.8
(2.3–3.2)
5.2
(3.7–6.7)
6 (2018–2019) 2411 87.0
(83.9–89.6)
0.60
(0.52–0.70)
<LOD 0.51
(0.45–0.56)
2.1Table 14.1.39 footnote E
(1.1–3.1)
5.5Table 14.1.39 footnote E
(2.8–8.3)
Males, 3–79 years
5 (2016–2017) 1304 90.2
(84.4–93.9)
0.55
(0.48–0.64)
<LOD 0.48
(0.37–0.58)
2.1
(1.7–2.5)
4.3
(2.9–5.8)
6 (2018–2019) 1194 89.8
(85.2–93.1)
0.57
(0.47–0.69)
<LOD 0.50
(0.43–0.57)
2.0Table 14.1.39 footnote E
(0.72–3.3)
4.1Table 14.1.39 footnote E
(1.4–6.9)
Females, 3–79 years
5 (2016–2017) 1305 90.2
(86.1–93.2)
0.76
(0.68–0.85)
<LOD 0.63
(0.51–0.76)
3.4
(2.2–4.7)
5.9Table 14.1.39 footnote E
(<LOD–9.2)
6 (2018–2019) 1217 84.1
(78.2–88.7)
0.63
(0.54–0.75)
<LOD 0.52
(0.43–0.60)
2.4Table 14.1.39 footnote E
(0.66–4.2)
6.5Table 14.1.39 footnote E
(2.8–10)
3–5 years
5 (2016–2017) 537 97.4
(91.5–99.3)
1.9
(1.6–2.3)
0.65
(<LOD–0.82)
1.8
(1.5–2.1)
6.2
(4.3–8.1)
10Table 14.1.39 footnote E
(5.2–16)
6 (2018–2019) 494 95.9
(92.8–97.7)
1.5
(1.3–1.8)
0.53
(0.38–0.68)
1.4
(1.0–1.7)
4.7
(3.5–5.9)
6.8Table 14.1.39 footnote E
(3.8–9.8)
6–11 years
5 (2016–2017) 517 97.5
(94.9–98.8)
1.2
(1.0–1.5)
0.44
(0.37–0.51)
1.1
(0.92–1.2)
3.9
(2.6–5.2)
5.9Table 14.1.39 footnote E
(2.7–9.0)
6 (2018–2019) 478 94.1
(86.8–97.5)
0.98
(0.89–1.1)
0.36
(<LOD–0.41)
0.88
(0.80–0.95)
2.4Table 14.1.39 footnote E
(1.4–3.4)
5.6Table 14.1.39 footnote E
(0.74–10)
12–19 years
5 (2016–2017) 518 94.4
(90.7–96.6)
0.71
(0.60–0.82)
0.24
(<LOD–0.29)
0.59
(0.50–0.68)
2.3Table 14.1.39 footnote E
(1.4–3.2)
5.7Table 14.1.39 footnote E
(1.9–9.5)
6 (2018–2019) 486 90.2
(82.2–94.8)
0.56
(0.48–0.66)
0.17
(<LOD–0.21)
0.51
(0.42–0.60)
1.8Table 14.1.39 footnote E
(1.0–2.7)
2.9Table 14.1.39 footnote E
(1.8–4.0)
20–39 years
5 (2016–2017) 354 88.4
(76.3–94.8)
0.60
(0.51–0.71)
<LOD 0.46
(0.35–0.57)
2.8Table 14.1.39 footnote E
(<LOD–5.6)
5.8Table 14.1.39 footnote E
(3.2–8.5)
6 (2018–2019) 318 88.0
(79.1–93.4)
0.56
(0.42–0.75)
<LOD 0.45
(0.36–0.53)
1.9Table 14.1.39 footnote E
(<LOD–4.3)
8.2Table 14.1.39 footnote E
(<LOD–18)
40–59 years
5 (2016–2017) 342 89.1
(75.9–95.5)
0.53
(0.44–0.64)
<LOD 0.50
(0.36–0.64)
2.2Table 14.1.39 footnote E
(1.0–3.3)
4.3Table 14.1.39 footnote E
(<LOD–7.6)
6 (2018–2019) 321 84.4
(76.9–89.8)
0.56
(0.44–0.71)
<LOD 0.51
(0.35–0.68)
1.8Table 14.1.39 footnote E
(<LOD–4.5)
5.1Table 14.1.39 footnote E
(2.4–7.9)
60–79 years
5 (2016–2017) 341 88.7
(84.1–92.1)
0.62
(0.53–0.73)
<LOD 0.55
(0.43–0.67)
2.1
(1.5–2.7)
4.3Table 14.1.39 footnote E
(2.3–6.3)
6 (2018–2019) 314 83.7
(76.1–89.3)
0.55
(0.46–0.67)
<LOD 0.42
(0.36–0.48)
2.1Table 14.1.39 footnote E
(0.71–3.4)
4.4Table 14.1.39 footnote E
(<LOD–8.3)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.40: Monohydroxyisononyl phthalate (MHiNP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.40 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2659 91.5
(88.1–94.0)
0.83
(0.72–0.97)
0.11Table 14.1.40 footnote E
(<LOD–0.19)
0.87
(0.74–1.0)
4.5
(3.6–5.5)
7.8Table 14.1.40 footnote E
(4.8–11)
6 (2018–2019) 2392 87.1
(83.2–90.2)
0.65
(0.56–0.75)
<LOD 0.77
(0.68–0.85)
3.5
(2.7–4.3)
5.4Table 14.1.40 footnote E
(1.9–9.0)
Males, 3–79 years
5 (2016–2017) 1317 90.9
(86.7–93.9)
0.81
(0.66–1.0)
0.077Table 14.1.40 footnote E
(<LOD–0.22)
0.86
(0.65–1.1)
4.2
(3.3–5.1)
6.7Table 14.1.40 footnote E
(4.0–9.4)
6 (2018–2019) 1179 89.8
(85.3–93.0)
0.75
(0.61–0.93)
<LOD 0.88
(0.71–1.0)
3.6
(2.6–4.6)
4.9Table 14.1.40 footnote E
(<LOD–10)
Females, 3–79 years
5 (2016–2017) 1342 92.1
(87.8–94.9)
0.85
(0.71–1.0)
0.13Table 14.1.40 footnote E
(<LOD–0.22)
0.88
(0.68–1.1)
5.0Table 14.1.40 footnote E
(3.1–6.9)
8.5Table 14.1.40 footnote E
(<LOD–20)
6 (2018–2019) 1213 84.5
(78.6–88.9)
0.56
(0.46–0.69)
<LOD 0.64
(0.48–0.79)
3.3
(2.2–4.3)
5.7Table 14.1.40 footnote E
(1.2–10)
3–5 years
5 (2016–2017) 546 98.8
(94.8–99.7)
1.6
(1.3–2.1)
0.43Table 14.1.40 footnote E
(0.26–0.60)
1.5
(1.1–2.0)
5.9Table 14.1.40 footnote E
(1.2–11)
11Table 14.1.40 footnote E
(1.9–19)
6 (2018–2019) 494 97.8
(95.1–99.0)
1.3
(1.1–1.5)
0.43
(0.30–0.56)
1.3
(1.1–1.4)
4.3
(3.0–5.6)
6.2
(5.0–7.5)
6–11 years
5 (2016–2017) 533 95.3
(88.8–98.1)
1.3
(1.0–1.7)
0.36
(0.26–0.46)
1.4
(0.99–1.9)
4.8
(3.7–5.9)
7.3Table 14.1.40 footnote E
(1.6–13)
6 (2018–2019) 474 96.2
(92.2–98.2)
1.2
(0.98–1.4)
0.26Table 14.1.40 footnote E
(0.099–0.43)
1.2
(0.92–1.5)
4.0
(2.6–5.5)
7.5Table 14.1.40 footnote E
(<LOD–17)
12–19 years
5 (2016–2017) 520 93.6
(88.0–96.7)
1.1
(0.91–1.3)
0.23Table 14.1.40 footnote E
(0.071–0.38)
1.1
(0.84–1.4)
5.8Table 14.1.40 footnote E
(3.4–8.2)
11Table 14.1.40 footnote E
(<LOD–22)
6 (2018–2019) 469 88.0
(80.7–92.8)
0.78
(0.60–1.0)
<LOD 0.98
(0.73–1.2)
3.9
(2.8–5.0)
5.5Table 14.1.40 footnote E
(2.1–8.9)
20–39 years
5 (2016–2017) 367 92.7
(80.8–97.5)
0.83Table 14.1.40 footnote E
(0.55–1.3)
<LOD 0.80Table 14.1.40 footnote E
(0.49–1.1)
3.7Table 14.1.40 footnote E
(2.3–5.2)
6.5Table 14.1.40 footnote E
(0.42–13)
6 (2018–2019) 309 83.7
(75.5–89.5)
0.68
(0.50–0.92)
<LOD 0.86
(0.73–1.0)
3.5Table 14.1.40 footnote E
(1.7–5.3)
8.2Table 14.1.40 footnote E
(<LOD–40)
40–59 years
5 (2016–2017) 347 90.5
(84.7–94.2)
0.77
(0.58–1.0)
<LOD 0.71
(0.48–0.94)
5.6
(3.8–7.4)
8.7Table 14.1.40 footnote E
(<LOD–24)
6 (2018–2019) 323 86.3
(76.5–92.4)
0.54
(0.38–0.75)
<LOD 0.59Table 14.1.40 footnote E
(0.37–0.80)
3.5Table 14.1.40 footnote E
(2.0–5.0)
3.7Table 14.1.40 footnote E
(2.1–5.4)
60–79 years
5 (2016–2017) 346 87.7
(80.1–92.7)
0.63
(0.50–0.79)
<LOD 0.69
(0.51–0.87)
4.3Table 14.1.40 footnote E
(2.4–6.2)
5.7
(4.3–7.2)
6 (2018–2019) 323 87.7
(83.2–91.1)
0.55
(0.44–0.68)
<LOD 0.59
(0.46–0.72)
2.4Table 14.1.40 footnote E
(1.3–3.4)
6.7Table 14.1.40 footnote E
(0.47–13)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Note: The LOD for cycles 5 and 6 is 0.065 μg/L.

Table 14.1.41: Monohydroxyisononyl phthalate (MHiNP) (creatinine adjusted) — Geometric means and selected percentiles of urine concentrations (μg/g creatinine) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.41 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2627 91.5
(88.1–94.0)
0.81
(0.73–0.90)
0.17
(<LOD–0.23)
0.74
(0.66–0.83)
4.0
(3.2–4.7)
7.4
(5.5–9.2)
6 (2018–2019) 2391 87.1
(83.2–90.2)
0.70
(0.59–0.82)
<LOD 0.73
(0.63–0.83)
3.1Table 14.1.41 footnote E
(1.9–4.3)
7.8Table 14.1.41 footnote E
(3.5–12)
Males, 3–79 years
5 (2016–2017) 1302 90.9
(86.7–93.9)
0.70
(0.59–0.82)
0.20Table 14.1.41 footnote E
(<LOD–0.32)
0.65
(0.50–0.80)
3.1
(2.3–4.0)
5.7
(3.7–7.8)
6 (2018–2019) 1178 89.8
(85.3–93.0)
0.69
(0.54–0.87)
<LOD 0.74
(0.63–0.86)
3.0Table 14.1.41 footnote E
(1.6–4.4)
4.7Table 14.1.41 footnote E
(<LOD–9.4)
Females, 3–79 years
5 (2016–2017) 1325 92.1
(87.8–94.9)
0.93
(0.82–1.1)
0.17
(<LOD–0.22)
0.86
(0.70–1.0)
4.8
(3.1–6.4)
8.1Table 14.1.41 footnote E
(<LOD–14)
6 (2018–2019) 1213 84.5
(78.6–88.9)
0.70
(0.59–0.84)
<LOD 0.71
(0.59–0.84)
3.5Table 14.1.41 footnote E
(0.97–6.1)
9.4Table 14.1.41 footnote E
(5.4–13)
3–5 years
5 (2016–2017) 535 98.8
(94.8–99.7)
2.8
(2.3–3.5)
0.94
(0.70–1.2)
2.6
(2.1–3.2)
9.7
(6.2–13)
14Table 14.1.41 footnote E
(<LOD–31)
6 (2018–2019) 493 97.8
(95.1–99.0)
2.1
(1.8–2.5)
0.81
(0.64–0.98)
2.1
(1.6–2.6)
7.1
(5.5–8.7)
9.5
(7.4–11)
6–11 years
5 (2016–2017) 525 95.3
(88.8–98.1)
1.6
(1.2–2.0)
0.54
(0.36–0.73)
1.4
(1.0–1.9)
5.5
(3.7–7.3)
9.4
(6.2–13)
6 (2018–2019) 474 96.2
(92.2–98.2)
1.4
(1.2–1.6)
0.52
(0.42–0.61)
1.3
(1.2–1.5)
4.0
(2.5–5.4)
7.3Table 14.1.41 footnote E
(<LOD–18)
12–19 years
5 (2016–2017) 513 93.6
(88.0–96.7)
0.85
(0.70–1.0)
0.25
(0.16–0.34)
0.81
(0.73–0.90)
3.1Table 14.1.41 footnote E
(1.1–5.1)
7.9Table 14.1.41 footnote E
(<LOD–15)
6 (2018–2019) 469 88.0
(80.7–92.8)
0.65
(0.51–0.82)
<LOD 0.76
(0.58–0.94)
2.9Table 14.1.41 footnote E
(1.8–3.9)
4.4
(3.1–5.6)
20–39 years
5 (2016–2017) 363 92.7
(80.8–97.5)
0.75
(0.58–0.97)
<LOD 0.70
(0.51–0.90)
3.7Table 14.1.41 footnote E
(1.7–5.8)
6.2Table 14.1.41 footnote E
(2.8–9.6)
6 (2018–2019) 309 83.7
(75.5–89.5)
0.61
(0.47–0.79)
<LOD 0.62
(0.50–0.74)
2.9Table 14.1.41 footnote E
(<LOD–6.2)
10Table 14.1.41 footnote E
(<LOD–28)
40–59 years
5 (2016–2017) 346 90.5
(84.7–94.2)
0.70
(0.56–0.87)
<LOD 0.60
(0.42–0.79)
3.9Table 14.1.41 footnote E
(1.9–5.9)
7.2Table 14.1.41 footnote E
(<LOD–15)
6 (2018–2019) 323 86.3
(76.5–92.4)
0.64Table 14.1.41 footnote E
(0.44–0.93)
<LOD 0.73
(0.52–0.94)
3.1Table 14.1.41 footnote E
(0.80–5.5)
8.4Table 14.1.41 footnote E
(2.2–15)
60–79 years
5 (2016–2017) 345 87.7
(80.1–92.7)
0.71
(0.58–0.88)
<LOD 0.71
(0.56–0.87)
3.8Table 14.1.41 footnote E
(2.1–5.6)
6.0Table 14.1.41 footnote E
(3.5–8.6)
6 (2018–2019) 323 87.7
(83.2–91.1)
0.64
(0.53–0.76)
<LOD 0.57
(0.44–0.70)
2.4Table 14.1.41 footnote E
(0.87–3.9)
6.3Table 14.1.41 footnote E
(<LOD–13)

CI: confidence interval; GM: geometric mean; LOD: limit of detection

Table 14.1.42: Monoisodecyl phthalate (MiDP) — Geometric means and selected percentiles of urine concentrations (μg/L) for the Canadian population aged 3–79 by age group, Canadian Health Measures Survey cycle 5 (2016–2017) and cycle 6 (2018–2019)
Cycle n Detection Frequency
(95% CI)
GMTable 14.1.42 footnote a
(95% CI)
10th
(95% CI)
50th
(95% CI)
90th
(95% CI)
95th
(95% CI)
Total, 3–79 years
5 (2016–2017) 2710 2.4Table 14.1.42 footnote E
(1.1–5.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 2528 3.7
(2.6–5.3)
<LOD <LOD <LOD <LOD
Males, 3–79 years
5 (2016–2017) 1348 2.4Table 14.1.42 footnote E
(1.0–5.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1254 4.9Table 14.1.42 footnote E
(2.9–8.2)
<LOD <LOD <LOD <LOD
Females, 3–79 years
5 (2016–2017) 1362 2.4Table 14.1.42 footnote E
(0.90–6.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 1274 2.5Table 14.1.42 footnote E
(1.1–5.7)
<LOD <LOD <LOD <LOD
3–5 years
5 (2016–2017) 554 2.0Table 14.1.42 footnote E
(0.70–5.2)
<LOD <LOD <LOD <LOD
6 (2018–2019) 511 0.50Table 14.1.42 footnote E
(0–6.6)
<LOD <LOD <LOD <LOD
6–11 years
5 (2016–2017) 535 1.2Table 14.1.42 footnote E
(0.40–3.7)
<LOD <LOD <LOD <LOD
6 (2018–2019) 498 0.80Table 14.1.42 footnote E
(0.30–2.0)
<LOD <LOD <LOD <LOD
12–19 years
5 (2016–2017) 537 1.9Table 14.1.42 footnote E
(1.1–3.4)
<LOD <LOD <LOD <LOD
6 (2018–2019) 504 2.8Table 14.1.42 footnote E
(1.0–7.7)
<LOD <LOD <LOD <LOD
20–39 years
5 (2016–2017) 373 1.7Table 14.1.42 footnote E
(0.60–5.0)
<LOD <LOD <LOD <LOD
6 (2018–2019) 330 7.5Table 14.1.42 footnote E
(3.7–14.4)
<LOD <LOD <LOD <LOD
40–59 years
5 (2016–2017) 358 3.7Table 14.1.42 footnote E
(1.3–9.9)
<LOD <LOD <LOD <LOD
6 (2018–2019) 343 2.5Table 14.1.42 footnote E
(0.70–8.8)